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Abstract 
Phospholipase Cγ1 (PLCγ1) is highly expressed in several tumours such as breast 
carcinomas and has been found overexpressed in metastases compared to primary 
tumour in breast cancer patients, indicating that PLCγ1 may be important in 
tumourigenesis and metastasis dissemination. PLCγ1 involvement in cancer cell 
motility and in cancer cell Matrigel invasion was investigated. Downregulation of 
PLC1 protein expression by siRNA or shRNA inhibited Matrigel cell invasion of 
highly invasive breast and melanoma cancer cell lines. Furthermore PLC1 
protein downregulation inhibits intracellular calcium mobilisation upon EGF 
stimulation demonstrating the essential role of PLC1 in EGF-induced calcium 
release. In the effort to identify specific PLC1 inhibitors, Inositol (1,3,4,5,6) 
pentakisphosphate (InsP5) and  2-O-Bn-InsP5, a synthetic compound based on 
InsP5 structure, were tested on Matrigel cell invasion and PLC1 activity. I found 
that InsP5 and 2-O-Bn-InsP5 reduce cell migration and Matrigel invasion in breast 
and melanoma cancer cell lines, with a complete inhibition displayed by 2-O-Bn-
InsP5 treated cells. Furthermore InsP5 and 2-O-Bn-InsP5 treatment reduces 
calcium release upon EGF stimulation, with a complete inhibition showed by 2-
O-Bn-InsP5 treated cells, suggesting a potential inhibition on PLC1 activity. 
Analysis of PLC1 phosphorylation in tyrosine 783 residue revealed that 2-O-Bn-
InsP5 inhibits EGF-induced PLC1 tyrosine phosphorylation. Kinase profile 
assay, performed  in vitro to test the inhibitory effect of InsP5 and 2-O-Bn-InsP5 
on different kinases, showed a specific inhibition by 2-O-Bn-InsP5 of the 3-
phosphoinositide-dependent-protein kinase 1 (PDK1) with an IC50 of 26 nM. 
Knock down of PDK1 using siRNA and shRNA in MDA-MB-231 showed 
impairment in cell migration and Matrigel invasion and inhibition of EGF-
induced calcium mobilisation. Co-immunoprecipitation and FRET analyses 
showed that PLC1 and PDK1 associate in a protein complex. My finding 
identified a novel pathway which involves PDK1 in PLC1 activation. 
Furthermore this work highlights PLC1 as a potential therapeutic target to 
prevent metastases spreading and identified 2-O-Bn- InsP5 as a leading compound 
for development of anti-metastatic drugs.  
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Chapter 1: 
Introduction  
1.1 Phosphoinositides  
Phosphoinositides are phospholipids within cell membranes. The general 
structure of the phosphoinositides comprises two fatty acid chains linked a 
glycerol moiety and to a water soluble inositol head-group, which can 
undergo differential phosphorylation (Figure 1.1). 
 
Figure 1.1: Structure of phosphatidylinositol, the compound for the 
synthesis of the whole family of phosphoinositides  
 
The inositol group may be phosphorylated in different positions 
generating all the different components of the phosphoinositide family 
(Figure 1.2). Some phosphoinositides, such as the PtdIns(3,4,5)P3, play a 
role as second messenger. Several protein domains are able to bind the 
different phosphoinositides such as PH, FYVE, PX, PHD, FERM, 
GRAM, ENTH and ANTH domains. Nowadays it is well understood the 
role of phosphoinositides as second messengers and their role in cell 
signalling in healthy and pathological conditions.   
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Figure 1.2: Schematic representation of phosphoinositides, kinases and 
phosphatases enzymes involved in their synthesis (adapted from Bunney 
and Katan, 2010).   
Phosphoinositides metabolism is strictly controlled in cells since 
activation of signalling molecules has to be well defined both temporally 
and spatially. Some phosphoinositides, such as PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 are absent in resting cells and are synthesised only upon 
cellular stimulation. This process involves protein kinases and protein 
phosphatases, the last in general involved in switching off the signalling. 
Phosphoinositides are involved in many cellular processes, and 
dysfunction of their metabolism is observed in several diseases such as 
cancer and diabetes (Wymann and Schneiter, 2008).  
 
1.1.1 Phosphatidylinositol-4,5-bisphosphate, PtdIns(4,5P)2 
Phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] represents 0.5% of 
total membrane lipids (Stephens et al., 2000). The major synthetic route of 
PtdIns(4,5)P2 is the phosphorylation of PtdIns4P at the 5-position by 
PtdIns4P 5-kinases (PIP5K) (van den Bout and Divecha, 2009). Three 
different classes of PIP5K have been identified: PIP5K, PIP5K and 
 
 
 
22 
 
PIP5K. A minor synthetic route is represented by the synthesis through 
the action of PtdIns5P 4-kinases that phosphorylate PtdIns5P in position 4 
(Rameh et al., 1997; Clarke et al., 2010). PtdIns(4,5)P2 has been 
extensively studied since different second messenger are generated from 
this phosphoinositide. Indeed PtdIns(4,5)P2 is the main substrate of the 
PI3K family which produces the second messenger PtdIns(3,4,5)P3. 
PtdIns(4,5)P2 is also the substrate of Phospholipase C family members 
(PLCs). PLCs cleave the polar head group of PtdIns(4,5)P2 generating 
diacylglycerol (DAG) and Inositol-(1,4,5)-trisphosphate (InsP3), which are 
second messengers that activate PKC and stimulate calcium release from 
internal stores (Irvine et al., 1984; Berridge and Irvine, 1989). 
PtdIns(4,5)P2 has many functions within cell signalling. Some of its 
functions, closely related to this thesis, are described in the following 
chapter. 
1.1.1.1 PtdIns(4,5)P2 and cytoskeleton remodelling 
 PtdIns(4,5)P2 plays an essential role in the regulation of cytoskeleton 
remodelling by binding to protein such as cofilin, profilin, gelsolin. This 
interaction binds these proteins to the plasma membrane in a mechanism 
that prevents its activation. Hydrolysis of PtdIns(4,5)P2 by phospholipase 
C (PLC) enzymes (Van Rheenen  et al., 2007) releases these proteins from 
the plasma membrane in a well-defined spatial and temporal manner, 
stimulating actin polymerization. The actin binding proteins (ABP) cofilin 
interacts with monomeric and filamentous actin promoting actin filament 
disassembly and severing actin filaments. The actin filament severing 
activity contributes to create new barbed ends promoting new 
polymerization-competent filaments (Adrianantoandro and Pollard, 2006; 
Pavlov et al., 2007). Similarly, PtdIns(4,5)P2 is involved in regulation of 
profilin and gelsolin, which play a central role in cytoskeleton remodelling 
and actin dynamics. The interaction between PtdIns(4,5)P2 and profilin 
inhibits the activity of profilin as actin-monomer sequestering, stimulating 
actin polymerisation and cytoskeleton remodelling (Saarikangas et al., 
2010). In particular profilin stimulates the incorporation of globular actin 
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in the actin filaments promoting their elongation. In parallel the ARP2/3 
complex (Actin Related Proteins) associates to the side of a “Mother” 
filament creating a new nucleation site which initiates a branching 
filament (Nurnberg and Grosse, 2011). Equally, PtdIns(4,5)P2 inhibits 
gelsolin actin filament severing activity by recruiting this protein to the 
plasma membrane (Saarikangas et al., 2010).  
 
1.1.1.2 PtdIns(4,5)P2 and membrane trafficking  
PtdIns(4,5)P2 is also directly involved in exocytosis (Martin et al., 1998), 
acting on plasma membrane proteins such as Ca
2+
-dependent activator 
protein for secretion (CAPS) and on vesicle proteins such as 
synaptotagmin (Di Paolo and De Camilli, 2006). Furthermore, 
PtdIns(4,5)P2 appears to be required in the ATP-dependent priming 
process of neurosecretory vesicles. During the exocytosis PtdIns(4,5)P2 is 
locally and transiently depleted by a PLC-dependent hydrolysis and is not 
detected on the membrane of the fusing granules (Hammond et al., 2006; 
Hammond and Schiavo, 2006).  
Exocytosis is often coupled to compensatory endocytosis, which is 
dependent on PtdIns(4,5)P2. Compensatory endocytosis can occur through a 
clathrin-mediated mechanism or through alternative mechanisms which do 
not involve complete vesicle fusion or clathrin-mediated vesicle recycling 
(Gundelfinger et al, 2003). PtdIns(4,5)P2 interacts with some endocytic 
clathrin adaptors such as AP-2,  P180/CALM and epsin and binds to many 
other endocytic factors such as dynamin, which controls the ﬁssion 
reactions. Other actions of PtdIns(4,5)P2 in endocytosis reflect its effects on 
the actin cytoskeleton, which is implicated in all internalization pathways 
(Di Paolo and De Camilli, 2006). 
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1.1.2 Phosphatidylinositol-3,4,5-trisphosphate, PtdIns(3,4,5)P3 
Phosphatidylinositol-3,4,5-trisphosphate, PtdIns(3,4,5)P3, is a well 
characterised second messenger. Indeed PtdIns(3,4,5)P3 is barely 
detectable in resting normal cells but its amount increases transiently in 
stimulated cells. PtdIns(3,4,5)P3 levels increase upon activation of some 
members of the family of enzymes phosphoinositide 3-kinase (PI3K), 
which phosphorylates PtdIns(4,5)P2 on position 3. PI3K is a family of 
enzymes, comprising eight mammalian isoforms grouped into three 
classes and PtdIns(3,4,5)P3 is the main in vivo product of class I isoforms. 
Class I A consists of a catalytic subunit and a regulatory subunit. The 
catalytic subunits consist of p110α, p110β, or p110δ, and are the product 
of three genes PIK3CA, PIK3CB and PIK3CD. The regulatory subunits 
consist of p85α, p85β or p55γ. Class I B consists of only one catalytic 
subunit, p110γ, and two regulatory units, p84 and p101. PIK3CA is 
frequently mutated in cancers, and around eighty percent of these 
mutations occur in the helical or kinase domain of the enzyme leading to 
gain of function p110 activity (Courtney et al., 2010; Wong et al., 2010). 
The levels of PtdIns(3,4,5)P3 are negatively regulated by the phosphatase 
tensin homology protein (PTEN), which dephosphorylates PtdIns(3,4,5)P3 
in position 3 and therefore switches off the PI3K-activated pathway. 
PTEN is the second most frequently mutated gene in human cancer 
following TP53 (Yuan and Cantley, 2008; Kok et al., 2009; Carracedo and 
Pandolfi, 2008). The lipid phosphatase activity is critical for PTEN 
tumour suppressor function. Therefore loss of PTEN activity leads to 
uncontrolled activation of the PI3K pathway, and the subsequent 
accumulation of PtdIns(3,4,5)P3 leads to cell transformation.  
1.1.2.1 PtdIns(3,4,5)P3-dependent AKT and PLC1 activation 
Accumulation of PtdIns(3,4,5)P3 has been observed in many cancers. For 
this reason the PtdIns(3,4,5)P3-dependent  pathway has been intensively 
studied. The main effector activated downstream of PtdIns(3,4,5)P3 is the 
protein kinase PKB/AKT, which controls different cellular functions. 
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AKT possesses a pleckstrin homology (PH) domain which specifically 
binds PtdIns(3,4,5)P3 and PtdIns(3,4)P2, both produced by PI3K. The PH 
domain- PtdIns(3,4,5)P3 interaction recruits AKT to the plasma membrane 
and this interaction causes a conformational change leading to its 
activation (Alessi et al., 1997; Sarbassov et al., 2005; Bellacosa et al., 
2005; Calleja et al., 2007). At the plasma membrane, 3-phosphoinositide-
dependent-protein-kinase-1 (PDK1) and mammalian target of rapamycin 
(mTOR), in particular the mTOR complex 2 (mTORC2), phosphorylates 
AKT at its residues in Thr308 and Ser473 respectively. The 
phosphorylation of AKT by PDK1 is PtdIns(3,4,5)P3-dependent (Alessi et 
al., 1997). In particular PDK1 possesses a PH domain which binds 
PtdIns(3,4,5)P3. This interaction allows AKT and PDK1 to co-localise at 
the plasma membrane and it is required for optimal phosphorylation of 
AKT (Waugh et al., 2009). Mice expressing a PDK1 mutated form unable 
to bind phosphoinositides present a strongly reduced AKT activation, 
insulin resistance and hyperinsulinaemia (Bayascas et al., 2008). Once 
phosphorylated, AKT activates different downstream effectors. AKT is 
involved directly and indirectly in many cellular processes, such as cell 
proliferation, growth and cell motility. For example the AKT-induced 
FOXO phosphorylation leads to the inhibition of the transcription of 
p21KIP and retinoblastoma-like-2, both inhibitors of cell cycle 
progression, and therefore it promotes progression through the cell cycle 
(Manning et al., 2007; Zhang et al., 2011). Furthermore activated AKT 
phosphorylates the pro-apoptotic Bcl-2 family member BAD, which is 
inactive in the phosphorylated form, and MDM2 that induces p53 
degradation (Wymann 2008; Duronio 2008). PtdIns(3,4,5)P3-mediated 
AKT activation leads to stimulation of cell growth through mTOR 
activation, which is one of the major effectors in tumourigenesis. Also 
PtdIns(3,4,5)P3 contributes to cell migration and cytokinesis. Indeed, 
another downstream effector of PtdIns(3,4,5)P3 is Phospholipase C 
gamma 1 (PLC) that translocates to the plasma membrane after cellular 
stimulation with growth factors such as EGF or PDGF in a PtdIns(3,4,5)P3 
dependent manner (Falasca et al., 1998). PLC1 plasma membrane 
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translocation is triggered by the PH domain which specifically binds the 
PtdIns(3,4,5)P3 and is essential for its activation.  
1.2 Phospholipase C (PLC) 
Historically, phospholipase C (PLC) was identified as an important 
enzyme involved in phosphoinositide metabolism (Hokins 1953, Michell 
1975). It was only in the 80’s that the link between the water soluble PLC 
product Ins(1,4,5)P3 and the release of calcium from intracellular stores 
was identified (Streb et al., 1983; Irvine et al., 1986). Several different 
PLC isoforms are currently known (see chapter 1.2.5), sharing common 
regions/domains, called X and Y flanked by EF motifs, which form the 
conserved catalytic domain. However different protein modules, such as 
PH domains or other protein binding modules are specific to each distinct 
isoform and are responsible for the different mechanisms of enzymatic 
activation and regulation. The following chapters will focus on the 
functions of domains common to all PLC isoenzymes. 
 
1.2.1 Catalytic domain 
The PLC isoenzymes catalyze the hydrolysis of the phosphodiesteric bond 
between the phosphoinositol headgroup and diacylglycerol (Figure 3A) 
(Bunney and Katan, 2010). The catalytic domain possesses alternating -
helixes and -sheets and resembles an incomplete triose-phosphate-
isomerase (TIM) / barrel (Figure 1.3B). The enzymatic reaction is 
catalysed by specific aminoacids in the catalytic domain which are 
conserved among the different family members (Hondal et al., 1998). In 
particular, production of a cyclic-1,2-inositol,4,5-bisphosphate 
intermediate is catalysed by histidine 392, which binds to the proton of the 
2-Hydroxyl of the inositol headgroup residues that acts as general base 
creating a cyclic intermediate (Essen et al., 1997). This intermediate is 
quickly hydrolysed in Ins(1,4,5)P3, while His-311 protonates the DAG 
leaving group (Figure 1.3A). The catalytic domain has been shown to be 
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able to bind calcium ions. Calcium binding has been reported to be 
essential for catalytic activity since single mutation of the calcium binding 
Glu-341 within the TIM barrel inhibits calcium binding to the catalytic 
domain impairing enzymatic activity (Cheng et al.1995). 
 
Figure 1.3: A) Enzymatic reaction catalysed by PLC isoenzymes (adapted 
from Bunney and Katan, 2010); B) Crystal structure of PLC1 (PH 
domain excluded) (Rebecchi et al, 2000) 
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1.2.2 EF Motifs 
The N-terminal domain consists of an EF motif, a Helix loop Helix 
domain found in all the PLCs and common to calcium binding proteins. 
PLC isoforms can have up to four EF domains organised in paired units 
(Nterm-EF1-EF2-EF3-EF4-Cterm) (Figure 1.4). The role of PLC EF domains 
in calcium binding is controversial. Indeed the EF3 and EF4 motifs do not 
show metal binding during structural analysis. EF1 and EF2 contain 
calcium ligands (Essen et al.,1996). However there is no evidence 
showing that EF motifs in PLC isoforms bind to calcium ions. Deletion of 
EF3 and EF4 in PLC1 completely blocks PLC enzymatic activity, 
indicating that this protein domain is essential for the correct function of 
the catalytic activity together with the TIM barrel domain (Nakashima et 
al., 1995).  
 
Figure 1.4: Structure of EF motifs of PLC1 isoform (Essen et al., 1996) 
 
 
1.2.3 C2 domain  
The C2 domain is a protein module of ~120 aminoacids present in 
different enzymes such as PKCs cPLA2 and PLCs. C2 domains possess 8 
antiparallel -sheets, which define three loops essential for calcium 
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binding (Figure 1.5). It has been proposed that C2 domain of PLCs can 
interact with phospholipids facilitating the tethering to the plasma 
membrane of the enzymes. Two possible mechanisms have been 
proposed: the bridging mechanism that involves calcium ions being 
sandwiched between the C2 domain and the phospholipid (Swairjo et al 
1995). Alternatively, it has been proposed that calcium binding does not 
cause conformational changes but it is essential for electrostatic potential 
change essential for a calcium-mediated binding of the target molecule 
(Newton et al.,1995). Therefore the C2 domain, together with the PH 
domain when present, could represent a second site for the binding of 
phosphoinositides important for the correct orientation of the catalytic 
domain (Bunney and Katan, 2010). 
 
Figure 1.5: Structure of the C2 domain of PLC1 (Essen et al., 1996) 
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1.2.4 PH domains 
The PH domain was first identified in the protein pleckstrin, the main 
substrate of PKC. Currently several proteins have been discovered 
containing the PH domain (Musacchio et al., 1993; Lemmon et al., 1996); 
among them PLC, PLC, PDK1 and AKT. The PH domain is a protein 
module consisting of ~120 amino acids with no catalytic activity. The 
sequence identities among the different PH domains are not sufficient to 
support structural homology. However it has been found that the 
secondary and tertiary structures are conserved among the different PH 
domains (Lemmon et al., 1995). Each domain consists of two nearly 
orthogonal antiparallel -sheets of four and three strands and an 
amphipathic -helix localised at the C-terminal portion of the domain 
(Figure 1.6). Each PH domain presents a well-defined charge polarisation. 
In particular the and  loops represent the most variable 
region in length and sequence. These regions define the positively charged 
portion needed for ligand interaction and recognition and define the 
binding pocket which presents the sequence motif KXn(K/R)XR 
(Ferguson et al.,1995) . The lysine (K) and arginine (R) represent the 
positive charged core responsible for the interaction with the phosphate 
groups. The side chains are responsible for further interactions which 
defines the identity of the ligand and the binding affinity (Lemmon and 
Ferguson, 2000).    
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Figure 1.6: PLC1 PH domain structures (adapted from Lemmon et al., 
1996) 
It has been noted that the majority of proteins hosting PH domains require 
membrane association to carry out their functions. The original idea was 
that PH domains were involved in protein-protein interactions, in similar 
manner to SH2 and SH3 domains (Gibson et al., 1994). Initial evidence 
suggested the  subunits of the heterotrimeric G protein as a potential PH 
domains target (Touhara et al., 1994; Tsukada et al., 1994). However in 
vitro experiments using lipid vesicles identified the phosphoinositides as 
the main target of PH domain (Harlan et al.1994). Since the original 
identification, other PH domains were shown to bind with high affinity 
and stereospecificity for specific phosphoinositides headgroups (Kavran et 
al., 1998). The PLC PH domain was identified to specifically interact 
with PtdIns(4,5)P2, leading to a plasma membrane recruitment of the 
enzyme and increasing its processivity (Garcia et al., 1995; Lemmon et 
al., 1995). However few PH domains, such us PLC1 PH domain, bind to 
phosphoinositides with high specificity. Most PH domains, such as PLC1 
PH domain can bind several phosphoinositides with different affinity and 
low specificity. The phosphoinositides/PH domain interaction has been 
demonstrated to be required for protein translocation to the plasma 
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membrane. A `tandem model' has been proposed as potential mechanism 
that stabilises a weak interaction of PH domain through a co-operation 
with other domains of the host protein (Maffucci and Falasca, 2001). The 
PLC1 PH domain was demonstrated to be essential for PLC1 plasma 
membrane recruitment and subsequent enzyme activation (Falasca et al., 
1998), together with PLC1 interaction with the phosphorylated EGF 
receptor.  
The PH domains bind to the phosphoinositide head groups but also to the 
soluble isolated head groups of phosphoinositides. The PH domain of 
PLC1, for example, binds to the soluble head group of PtdIns(4,5)P2, D-
myo-Ins(1,4,5)P3. Similarly Grp-1 PH domain binds with high affinity to 
D-myo-Ins(1,3,4,5)P4, the soluble PtdIns(3,4,5)P3 head group. 
Interestingly, the isolated head group may show a higher affinity for the 
PH domain binding compared to the head group membrane-embedded. 
This is the case of Ins(1,4,5)P3, which is able to bind to PLC1 PH 
domain with an higher affinity (KD=0.21 M) compared to PtdIns(4,5)P3 
(KD=1.66 M), leading to the displacement of PLC1 when Ins(1,4,5)P3 is 
generated, in an auto-inhibitory mechanism (Lemmon et al., 1995; Kavran 
et al., 1998, Lemmon, 2008).  The properties of PH domains to bind to the 
soluble phosphoinositide head groups opened the field for a novel 
strategy, aiming to antagonise the activation of PH domain containing 
proteins by inhibiting their translocation to the plasma membrane. Indeed 
since different PH domains present different affinities for different inositol 
phosphates, it may be possible to specifically block a particular 
membrane-targeted protein using inositol phosphate derivative 
compounds. 
 
1.2.5 PLC Isoenzymes 
Several PLCs are known, diverging for aminoacid sequence, structure, 
regulation and tissue localisation. In particular the PLC isoenzyme family 
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is composed of the following members, which are present in the tissues 
listed in Table 1.1.  
Member Isoforms Tissue expression (Suh et al., 
2008) 
PLC PLC1, PLC2, 
PLC3, PLC4 
PLC1: Brain, intestine, 
prostate, ovary 
PLCMainly hematopoietic 
tissue; present in ovary and brain 
PLCBrain, liver, parotid 
gland, skin, ovary 
PLCMainly brain 
PLC PLC1, PLC2 PLC1: ubiquitous 
PLC2: Hematopoietic tissue 
PLC PLC1 
PLC3 
PLC4 
PLC1: Brain, lungs, muscles, 
testis 
PLC3: Brain, heart, muscles, 
testis, kidney 
PLC4: Ubiquitous with high 
levels of expression in brain, 
muscles and kidney 
PLC PLC1a, PLC1b High expression in heart; present 
in brain, lungs, colon 
PLC PLC Sperm-specific 
PLC PLC1, PLC2 
 
High level in brain and kidney; 
low level in lungs, intestine and 
pancreas 
 
Table 1.1: PLC family members and respective tissue expression 
Beside the tissue localisation, the most important difference among the 
PLC isoenzymes is the modality of their activation and their structure. 
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Schematic structures of the different PLC isoenzymes are illustrated in 
Figure 1.7. 
 
 
Figure 1.7: Schematic representation of PLC isoenzymes structures 
showing the differences in protein domains present in the family members 
(adapted from Bunney and Katan., 2010) 
 
Different extracellular stimuli activate distinct PLC isoenzymes through 
different molecular mechanisms. However some stimuli can activate 
different PLC isoenzymes simultaneously, which complicate the 
understanding of the role of each single isoform. In this chapter the main 
mechanism of activation of all PLCs, except PLC, are described. PLC 
will be discussed in the following chapter 1.3.  
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PLC 
The PLCs are activated by the rhodopsin superfamily membrane 
receptors which respond to a plethora of stimuli. These receptors belong 
to the class of G-protein-coupled-receptor (GPCR) and activate G-proteins 
to activate signal transduction. Among the different PLCs, PLC but not 
PLC or PLC are activated by G-proteins (Rebecchi and Pentyala, 
2000). The G-proteins form a heterotrimeric complex in the inactive GDP-
binding state formed by G, G and G subunits. Upon stimulation of the 
receptor, the G subunit is activated through exchanging GDP with GTP. 
This event causes the dissociation of G from G. The GTP-bound 
Gsubunit, together with the G heterodimer, activate PLC isoenzymes. 
It has to be pointed out that within the PLC isoenzymes, each enzyme 
shows different responsiveness to the different subunits, indicating a 
subtle regulation of their differential activation (Rebecchi et al., 2000). 
PLC1 is the least sensitive to G activation and PLC4 is completely 
insensitive to G (Figure 1.8). Recent works demonstrate that PLC can 
also be activated by the Rho-GTPase family member Rac, which is able to 
interact with the PH domain (Snyder et al., 2003). 
 
 
 
Figure 1.8: Regulation of PLC by GPCR (Rebecchi et al., 2000)  
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PLC 
A different mechanism controls the activation of PLC isoenzymes. 
PLCs are the most sensitive to intracellular calcium variation compared 
to other PLC isoenzymes. PLC, the most studied of its family, can be 
activated by calcium and in turn it can amplify the calcium signal. PLC1 
can also be activated by adrenergic receptors through atypical G-
protein (Gh) and by Gi coupled receptor agonists (Murthy et al., 2004) and 
RhoGAP which stimulates PLC1 activity up to 10-fold (Rebecchi et al., 
2000). 
PLC 
In 2001 a novel group of PLC was identified. PLC isoenzymes are the 
newest and most complex PLC isoenzymes since they present the highest 
number of different protein domains, which regulate their activation 
(Kelley, et al 2001). PLC is activated by Ras family members. In 
particular PLC possesses two RA domains that associate with Ras and 
Rap1 and are essential for PLC activation (Figure 1.9) (Song et al., 
2002). Notably, Ras-mediated PLC activation induces translocation of 
the enzyme to the plasma membrane, while Rap1-induced activation 
recruits the enzyme to the perinuclear region (Song et al., 2002). 
Furthermore the PLC family presents a CDC25 homology domain. The 
CDC25 homology domain was first identified in the CDC25 protein 
isolated from S. cerevisiae, and possesses guanine nucleotide exchange 
(GEF) factor properties for RAS proteins. The CDC25 domain of PLC 
has GEF activity towards RAP1, but not towards any other Ras members,  
therefore it is able to stimulate Rap1 GTP binding and activation which in 
turn activates PLC activity and perinuclear translocation of the enzyme 
(Jin et al., 2001). In addition to Ras family members, PLC are activated 
by a plethora of stimuli. Ligands able to bind GPCRs, such as 
lysophosphatidic acid or sphingosine-1-phosphate, can activate 
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PLCisoenzymes together with PLC isoenzymes. Growth factors such 
as EGF, activate PLC as well as the PLC isoforms (Citro et al., 2007).  
 
 
Figure 1.9: Schematic mechanism of activation of PLC showing the 
activation of the enzyme by GPCR through G subunit and RAP1 and by 
RTKs which are able to activate PLC through activation of RAS and 
RAP1. The CDC25 homology domain of PLC, illustrated in the figure, 
acts as a GEF for RAP1, increasing its activation, which in turn 
contributes to a sustained activation of PLC  
PLC 
PLCis a sperm-specific PLC isoform. Recombinant protein injected in 
egg cells causes calcium oscillation. PLC isoenzyme is the shortest of the 
family and lacks the PH domain. The lack of PH domain, important for 
phosphoinositide binding, raised the question of how the enzyme is able to 
maintain processive substrate hydrolysis. It has been shown that the C2 
domain is sufficient for membrane tethering of the enzyme and its deletion 
inhibits calcium oscillations upon PLC activation (Suh et al., 2008). 
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PLC 
PLCactivation is still not completely understood. The plasma membrane 
localisation of the enzyme is independent from extracellular stimuli and is 
dependent on the PH domain. Indeed deletion of PH domain induces 
cytosolic localisation of the enzyme. Recent data showed that PLC1 is 
involved in the signal amplification downstream of GPCR and is activated 
by intracellular calcium. Indeed LPA-induced calcium release was 
inhibited in PLC1 knockdown cell lines (Kim et al., 2011).  
 
1.3 PLC
The PLC subgroup includes two members: PLC1 and PLC2. PLC1 is 
ubiquitous, while PLC2 is mainly expressed in the hematopoietic system 
although it was originally identified in brain tissues (Rebecchi et al., 2000; 
Suh et al, 2008). The detailed structure of PLC is illustrated in Figure 
1.10.  
 
Figure 1.10: Representation of PLC isoenzymes with their different 
protein domains and the position of known phosphorylation sites 
(Rebecchi et al., 2000).  
 
PLC isoenzymes possess some unique protein modules that are essential 
for enzyme regulation. The X and Y domains, together with the EF 
domain are common to the other PLC isoforms. As indicated in Figure 
1.10 PLC members also present two SH2 domains, one SH3 domain, a 
split PH domain and the N-terminal PH domain (Rebecchi et al., 2000). 
This long region is inserted between the X and Y domains which form the 
catalytic domain and it has an important role in regulating PLC catalytic 
activity (Katan and Williams, 1998). The SH2 domain (Src homology 
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domain 2) is responsible for protein-protein interaction, recognising 
specific phosphorylated on tyrosine. Indeed the SH2 domains are essential 
for interaction with phosphorylated tyrosine residues in activated tyrosine 
kinase receptors, which dimerise upon ligand engagement and get auto-
phosphorylated in tyrosine residues. The SH3 domain recognizes and 
interacts with proteins expressing polyproline sequences. PLCfamily 
members possess an N-terminal PH domain (see chapter 1.2.4) and a split 
PH domain. The N-terminal PH domain is essential for PLC1 activation 
and binds PtdIns(3,4,5)P3 (with a KD=1M) (Falasca et al.,1998). The 
synthesis of PtdIns(3,4,5)P3 increases the Ins(1,4,5)P3 production and the 
following intracellular calcium release, potentially via enhanced PtdIns(4, 
5)P2 substrate availability due to PtdIns(3,4,5)P3-mediated recruitment of 
PLC1 to the plasma membrane through the PH domain (Bae et al., 1998; 
Rameh et al., 1998).  The split PH possesses its two halves flanking the 
SH2-SH2-SH3 domains and its function is still not completely 
understood. Recent data showed that the split PH domain is required for 
the direct interaction of PLC1 with the transient Receptor Potential C3 
(TRPC3) chanel and is not involved in phosphoinositides binding (van 
Rossum et al, 2005) (Wen et al., 2006). However another report showed 
that the split PH domain of PLC1 is involved in phosphoinositides 
binding, in particular in PtdIns(4)P and PtdIns(4,5)P2 binding (Kim et al., 
2004).  
 
1.3.1. Growth factor-induced stimulation of PLC1 
PLC family is composed of two members: PLC1 and PLC2. Although 
PLC1 is ubiquitary expressed, PLC2 is expressed mainly in the 
hematopoietic tissue. This introductory chapter will focus on PLC1 
isoenzyme, which was the focus of my PhD project.  
PLC1 is activated by different growth factors such as EGF, PDGF and 
FGF, which activate their respective tyrosine kinase receptors (TKR) 
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(Nishibe et al., 1990; Mohammadi et al., 1992; Rhee, 2001). Engagement 
of the ligand to the TKR induces the dimerisation of the receptor and its 
auto-phosphorylation in tyrosine residues. The phosphorylated receptors 
recruit PLC1 and this allows TKRs to phosphorylate PLC1 in specific 
tyrosine residues. The protein-protein interaction between PLC1 and 
TKRs is promoted by the SH2 domain present in the PLC family, which 
recognizes the phosphotyrosine residues on the activated TKRs. Both SH2 
domains are involved in the interaction, with a more specific role for the 
N-terminal SH2 compared to the C-terminal SH2 domain (Chattopadyay 
et al., 1999; Poulin et al., 2000). Indeed mutation of the C-terminal SH2 
domain, which inhibits the SH2 binding to its target, causes a slight 
reduction of PLC1 phosphorylation and activation. On the contrary, 
mutation targeting the N-terminal SH2 completely inhibited PLC1 
phosphorylation and activation. Therefore, the N-terminal-SH2 and the C-
terminal-SH2 domains of PLC1 play different roles in PLC1 regulation 
(Stoica et al., 1998).  
Growth factor stimulation induces PLC1 recruitment to the membrane 
and interaction with TKRs, which in turn phosphorylate PLC1 at specific 
tyrosine residues: Tyr 771, Tyr 783 and Tyr 1253. The phosphorylation is 
essential for PLC1 activation (Kim et al., 1990; Kim et al. 1991; Bunney 
and Katan, 2010) although plasma membrane recruitment through the PH 
domain is essential (Falasca et al., 1998). Mutation of Tyr 783 to 
phenylalanine (Phe) completely inhibits PLC activity upon EGF or PDGF 
stimulation. On the contrary substitution of Tyr 1253 or Tyr 771 causes 
limited or no inhibition. These data indicate that phosphorylation at Tyr 
771 and Tyr 1253 is dispensable, whereas phosphorylation at Tyr 783 is 
essential for PLC1 activation (Kim et al., 1991; Sekiya et al., 2004). 
Evidence showed that PLC1 is maintained in an auto-inhibitory 
conformation that keeps the enzyme in an inactive form in the absence of 
extracellular stimulation. The inhibition is promoted by the X-Y linker, 
constituted by SH2-SH2-SH3 domain that occludes the access of the 
substrate to the catalytic domain. In particular it has been demonstrated 
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that a minimal inhibitory protein module consists of the C-terminal-SH2 
and that phosphorylation of Tyr 783 is essential for reliveing of the auto-
inhibitory interaction (Gresset et al., 2010) (Figure 1.11). A relative 
stabilising contribution to the auto-inhibitory interaction has been 
attributed to the split PH domain. Indeed mutation of this domain slight 
increases the activity of the purified PLC enzyme in vitro (Gresset et al., 
2010).     
 
 
 
 
Figure 1.11: Relief of the auto-inhibitory interaction. The catalytic 
domain (represented in grey) is inhibited by the interaction with the C-
SH2 (purple cylinder). Phosphorylation of the TRK provides the docking 
site for the N-SH2 (blue cylinder). The following phosphorylation (red 
sphere) induces a conformational change that releases the catalytic domain 
from the auto-inhibitory interaction (Gresset et al., 2010). 
 
 
 
1.3.2 PI3K and PLC1 activation 
The mechanism described in the previous chapter explained the 
mechanism of PLC1 activation by TKRs. However it has to be noted that 
the recruitment to the membrane is not only due to the interaction of N-
 
 
 
42 
 
terminal-SH2 with the receptor. The PLC1 PH domain is essential for the 
growth factor-induced membrane translocation of PLC1. As described in 
chapter 1.2.4, it has been shown that PLC1 PH domain specifically binds 
to the PI3K product PtdIns(3,4,5)P3 (Falasca et al., 1998). Specifically, 
mutation of the 3/4 loop of the PH-PLC1 completely abolishes the 
membrane translocation of PH-PLC1 upon PDGF stimulation. Therefore 
the PH domain is essential for PLC1 plasma membrane recruitment 
(Falasca et al., 1998).  
By expressing the GFP-tagged PLC1 PH domain in live cells, it is 
possible to follow the growth factor-induced translocation of the PH 
domain in living cells. The GFP-PH translocation to the plasma membrane 
starts within 3-5 minutes from stimulation with PDGF and becomes more 
evident within 15 minutes. It localizes with ruffles-like structures and 
gradually disappears from the plasma membrane after 30 minutes from 
stimulation (Falasca et al., 1998). Inhibition of PI3K using the irreversible 
PI3K inhibitor wortmannin blocks the PDGF-induced translocation of 
overexpressed recombinant GFP-PH-PLC1. This study demonstrated that 
there is a crosstalk between PLC1 and PI3K pathway and added 
important information to understand the mechanism of PLC1 activation 
(Figure 1.12). Furthermore the observation that PH/PtdIns(3,4,5)P3 
interaction is essential for PLC1 activation suggested the possibility of 
inhibiting PLC1 activation using molecules that block PLC1 
translocation by competing with this interaction. 
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Figure 1.12: Crosstalk of PI3K/PLC1: PLC1 and PI3K are activated by 
growth factors. Binding of PtdIns(3,4,5)P3 to PLC1 the PH domain and 
the interaction of  SH2 domains of PLC1 with phosphotyrosine of TKRs 
lead to translocation of PLC1 to the plasma membrane and its activation 
(Falasca et al., 1998). 
1.3.3 PLC1 activation and integrins 
Extracellular Matrix Components (ECM) represent the main tissue’s 
mechanical support and a barrier for cell migration. ECM components 
provide the substrates for cellular migration triggering outside-in 
signalling promoting cell migration. Integrins are a family of 
glycoproteins, composed of -subunits and -subunits, which are 
responsible for cellular interaction with ECM components. Integrins form 
specific heterodimers with different binding specificity to ECM 
components. Each heterodimer presents an extracellular domain required 
for ECM component engagement and an intracellular domain responsible 
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for the propagation of the outside-in signal (Figure 1.13) (Friedl and Wolf, 
2003). 
 
Figure 1.13: Representation of integrins heterodimer (adapted from 
Cooper, 2000).  
The outside-in signal activated by engaged integrins leads to activation of 
downstream pathways that control survival and migration. The focal 
adhesion kinase (FAK) is phosphorylated after integrin engagement with 
ECM components. FAK presents a FERM domain able to interact with 
growth factor receptors and the -integrin subunit. Following integrin 
engagement FAK gets autophosphorylated at Tyr 397, the main 
phosphorylation site of the protein (Sieg et al., 2000). This activated 
conformation promotes the interaction with the kinase Src which is 
mediated by the Src SH2 and SH3 domains that recognise FAK 
phosphotyrosine and FAK proline-rich sequence respectively (Thomas et 
al., 1998; Frame et al., 2010). Therefore ECM-integrin engagement 
activates FAK and Src together with other effectors such as PI3K and 
ERK, promoting cell survival and cellular migration. PLC1 is also able to 
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interact with the phosphorylated form of FAK through its C-terminal SH2 
domain. This interaction stimulates the tyrosine phosphorylation of PLC1 
and its enzymatic activity, although FAK is not directly involved in 
PLC1 phosphorylation (Zhang et al., 1999). ECM-integrins engagement 
activates PLC1, as indicated by PLC1 tyrosine phosphorylation in cells 
seeded on Matrigel or fibronectin (Langholz et al., 1997; Tvorogov et al., 
2004) and it is important for cell migration and changes in morphology 
upon integrin engagement (Kassis et al 1999; Jones et al., 2005). Indeed, 
an integrin-blocking antibody inhibits PLC1 phosphorylation. Similarly, 
PLC1 inhibition through specific siRNAs or using the pan-PLC chemical 
inhibitor U73312 blocks the integrin induced cellular morphology change 
and cell migration. It has been demonstrated that the ECM-integrin 
induced PLC1 activation occurs downstream of Src kinase, which 
phosphorylates PLC1 in Tyr 783. Indeed inhibition of Src with the 
specific Src-inhibitor PP2, blocks Ins(1,4,5)P3 production and calcium 
release (Jones et al., 2005) (Figure 1.14). Furthermore PLC1 and Src co-
immunoprecipitate in a complex together with GIT1, that acts as a 
molecular adapter between PLC1 and Src (Haendler et al., 2003).  
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Figure 1.14: Model of ECM-integrin-induced PLC1 activation (adapted 
from Jones et al., 2005) 
 
1.3.4 Biological functions of PLC1 
In the previous chapter the different modalities of PLC1 activation were 
described. This chapter will focus on the role of PLC1. Mice PLC1-/- are 
not viable and die after the first week of gestation. In particular mice 
PLC1-/- develop normally at E8.5, but at E9.5 are markedly reduced in 
size and die in the following stages. These data indicate that PLC1 plays 
an essential role in development (Ji et al., 1997). Fibroblasts isolated from 
these embryos proliferate normally upon addition of different mitogenic 
factors but fail to mobilize calcium upon EGF stimulation (Ji et al., 1998). 
However other reports showed that PLC1 promotes cell growth in 
fibroblasts in a catalytic-independent mechanism (Huang et al., 1995). In 
particular the SH3 domain of PLC1 has been reported to interact with the 
Ras exchange factor SOS1, promoting Ras activation (Kim et al., 2000). 
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Similarly the SH3 domain of PLC1 interacts with the protein kinase Jak2 
in a process implicated in the modulation of growth hormone signalling 
(Choi et al., 2006). Several lines of evidence suggest a catalytic-
independent role of PLC1 as guanine nucleotide exchang factor (Ye et 
al., 2002; Choi et al, 2004) and also as a key regulator of agonist-induced 
Ca
2+
 entry (Patterson et al., 2002). Analysis of mouse embryos revealed 
that PLC1 is essential in angiogenesis. Embryos PLC1-/- showed no 
erithropoyesis, reduced vasculogenesis and reduced levels of vascular 
endothelial growth factor (VEGF) receptor expression (Liao et al., 2002). 
Similarly, mutation of the PLC1 orthologue causes defects in arteries 
formation (Lawson et al., 2003) in zebra fish. In umbilical vein 
endothelial cells (HUVEC), FGF-2 activates PLC1 in a PI3K-dependent 
manner. In these cells pharmacological inhibition or downregulation of 
PLC1 inhibits the FGF-2 induced cell migration and the tubulogenesis in 
vitro (Maffucci et al., 2009). Altogether these data indicate that, although 
PLC2 is the PLC isoform specifically expressed in the hematopoietic 
tissue, PLC1 is essential in early stage of development and the two 
isoforms have not overlapping roles.    
It has been reported that PLC1-/- fibroblasts show a significant decrease 
in fibronectin-induced adhesion compared to normal fibroblasts 
(Tvorogov et al., 2005). Furthermore inhibition of PLC1 by siRNA or 
pharmacological inhibition affects cell morphology of cells seeded on 
ECM components such as Matrigel. In particular both HUVEC 
endothelial cells and cancer cells such as BE (colon carcinoma) and 
DU145 (prostate cancer) showed a rounded morphology when plated on 
Matrigel upon PLC1 knockdown or after treatment with U73122 (Jones 
et al., 2005). PLC1 plays an important role in cell movement regulation 
and cytoskeleton remodelling upon integrin engagement or growth factor 
stimulation. Inhibition of PLC1 reduces growth factor-induced cell 
motility in cancer cell lines and endothelial cells (Kassis et al., 1999; 
Maffucci et al., 2009). EGF-induced motility has been extensively 
investigated in cancer cell lines. EGF stimulation induces cytoskeleton 
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rearrangement, stimulating actin filament polymerisation (Chan et al., 
1998). As described in chapter 1.1.1.1 PLC1 is involved in the regulation 
of actin polymerisation activating actin binding proteins (ABPs) such as 
cofilin, profilin and gelsolin through hydrolysis of PtdIns(4,5)P2 (Wang et 
al., 2007). PLC1 inhibition blocks the cofilin activity and inhibits the 
early actin polymerisation and the generation of new barbed ends (Figure 
1.15) (Mouneimne et al., 2004). During chemotaxis, the asymmetric actin 
polymerization generates a cell polarity towards the stimulus, essential for 
chemotaxis and for cell directionality. Chemotaxis assays showed that the 
normal EGF-induced polymerisation of actin filaments at the leading edge 
of the cells, which induces a well-defined cell polarity, is completely 
blocked following inhibition of PLC1. Indeed cells treated with U73122 
failed to develop a well-defined cell polarity indicating that PLC1 is 
essential for protrusion formation upon EGF stimulation (Jones et al., 
2005). The activation of PLC1 at the leading edge is PI3K dependent. 
Indeed inhibition of PI3K pathway inhibits PLC1 translocation at the 
leading edge (Piccolo et al., 2002).  
 
 
Figure 1.15: Model of cofilin activation (adapted by Wang et al., 2007) 
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1.3.5 Overview of the cell migration process.  
The ability of cells to migrate and to move towards a chemo-attractant is 
an important process occurring in many physiological conditions such as 
embryogenesis, wound healing and the immune system response. Cell 
migration and invasion play also a very important role in cancer, allowing 
tumour cells to invade the surrounding tissue and eventually leading to 
dissemination of cancer cells during the metastatic process. Extracellular 
Matrix Components (ECM) represent the main tissue’s mechanical 
support and a barrier for cell migration. Integrins play an essential role in 
ECM-induced signalling (see chapter 1.3.3), and growth factors stimulate 
cell motility. During cell migration, integrins become locally enriched in 
regions of the plasma membrane defined as focal complexes which 
eventually evolve in focal contact regions (Burridge and Chrzanowska-
Wodicka, 1992). The composition of focal complex depends on the 
relative abundance of the different ECM components and results in local 
enrichment of integrin heterodimers accordingly to the different ECM 
components available. Upon integrin engagement and growth factor 
stimulation, the cytoskeleton remodelling machinery becomes activated. 
In this process PI3K, PLC1 and the Rho family of small GTPase play an 
essential role stimulating cytoskeleton remodelling and the formation of 
cell protrusion at the leading edge of the cells (see chapter 1.1.1.1 and 
1.3.4). The ECM-engaged integrins are able to associate with -actinin, 
tensin, vinculin that bind integrins directly to the cytoskeleton, creating a 
direct link between focal adhesions and cytoskeleton (Figure 1.16-1,2) 
(Zamir and Geiger, 2001). These complexes are essential to generate the 
forces necessary to extend cellular protrusion. During the initial steps, 
when little adhesion is present at the leading edge, actin filament 
elongation extends the leading edge pushing the membrane in an outward 
direction. Movements within the ECM often require proteolysis of the 
ECM itself allowing the cells to create a path of migration. For this reason 
membrane-type matrix metalloproteinase enzymes are required for ECM 
digestion in order to create the space for cellular migration (Figure 1.16-3) 
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(Friedl and Wolf, 2003). Late the contraction driven by myosin II along 
the stress fibres leads to the contraction of the cell body towards the 
leading edge, pushing the cells forward (Figure 1.16-4). The coordinated 
sequence of these steps leads to the movement of the cell on the ECM or 
toward a chemo-attractant. Inhibition of one of these phases results in 
inhibition of cell migration and motility. As described in chapter 1.3.4, 
PLC1 is an important hub in cell motility regulation. Indeed its inhibition 
reduced cell motility upon growth factor and integrin-engagement 
stimulation, due to its important role in regulating the cytoskeleton 
remodelling through the activation of effectors such as Rac1 and cofilin 
(Li et al., 2009; Mouneimne et al.,  2004; van Rheenen et al., 2007).  
 
Figure 1.16: Model of cell migration summarising the process in 4 steps: 
1-pseudopod protrusion at the leading edge, 2-formation of focal contact, 
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3- focalized proteolysis, 4-actomyosin contraction (Friedl and Wolf, 
2003). 
1.3.6 PLC1 and Rac1 
The Rho GTPase family belongs to the Ras superfamily and has an 
important role in cytoskeleton rearrangement and actin polymerisation. 
The small GTPases are guanine-nucleotide-binding proteins which are in 
an “OFF” conformation when bound to GDP but switch to an “ON” 
conformation when bound to GTP. The cycling between the two forms is 
controlled by the activity of GEFs proteins (Guanine Exchange Factor), 
which induces the release of GDP from the small GTPase proteins and its 
replacement with GTP  and GAPs (GTPase activating protein) which 
activate the GTPase activity and induce the hydrolysis of GTP to GDP. 
The Rho family presents, among other members, three subfamilies that 
control different processes within the cytoskeleton remodelling: Cdc42, 
Rac and Rho subclasses. In particular, Rho members are involved in 
formation of stress fiber and focal adhesion, Cdc42 in filopodia 
organisation and Rac in lamellipodia and membrane ruffles formation. 
Rac in particular activates the WASP and WAVE proteins that in turn 
activate the ARP2/3 complex and therefore induce actin nucleation 
(Haesman and Ridley, 2008). These structures are essential for cellular 
migration and motility. Both PLC1 and Rac1 have been shown to 
regulate cytoskeleton remodelling upon EGF stimulation (Wells et al., 
2002; Ridley et al, 1992). A direct link exists between PLC isoforms and 
Rac1. While binding of Rac1 to the split PH domain of PLC2 is 
important for the Rac1-dependent activation of PLC2 (Walliser et al., 
2008), the direct interaction of Rac1 with PLC1 promotes Rac1 
activation (Jones and Katan, 2007). Indeed PLC1 associates with Rac1 
upon EGF stimulation and promotes its activation. The SH3 domain of 
PLC1 is essential for this interaction and mutation of this domain 
abrogates Rac1 binding and its activation (Figure 1.17) (Li et al., 2009). 
Similarly, downregulation of PLC1 inhibits EGF- and serum-induced 
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activation of Rac1. It has been shown that PLC1 is a GEF specific for 
Rac1, which is consistent with the ability of PLC1 to activate Rac1. In 
particular the SH3 domain of PLC1 is responsible for the GEF activity. 
Indeed in vitro assay showed that PLC1 SH3 domain alone induces 
Rac1-GTP binding. (Li et al., 2009). 
 
 
Figure 1.17: Model of EGF-induced Rac1 activation downstream of 
PLC1 
 
1.4 Role of PLC1 in cancer 
As a key downstream effector of EGF receptor (EGFR), PLC1 is likely 
to be involved in tumour progression. EGFR family members are often 
overexpressed in many cancers such as prostate, breast, head and neck 
cancers and many others (Agus et al., 2002; Scagliotti et al., 2004). 
Increased PLC1 expression was reported in breast carcinoma samples 
compared to healthy tissue, although this study did not connect the 
overexpression pattern to any particular stage of the disease (Arteaga et 
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al., 1991). In parallel other studies demonstrated the activation of PLC1 
downstream of EGF. In particular, EGFR overexpression in fibroblasts 
induced PLC1 phosphorylation and increased motility upon EGF 
stimulation. Pharmacological inhibition of PLC1 or expression of a 
PLC1 dominant negative inhibited cell migration but it had no effect on 
EGF-induced mitogenesis, demonstrating the specific role of PLC1 in 
cell motility (Chen et al., 1994).  
Increased cell motility plays an essential role in invasive cancers and 
metastasis. The role of PLC1 in cell invasion was assessed in vivo by 
injecting mice with DU145 prostate cancer cells expressing a PLC1 
dominant negative mutant (PLCz). This dominant negative mutant of 
PLC1 inhibited primary tumour spreading and local invasion. Notably 
PLC1 inhibition had no effect on cell growth confirming the main role of 
PLC1 in cell invasion downstream of EGFR (Turner et al., 1997). Further 
in vitro invasion experiments using different breast and prostate cancer 
cell lines showed the broad role of PLC1 in cell invasion. Indeed 
pharmacological inhibition of PLC1 was able to inhibit in vitro Matrigel 
invasion in all the cell lines tested (Kassis et al., 1999), demonstrating the 
role of PLC1 in cell invasion. These results highlighted PLC1 as a 
potential target to inhibit carcinoma.  
Although these reports provided a “proof of concept” that PLC1 can be 
targeted to inhibit tumour invasion, there was no clear in vivo proof of its 
importance in the metastatic process. The MMTV-PyVmT and TRAMP 
mice models, which respectively express the oncogenic Mice Mammary 
Tumour virus and the Polyoma middle T antigen, develop respectively 
breast cancer and prostate cancer and therefore represent a good model to 
study metastasis arisen from oncogene-induced primary tumour. The 
expression of breast- and prostate-localised PLCz dominant negative 
peptide had no effect on the primary tumour size but decreased the 
invasiveness of primary tumours and, most importantly, reduced 
formation of distant lung metastasis, showing the importance of PLC1 in 
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metastasis development (Shepard et al., 2007). A recent work published 
by our laboratory, in which I contributed as co-author, showed that 
downregulation of PLC1 had no effect on primary xenografted tumour 
whereas it inhibited the development of lung metastases derived from 
human breast cancer cell line MDA-MB-231 injected in the tail vein 
(Figure 1.18A) (Sala et al., 2008). In particular the downregulation of 
PLC1 in the injected MDA-MB-231 was achieved using specific 
shRNAs which were expressed in a stable or tetracycline inducible 
system. The shRNA represents a more specific system compared to the 
dominant negative system used in previous works. Furthermore the 
inducible downregulating system allowed us to downregulate PLC1 after 
the injection. Mice injected with breast cancer cells MDA-MB-231 stably 
downregulated for PLC1 showed inhibition of lung metastases 
development compared to mice injected with cell expressing PLC1 (Sala 
et al., 2008). To further understand the role of PLC1 in metastasis, mice 
were injected with MDA-MB-231 expressing the tetracycline inducible 
downregulating system targeting PLC1. Mice were not treated with 
tetracycline after the injection in order to maintain the expression of 
PLC1 in the cancer cells. Micro-metastases were detectable after 15 days 
from the injection. Therefore after 15 days from the injection, mice where 
treated with tetracycline, in order to activate the tetracycline-induced 
downregulation of PLC1 in the cancer cells. PLC1 downregulation 
induced regression of lungs metastases (Figure 1.18B). In fact, four of five 
lung tissues in both stable and inducible PLC1 knockdown were 
completely metastasis-free and only one mouse showed few metastases 
(Sala et al., 2008). These data showed that PLC1 is important in the early 
steps of metastases development and, more important, that it is required 
for metastatic development since its downregulation induces metastases 
regression. These data enhanced the importance of PLC1 in cancer cell 
invasion highlighted by previous work and suggested that PLC1 may 
represent a novel anti-metastatic strategy.    
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Figure 1.18: PLC1 is important for metastasis development and 
progression. A) Control MDA-MB-231 expressing a tetracycline 
inducible non-targeting sequence (3MUT) and MDA-MB-231 expressing 
a tetracycline inducible targeting shRNA for PLC1 (shPLC1), were 
injected in mice and lung metastases were assessed after 60 days from the 
injection. Downregulation of PLC1 protein level upon induction by 
tetracycline was assessed by western blot. B) Representative lung sections 
from untreated mice or mice treated with tetracycline after 14 days from 
injection are shown. Arrows indicate micrometastases (Sala et al., 2008).   
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1.5 The metastatic process 
 
The initiating events in the arising of cancer are mutating oncogenic 
events, defined tumour initiating mutations that provide cells with 
enhanced proliferation rate, resistance to cell death and chromosomal and 
genetic instability (Figure 1.19-a,b) (Fidler, 2002). Mutation of EGFR and 
altered PI3K pathway, due to PI3K overexpression or inactive mutations 
of PTEN or its deletion are a well-established example of oncogenic 
events (Kok et al., 2009; Gonzalez-Angulo et al., 2011). In some cases 
tumour cells migrate from the primary tumour to distant healthy tissues 
initiating a second cancerous lesion called metastasis. Often metastasis 
remains dependent on such alterations, and inhibition of those pathways 
leads to tumour and metastatic regression. However, very often, 
metastases develop new mutations and become resistant to treatment, 
resulting in poor prognosis. Cells crossing the tissue boundaries find 
themselves in a different environment and altered pathways help these 
cells to survive and proliferate (Nguien et al., 2009). The initiation of a 
novel tumour occurs in specific host organs whose microenvironment 
stimulates metastasis development. In particular physical characteristics of 
the organ structure and specific cytokines, determine the homing of 
metastatic cancer cells. For example expression of epiregulin, 
prostaglandin G/H, matrix metalloproteinase 1 (MMp1) and MMp2 in 
breast cancer cell lines has been implicated in breast cancer lung 
metastasis (Minn et al., 2007). The mutual relationship between the origin 
of cancer cells and the site for metastasis development was observed by 
Paget more than 100 years ago when he compared cancer cells to the 
“seed” and the specific host organ as the “soil” and highlighted the 
“conditio sine qua non” seed and soil has to be compatible (Fidler, 2002). 
The metastatic process can be subdivided into intravasation, survival in 
the circulation, extravasation and colonisation at distant site (Fidler, 2003; 
Nguyen et al., 2009). During this process, usually characterised by 
tumour-driven-angiogenesis, the tumour reaches the tissue boundaries 
allowing some cancer cells to enter the circulatory system (Figure 1.19-
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c,d), during the intravasation phase. Cells entering the circulatory system 
undergo mechanical stress and they are targeted by the immune system. 
Therefore only few cells survive during this phase, which eventually is 
followed by extravasation. In this phase cells expressing extravasation 
genes such as metalloproteinases genes (MMPs) and CCL5 are 
characterised by enhanced ability to adhere to the blood vessel wall,  to 
invade distant tissues and to initiate novel distant tumours (Figure 1.19-e) 
(Nguyen et al., 2009). It is well established that different steps are 
necessary for development of metastatic tumours and each step requires a 
highly selective process which selects cancer cells with metastatic 
characteristics. This is due to the fact that metastases are the results of a 
high selective process that selects populations of cancer cells presenting 
enhanced expression of metastasis initiating genes and metastasis 
progression-related genes which allows them to resist the environment of 
the newly colonised organ and often confers resistance to anti-cancer 
treatments. For example parathyroid hormone related protein (PTHRP) 
and interleukin 11 (IL-11) expression enable breast cancer cells to 
generate osteolytic metastases but they have no effect on primary tumour 
growth (Yin et al., 1999; Kang et al., 2003). The increased invasiveness 
and the ability of cancer cells to reach and colonise distant tissues are the 
main characteristics of metastasis. The tumour cell invasion role is a 
complex process whereby a group of epithelial-derived cells invade 
adjacent tissue in a coordinated fashion. The invasion is accompanied by 
cell proliferation and morphogenic differentiation. In this context the fact 
that PLC1 has been demonstrated to be essential for metastasis 
development and progression (chapter 1.4), but not for primary tumour 
growth, highlights PLC1 as an important determinant protein for 
metastasis development and a potential antimetastatic target. 
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Figure 1.19: Model of metastasis dissemination and initiation of a novel 
distant tumour (Fidler, 2002). 
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1.6 Breast cancer  
 
In 2008 47,700 woman were diagnosed with breast cancer in UK (Official 
Cancer Research UK cancer statistical analysis). Breast cancer is a 
heterogeneous disease and therefore treatments have different outcomes 
according to the origin of the carcinoma and the tumour stage. The breast 
gland consists of lobules and ducts. In particular lobules present a luminal 
compartment surrounded by luminal cells. Ducts consist of ductal cells 
which define a tubular structure necessary for carrying the milk secreted 
in the lobules.  Cancer cells can originate from both ducts (ductal 
carcinoma) and lobules (lobular carcinoma). Histopathological 
classification defines breast cancer as carcinoma in situ, when it is still 
limited by the basal membrane of the ducts and therefore it is not spread. 
The invasive carcinoma presents local infiltration of cancer cells and 
fixation of the tumour to skin and the underlying pectoralis fascia. Breast 
cancer-derived metastases may be found in lymph node, lungs, brain and 
bones. In general breast cancers are classified according to the tumour size 
(T), presence of nodule (N) and distant metastases occurrence (M). 
However molecular biology approaches, such as microarray analysis of 
breast cancer patient tissues, classify breast cancer on the basis of gene 
expression signature as: normal breast-like, ERBB2, basal-like and 
luminal-like breast cancer. In particular luminal breast cancer-like is 
associated with high levels of oestrogen receptor (ER), while normal 
breast-like, ERBB2, and basal-like breast cancers are associated with low 
level of ER (Perou et al., 2000; Sorlie et al., 2001). Tumours 
overexpressing ER depend on oestrogen for proliferation, therefore these 
tumours are responsive to hormone therapy. However selective pressure 
contributes to select ER
-
 cell populations, which are not dependent on 
oestrogen to proliferate and therefore are resistant to hormone therapy 
context. Generally in breast cancer, selective pressure contributes to the 
generation of ERBB2 and EGFR gene amplification. The overexpression 
of these receptors provides the tumour cells with enhanced growth and 
motility. EGFR and ERBB2 belong to the family of epidermal growth 
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factor receptors composed by EGFR/ERBB1, ERBB2, ERBB3 and 
ERBB4. Ligand binds to the extracellular domain, induces 
heterodimerisation and activates receptor autophosphorylation activating 
the downstream pathways. The ERBBs receptors present heterogeneous 
characteristics. ERBB2 for example possesses an extracellular domain but 
no ERBB2 ligand is known, while ERBB3 possesses a non-functional 
kinase domain. However ERBB3 seems to be essential for the 
tumorigenesis induced by ERBB2. Increased expression of ERBB3 
potentiates the ERBB2 induced transformation, while ERBB3 loss inhibits 
ERBB2-induced transformation. Since the epidermal growth factor has a 
crucial role in breast cancer, specific drugs targeting the HERBB receptors 
were developed. For example, Trastuzumab is a monoclonal antibody that 
recognizes the extracellular domain of ERBB2 receptor, inhibiting the 
activation of the receptor (Molina et al., 2001). In the case of ERBB2 
overexpressing metastatic breast cancers, Trastuzumab extended the 
progression-free and recurrence-free survival when combined with 
cytotoxic drugs like taxanes or cisplatin (Burstein et al., 2007). 
Trastuzumab and hormone therapy are a valid therapy in case of ER
+
 and 
ERBB2-overexpressing breast cancers. However about 15% of breast 
cancer tumours belong to the basal-like breast cancer subtype, which are 
also ER
-
. The almost totality of this subtype do not present expression of 
oestrogen, progesterone and ERBB2 receptors and therefore are called 
triple negative (Bauer et al., 2007). Triple negative cancer patients have 
poor prognosis and do not respond to endocrine therapies or ERBB2 
targeting therapies. It has been demonstrated that triple negative 
phenotype correlates with mutation of the tumour suppressor BRCA1 and 
EGFR is often overexpressed in this tumour type. Clinical trials, which 
employ an EGFR targeting approach such as the tyrosine kinase inhibitor 
lapatinib and the EGFR-targeting antibody Cetuximab, showed a positive 
response when combined with genotoxic treatments such as carboplatin 
and DNA-damaging treatment (Cleator et al., 2007). The overall progress 
in breast cancer treatment and molecular mechanisms involved in breast 
cancer, early diagnosis and screening programs contributed to decrease 
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mortality rate of 37% compared  to 1989 (Breast cancer UK, 2009). 
However, very little progresses has been done in curing metastatic breast 
cancer. Despite the therapeutic improvements about 30% of patients with 
breast cancer develop recurrent advanced metastases, indicating no 
significant advances in anti-metastatic treatment for metastatic breast 
cancer, and for metastasis spreading in general. Currently no effective 
anti-metastatic drugs are available and metastasis remains the main cause 
of cancer-related death. 
 
1.7 3-Phosphoinositide-Dependent-Protein-Kinase-1 (PDK1) in cancer 
as potential therapeutic target  
 
Cancer cell proliferation and survival is tightly regulated by hormones and 
growth factors that activate specific intracellular pathways inside the cell. 
Understanding the signalling pathways involved in these processes may 
help us to find predictive factors for tumour aggressiveness and develop 
new anticancer drugs. Among the different pathways, signals transmitted 
by the PI3K/AKT pathway have proven to be important for cell survival 
in many cell types (Chapter 1.1.2). Although Akt is considered to be one 
of the key enzymes regulating growth and proliferation of cancer cells, 
there is increasing evidence that Akt-independent pathways, downstream 
of PI3K activation, may also play a crucial role in driving tumour 
progression. In this respect, the existence of PDK1-mediated/Akt-
independent pathways has been recently identified (Vasudevan et al., 
2009). Despite the importance of PDK1 in cell signalling, less attention 
has been paid to this kinase for its role in cancer and as a therapeutic 
target.  
 
1.7.1 Biological functions of PDK1  
 
The role of PDK1 has been investigated in vivo in yeast, Drosophila 
(Casamayor et al., 1999; Cho et al., 2001; Lawlor et al., 2002) and mice. 
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In the examined organism the absence of PDK1 is lethal. Mice PDK1
-/-
 
lack branchial arches and exhibit problems in neural crest specification 
and forebrain development, and several disruptions in the development of 
a functional circulatory system, which eventually causes death at E9.5 
(Lawlor et al., 2002). In order to study the role of PDK1 in development, 
hypomorphic mice for PDK1 were generated showing a reduced 
expression of PDK1 in all tissues. These mice showed a decreased body 
size of 40-50% compared to the wild type littermates, but showed no 
significant differences in the activation of AKT induced by insulin 
compared to their littermates. Analysis of organs revealed that the 
difference in size is due to a decreased cell size rather than reduction in 
cell number. Furthermore mice expressing a PDK1 mutated form unable 
to bind phosphoinositides present a strongly reduced AKT activation, 
insulin resistance and hyperinsulinaemia (Bayascas et al., 2008). 
 
1.7.2 PDK1 in cancer 
Hyperactivation of the PI3K/PDK1/AKT pathway is found in many human 
cancers. As described in chapter 1.1.2, PTEN is often mutated in human 
cancer and its absence causes a hyperactivation of the mitogenic signal 
promoted by PI3K, promoting tumourigenesis. The hypomorphic PDK1 
mice model was a useful tool to investigate the role of PDK1 under 
increased PI3K signalling pathway.  Hypomorphic PDK1 mutations in mice 
showed increased resistance to develop tumours when crossed with mice 
PTEN
+/-
 indicating that PDK1 can be an important therapeutic target in 
cancers that present hyperactivation of the PTEN/PI3K/AKT pathway 
(Bayascas et al., 2005). PDK1 plays a pivotal role in breast cancer 
development. Increased copy number of PDK1 is often present in human 
breast cancer compared to normal breast epithelia and correlates with 
upstream PI3K pathway activation. In particular, increased copy number of 
PDK1 correlates with the presence of activating mutation of PI3K class 1 
p110 or with ERBB2 overexpression (Maurer et al., 2009). Furthermore, 
using an RNA interference library targeting 779 kinases and related 
proteins, the PDK1 signalling pathway has been identified as a strong 
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determinant of sensitivity to multiple ER antagonists, including tamoxifen 
the most commonly used drug to treat breast cancer whose usefulness is 
limited by the development of resistance (Iorns et al., 2009; Peifer and 
Alessi, 2009). Whether PDK1 is essential for tumourigenesis initiation or it 
is required in later stages is still unclear. Overexpression of PDK1 in non 
tumourigenic breast epithelial cell line MCF10A does not alter cell growth 
and the normal multiacinar morphology in three-dimensional culture 
conditions. Strikingly, co-overexpression of PDK1 and of the active mutant 
rat homolog of ERBB2 in MCF10A causes a profoundly distorted three-
dimensional multiacinar organization and confers increased cell motility 
regardless of the presence of chemo-attractant (Maurer et al., 2009). Indeed, 
PDK1 positively regulates ROCK1 in a kinase-independent manner. 
ROCK1 is a protein kinase involved in the phosphorylation of the myosin 
light chain and it is therefore involved in acto-myosin contractility. In 
particular promoting ROCK1 is essential for cell motility in three-
dimensional conditions and in vivo. Several studies have shown that 
upregulation of Rho-ROCK signalling in tumours is linked to increased 
invasion and metastatic potential (Pinner and Sahai, 2008). Noteworthy, the 
PDK1-dependent regulation of ROCK1 seems particularly important in 
three-dimensional environments. Interestingly, knock down of PDK1 has 
no effect on cell growth under standard tissue culture conditions in a panel 
of breast, colon, lungs and prostate cancer cell lines. However 
pharmacological inhibition of PDK1 or PDK1 knockdown inhibits cell 
growth in three-dimensional culture conditions on Matrigel or the 
anchorage-independent growth. Furthermore PDK1 inhibition inhibits 
Matrigel cell invasion in breast cancer cell lines, prostate cancer and 
melanoma (Pinner and Sahai, 2008; Nogashima et al., 2010), in line with 
data showed in this thesis. 
 
 
 
 
 
 
 
 
64 
 
1.7.3 PDK1-dependent pathways 
3-phosphoinositide-dependent-protein kinase 1 (PDK1) is a kinase 
belonging to family of the AGC kinases. The AGC kinase family includes 
serine and threonine kinases with high identity of their catalytic domain to 
cAMP-dependent protein kinase 1 (PKA), cGMP-dependent protein 
kinase (PKG) and protein kinase C (PKC). The AGC kinases possess a 
conserved bi-lobed structure which defined the catalytic domain. The 
amino-terminal small lobe and the carboxy-terminal large lobe sandwich 
one ATP molecule essential for the subsequent substrate phosphorylation. 
Many AGC kinases possess two phosphorylation sites that regulate their 
activation: the activation loop, which is located within the kinase domain, 
and the hydrophobic motif which is located in a region adjacent to the 
catalytic domain. Phosphorylation of these sites increases the kinase 
activity and leads to enzymatic full activation.  PDK1 was originally 
discovered in 1997 as the kinase responsible for the phosphorylation of 
AKT activation loop at the residue threonine 308, essential for enzyme 
activation (Alessi et al., 1997). Furthermore AKT phosphorylation at 
Thr308 was dependent in vitro on PtdIns(3,4,5)P3 concentration, linking 
PDK1 to the upstream activation of PI3K. PDK1 is a protein of 556 amino 
acids that possesses a catalytic domain and a PH domain. As a member of 
the AGC kinase, PDK1 shows a phosphorylation site in S241 which is 
located in the activation loop. The PDK1 activation loop is 
phosphorylated in resting cells and this event is not affected by growth 
factor stimulation. Phosphorylation of PDK1 at S241 is catalysed by an 
autophosphorylation reaction in trans, meaning that PDK1 is 
autophosphorylated by another PDK1 molecule (Wick et al., 2003). 
Therefore PDK1 kinase activity is constitutively active and regulation of 
PDK1-activated signalling involves other mechanisms. The first 
mechanism was discovered investigating the steps involved in AKT-T-
loop phosphorylation in living cells. PDK1 is localised at the plasma 
membrane because of the interaction of its PH domain with the 
phosphoinositides PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(4,5)P2, with 
 
 
 
65 
 
the highest affinity towards the PI3K lipid products (Currie et al., 1999). 
The affinity of PDK1-PH domain for the PI3K products suggested a 
potential PI3K-dependent PDK1 membrane translocation. Although 
PDK1 membrane localisation has been largely investigated and supported, 
the dynamic of this localisation is controversial. Whether PDK1 
translocates to the plasma membrane following growth factor stimulation, 
or it is constitutively localised to the plasma membrane is still debated. 
Growth factor-induced PDK1 membrane translocation was observed by 
confocal analysis (Anderson et al., 1998; Filippa et al., 2000). However 
another study employing high resolution electron microscopy analysis 
revealed a constitutive PDK1 membrane localisation without further 
translocation following growth factor stimulation (Currie et al., 1999). 
PDK1 membrane localisation is essential for AKT phosphorylation at 
Thr308. Growth factor-induced AKT membrane translocation leads to 
PDK1 and AKT co-localisation at the plasma membrane following PI3K 
activation, since both proteins bind PtdIns(3,4,5)P3. AKT membrane 
recruitment causes conformational changes in AKT which allow the 
phosphorylation of AKT by PDK1 (Calleja et al., 2007) (Figure 1.20). 
Expression of a mutant AKT constitutively associated to the membrane 
resulted in full AKT phosphorylation at Thr308 in unstimulated cells 
(Andjelkovic et al., 1997), which may occur only in the presence of a 
membrane located PDK1 pool. On the contrary, mutation of the AKT-PH 
domain that abolishes AKT membrane recruitment strongly decreases 
AKT phosphorylation. Similarly, mutation or deletion of PDK1-PH 
domain strongly reduces AKT phosphorylation (Currie et al., 1999). 
PDK1-dependent AKT phosphorylation is therefore promoted by the co-
localisation of both proteins to the plasma membrane, mediated by the 
interaction of the respective PH-domains with the PtdIns(3,4,5)P3. 
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Figure 1.20: Molecular mechanism of AKT activation by PDK1 (adapted 
from Mora et al., 2004)  
 
A recent study reported that PDK1 exists as a homodimeric complex 
through PH domain interaction of two PDK1 monomers, and that this 
interaction is important in the regulation of AKT phosphorylation. 
Extracellular stimulation increases the basal homodimerisation in live 
cells in the cytosol and at the plasma membrane in a PI3K-dependent 
manner. Deletion of the entire PH domain or mutation of the threonine 
513 within the PH domain, which is phosphorylated by PDK1 itself, 
inhibits the homodimer formation, favouring the monomeric PDK1 
fraction and increases AKT Thr308 phosphorylation (Masters et al., 
2010). This report identified the monomeric PDK1 form as a more active 
form in activating AKT compared to the homodimeric PDK1 form which 
resulted in an inhibited conformation. Therefore different mechanisms are 
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involved in AKT activation and the different steps showed above 
demonstrate a fine regulation of PDK1 pathway (Figure 1.20).     
Although PDK1 was discovered for its ability to phosphorylate AKT, 
many other kinases are now known to act downstream of PDK1. For 
example the AGC kinases members serum glucocorticoid kinase (SGK), 
p70 ribosomal protein S6 kinases (S6K), p90 ribosomal protein S6 kinase 
(RSK), P21-activated kinases 1 (PAK1) and atypical protein kinase C 
(PKC) isoforms are known to be direct targets of PDK1, which 
phosphorylates specific serine/threonine residues of their activation loops 
(Mora et al., 2004). For this reason PDK1 has a main role in controlling 
cell proliferation, survival and cell motility and it has been termed “master 
AGC kinase”. The mechanism of activation of the PDK1-dependent 
kinases differs from the AKT activation mechanism. These protein 
kinases lack the PH domain but possess a hydrophobic motif that interacts 
with PDK1. The hydrophobic motif, also called PDK1 interacting 
fragment (PIF), lies in a conserved Phe-Xaa-Xaa-Phe/Tyr-Ser/Thr-
Phe/Tyr sequence that undergoes phosphorylation in serine or threonine 
(Pearce et al., 2010). Phosphorylation of this site increases the binding of 
PDK1 to the hydrophobic motif, leading to the phosphorylation of the 
targeted kinases activation loop (Pullen et al., 1998; Alessi et al., 1998) 
(Figure 1.21). Mutagenesis of the hydrophobic motif decreases the PDK1-
dependent phosphorylation of the activation loop. PDK1 is the only 
member of the AGC kinase family that lacks the hydrophobic motif, but 
structural analysis revealed that PDK1 presents a hydrophobic pocket, 
termed PDK1 interacting fragment pocket (PIF pocket), which is essential 
for PDK1 interaction with the hydrophobic motif of the targeted protein 
kinases (Biondi et al 2002). Mutations within the PDK1 PIF pocket 
abolish the binding of PDK1 to PKC, S6K and SGK1 and their subsequent 
phosphorylation and activation (Biondi et al., 2002). Therefore the PIF 
pocket represents a docking site that binds the PIF hydrophobic motif and 
promotes the phosphorylation of the activation loop of the targeted kinase.  
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Figure 1.21: Mechanism of activation of S6K and SGK kinases by PDK1 
(adapted from Mora et al., 2004) 
 
1.7.4 PDK1 as therapeutic target 
Although several data showed that PDK1 plays an important role in 
cancer, no inhibitors were found to specifically inhibit PDK1. Many 
compounds able to inhibit PDK1 are small molecule inhibitors belonging 
to the class of ATP-competitive protein kinases inhibitors. These 
inhibitors compete for the ATP-binding to the kinase domain but often 
present off-target effects, being able to compete with the ATP binding of 
other protein kinases (Peifer and Alessi, 2008). Biochemical and structural 
data on the mechanism of action of PDK1 indicate that two additional 
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classes of PDK1 inhibitors could be exploited as druggable targets: the 
PIF pocket binding allosteric ligands and the PH domain competitors. A 
compound has been recently discovered in recent work performed by my 
group. The 2-O-Bn-InsP5 is an inositol derivative compound with specific 
PDK1 inhibitor acivity presenting anticancer and pro-apoptotic properties 
in vivo, able to block AKT Thr308 phosphorylation in cell lines and in 
excised tumours (Falasca et al., 2010). It has been proposed that inositol 
phosphates can bind PDK1 PH domain and retain this kinase in the 
cytosol, preventing Akt phosphorylation at Thr308 (Komander et al., 
2004). New specific and potent inhibitors such as GSK2334470 (Najafov 
et al., 2010) and a pyridinonyl-based compound (Nagashima et al., 2010) 
were recently characterised and showed high selectivity and high potency 
in inhibiting PDK1. Therefore an increasing number of reports discovered 
the importance of PDK1 as a central hub in cancer development. However 
in the future it will be important to investigate in vivo the pharmacological 
inhibition of PDK1 on tumour models, and eventually determine the 
pharmacokinetic and metabolic properties of specific PDK1 inhibitors 
identified for pre-clinical trials.  
 
1.8 Inositol phosphates: promising lead compound for anticancer 
molecule development 
Key enzymes such as AKT, PDK1 and PLC1 which are involved in cell 
proliferation, resistance to apoptosis and increased cell motility possess a 
PH domain that interacts with phosphoinositides and in particular with the 
3-phosphorylated- phosphoinositides, in a mechanism that is essential for 
the enzyme activation. As described in chapter 1.2.4 it has been reported 
that PH domains can also bind to inositol polyphosphates, the soluble 
head-group of phosphoinositides. For instance Grp1-PH domain binds 
with high affinity the Ins(1,3,4,5)P4 with a KD of 27.3 nM and with lower 
affinity to other inositol polyphosphates (Lemmon et al., 1998). Similarly, 
structural studies showed that BTK-PH domain and AKT-PH domain 
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binds to Ins(1,3,4,5)P4. BTK-PH domain interacts with 3-, 4- and 5-
phosphates with the side chains of two acidic residues and with the 
backbone of the L1/L2 loop. This high number of contacts is sufficient to 
guarantee a stable interaction and accounts for the high affinity and 
specificity of the Btk PH domain for Ins(1,3,4,5)P4 over Ins(1,4,5)P3 
(Maffucci and Falasca 2001). In the case of AKT PH domain, the 
interaction with Ins(1,3,4,5)P4 leaves  the 6-OH group exposed to the 
solvent, suggesting that the binding site could accommodate the phosphate 
group presented in the Ins(1,3,4,5,6)P5 (Thomas et al 2003). These data 
suggested that inositol polyphosphates may be used as phosphoinositides 
antagonist, competing for binding the PH domain (Figure 1.22).  
 
Figure 1.22: Representation of the mechanism through which 
Ins(1,3,4,5,6)P5 may inhibits AKT by competing with PtdIns(3,4,5)P3 for 
binding AKT-PH domain.   
 
 
 
71 
 
It has been proposed that just as specific phosphoinositides activate 
different pathways in cells, specific inositol phosphates may block those 
pathways acting as specific antagonists (Berrie and Falasca, 2000). About 
20 years ago it was discovered that a diet rich in inositol hexakisphosphate 
(InsP6), named also phytic acid, correlates negatively with colon cancer 
(Vucenik et al., 2003).It was demonstrated that InsP6 is internalized by 
cancer cells (Vucenik et al., 1994). Analysis of 
3
H labelled InsP6 uptake 
and metabolism showed that InsP6 is quickly uptaken in colon cancer cell 
lines and after 1 hour 56% of radioactivity is in InsP6 form while the rest 
is in form of dephosphorylated inositol phosphates metabolic products 
(Sakamoto et al., 1993).  
 
InsP6 is a dietary supplement with antioxidant properties and it is also 
found in mammalian cells (Szwergold et al., 1987). InsP6 has been found 
to be active in inhibiting tumour growth of leukemic hematopoietic cell 
line, breast, hepatoma, colon cell lines in vitro with different degrees of 
sensitivity accordingly to the cell lines (Shamsuddin et al., 1999; Singh et 
al., 2003). Furthermore InsP6 showed protective effect for colon and 
breast cancer induced by different carcinogens and metastases formation 
in mice models injected with fibrosarcoma cells (Vucenik et al., 2003) and 
presents antiangiogenic properties in vitro and in vivo being able to  
inhibit tubulogenesis in vitro and blood vessel neogenesis induced by b-
FGF in vivo (Vucenik et al., 2004). Treatment of Transgenic 
Adenocarcinoma of Mouse Prostate (TRAMP) mice with InsP6 in 
drinking water reduced the progression of prostate cancer lesions without 
any toxicity (Raina et al., 2008). All these evidences together points out 
that InsP6 is able to prevent tumour growth and correlates with etiological 
evidences that diet rich in InsP6-containing foods associates with 
protection against colon and prostate cancer (Vucenik et al., 2003). InsP6 
was shown to enhance the effect of Tamoxifen and Doxorubicin in breast 
cancer cell lines MDA-MB-231 and MCF7 and in breast cancer cells 
derived from primary tumour, in a synergistic manner in vitro, suggesting 
the potential usage of this compound as adjuvant therapy (Tantivejkul et 
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al., 2003). However the IC50 of InsP6 in inhibiting tumour cell growth in 
vitro is between 1.26mM and 4.18mM according to the sensitivity of 
cancer cells. Although InsP6 treatment does not result in toxic effect in 
mice even at elevated concentrations (Ullah et al., 1990, Vucenik et al., 
1995; Raina et al., 2008), it has to be noted that concentration of InsP6 (up 
to millimolar range) may result in reduced levels of multivalent cations 
and subsequent cell death due to its polyvalent cation-binding-properties 
(Torres et al., 2005). Moreover the high dose required to inhibit cell 
growth underlines a lack of molecular selectivity and specificity. One or 
more catabolic products of the InsP6 metabolism within the cells may be 
the InsP6-derivated active compounds responsible for the biological 
effects of InsP6. This could also explain the high doses needed to inhibit 
tumour growth. It was recently demonstrated that in vivo exogenous IP6 is 
rapidly dephosphorylated in plasma to inositol and to lower IPs (Eiseman 
et al., 2011). Moreover several lines of evidence suggest that the gut flora 
plays an essential role in InsP6 dephosphorylation and absorbtion. Indeed 
animals lacking the gut flora fail to incorporate detectable InsP6 (Wise and 
Gilburt, 1982; Sakamoto et al., 1993). These data suggest that although 
inositol phosphates present anti-tumour effects their effectiveness could 
be limited on toumour distant from the gastro-intestinal tract (Eiseman et 
al., 2011). 
  
The effect of inositol phosphates has been tested in vitro and in vivo on 
tumour growth in the last 10 years. In particular among all the inositol 
polyphosphates, the inositol tetrakisphosphates Ins(1,4,5,6)P4 and 
pentakisphosphates Ins(1,3,4,5,6)P5  were found to inhibit cell growth and 
the anchorage-independent growth in breast cancer, ovarian and small cell 
lung cancer (SCLC) cell lines. Furthermore pre-treatment of cells with 
50M Ins(1,4,5,6)P4 blocked the growth factor-induced membrane 
translocation of overexpressed GFP-PH-AKT, indicating that this 
compound might be a selective inhibitor of PI3K/AKT pathway. Indeed, 
cell lines whose cell growth is PI3K independent and insensitive to the 
PI3K inhibitors LY294002 and Wortmannin, are also insensitive to 
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Ins(1,4,5,6)P4 treatment (Razzini et al., 2000). Further work demonstrated 
that Ins(1,3,4,5,6)P5 is the most potent inhibitor of PI3K/AKT pathway 
among the totality of inositol phosphates. Indeed Ins(1,3,4,5,6)P5 induced 
apoptosis in ovarian cancer similarly to cisplatin and etoposide treatment 
and inhibited AKT S473 phosphorylation in ovarian and breast cancer cell 
lines that present increased activation of PI3K pathway. On the contrary 
proliferation of MDA-MB-231 and MCF7, which do not posses a 
constitutively activated PI3K/AKT pathway, were insensitive to 
Ins(1,3,4,5,6)P5 treatment (Piccolo et al., 2004). In vivo experiments 
showed that Ins(1,3,4,5,6)P5 blocks tumour growth in ovarian cancer cell 
line SKOV3 xenografted in mice and inhibits AKT S473 and T308 
phosphorylation and also inhibits FGF-2-induced angiogenesis. Indeed 
Ins(1,3,4,5,6)P5 prevents cell migration and tubulogenesis induced by 
FGF-2 in human umbilical vein endothelial cells (HUVEC) both in vitro 
and in vivo through the inhibition of PI3K/AKT pathway which is also 
involved in the angiogenesis process (Maffucci et al., 2005). Therefore 
targeting PI3K/AKT pathway is an attractive therapeutic target as much as 
the possibility to use natural compounds such as Ins(1,3,4,5,6)P5 or 
synthetic derivative compound in order to inhibiting this pathway.  
 
Since mono therapy in cancer treatment showed limited effects, adjuvant 
therapies are often applied to cancer patient. In this prospective in vitro 
treatment of SKOV3 cells with Ins(1,3,4,5,6)P5 and cisplatin, the main 
anticancer drug used for ovarian cancer treatment, showed a more than 
additive effects providing evidence that this compound is able to sensitise 
cancer cells to the cytotoxic anti-cancer drugs (Piccolo et al., 2004).  
 
The constant research for novel PI3K/AKT pathway inhibitors, 
characterised by decreased toxic effects and improved potency and 
selectivity, induced my group in the last years to test inositol derivative 
compounds for their ability to inhibit the PI3K/AKT pathway. It was 
recently published that a benzene-tetrakisphosphate compound 
[Bz(1,2,3,4)P4], an inositol phosphate surrogate, binds to AKT PH domain 
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with similar affinity to Ins(1,3,4,5)P4 (Mills et al., 2007). Modification of 
the Ins(1,3,4,5,6)P5 and analysis of X-ray structure of AKT PH domain 
showed that a tyrosine residue near the 6-OH of bound Ins(1,3,4,5,6)P4 
might interact with an aromatic group. As reported in Falasca et al., 2010, 
among different inositol phosphates tested on AKT activation, 2-O-Bn-
InsP5 resulted in AKT inhibition. In particular, 2-O-Bn-InsP5 was more 
effective than Ins(1,3,4,5,6)P5 in inhibiting growth and inducing apoptosis 
in SKBR3 and SKOV3 cell lines, which are sensitive to Ins(1,3,4,5,6)P5 
treatment. Strikingly, 2-O-Bn-InsP5 induced apoptosis in Ins(1,3,4,5,6)P5-
resistant cell lines such as prostate cancer PC3, pancreatic cancer ASPC1 
and breast cancer MDA-MB-468, inhibiting the phosphorylation of AKT 
in Ser473 and Thr308 in vitro. In vivo xenograft experiments using PC3 
cells showed that 2-O-Bn-InsP5 inhibited tumour growth and 
phosphorylation of AKT at Ser473 and Thr308, while Ins(1,3,4,5,6)P5 had 
no effect on tumour growth and AKT phosphorylation. Kinase profiling 
showed that 2-O-Bn-InsP5 is a very specific and potent inhibitor of PDK1 
which is involved in AKT activation (Falasca et al., 2010).  
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Chapter 2 
Materials and Methods 
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2.1 Cell culture 
2.1.1 Cell lines 
The cell lines used in the experiments performed in this thesis are listed in 
Table 2.1 Cells were available in the laboratory of Professor Marco Falasca 
unless otherwise stated. 
MDA-MB-231 Organ: mammary gland; breast  
Disease: adenocarcinoma  
Derived from metastatic site: pleural effusion  
Cell Type: epithelia 
The cell line originates from a pleural effusion of an 
earlier breast adenocarcinoma. MDA-MB-231 shows 
aneuploidy (modal number = 64, range = 52 to 68), with 
chromosome counts in the near-triploid range. 
MDA-MB-435 Organ: mammary gland; breast  
Disease: adenocarcinoma  
Derived from metastatic site: pleural effusion  
Cell Type: epithelial 
A controversy originates about the true origins of these 
cells. MDA-MB-435 cell line was identified as breast 
cancer cells. Marker expression studies and genomic 
analysis questioned the breast origin and classified this 
cell line as melanoma cell line (Elison et al., 2002; 
Garraway LA). Recent update confirmed the MDA-MB-
435 as a poorly differentiated breast tumour cell line with 
expression of both melanocytic and epithelial markers 
(Chambers 2009) 
TSA Organism: Mus Musculus 
Organ: mammary gland 
TSA is an aggressive and poorly immunogenic cell line 
established from a moderately differentiated mammary 
adenocarcinoma that arose spontaneously in a 
multiparous BALB/c mouse. 
 
A375M Organ: Skin 
Disease: Invasive melanoma 
HEK293T Organ: embryonic kidney 
Cell type: transformed with adenovirus 5 DNA 
4T1 Organism: Mus musculus 
Organ: mammary gland 
Disease: tumour 
4T1 cell line is a mouse syngenic model of breast cancer. 
4T1 produces highly metastatic tumors in BALB/c mice 
that can metastasise to the lung, liver, lymph nodes and 
brain while the primary tumor is growing in situ. 
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HUVEC Organ: Human umbilical vein  
Cell type: Endothelial 
HUVEC are responsive to cytokine stimulation and are 
commonly used for physiological and pharmacological 
investigations. 
 
 2.1.2 Cell culture and propagation 
MDA-MB-231 and Human embryonic kidney cells were cultured in DMEM 
growth media (Invitrogen) supplemented with 10% (v/v) Foetal Bovine Serum 
(FBS) (Invitrogen), Sodium Pyruvate 1% (v/v), 1X L-
glutamine/penicillin/streptomycin (Invitrogen) and 0.1% gentamycin (v/v) 
(Invitrogen, UK). MDA-MB-435, 4T1, TSA and A375M were cultured in 
RPMI 1640 growth media (Invitrogen or PAA, UK) supplemented with 10% 
(v/v) Foetal Bovine Serum (FBS), Sodium Pyruvate 1% ( v/v), 1X L-
glutamine/penicillin/streptomycin and 0.1% gentamycin (v/v). Cells were 
seeded in tissue culture treated plastic 10 cm dishes  or the appropriate 6 cm 
petri dishes, multi-well dishes (BD, UK) and grown in humidified incubator at 
37°C in a 5% CO2 atmosphere. 
 
2.1.3 Cell amplification and passage 
All cells lines were passaged when 80-85% confluent. Growth medium was 
aspirated and cells were washed twice in 5ml of sterile phosphate buffered 
saline solution (PBS) (PAA, Austria) for 20-30 seconds and then incubated 
with 3ml of trypsin (0.25%)/EDTA(0.2g/l) (PAA, Austria) solution to detach 
the cells. After 3-5 minutes, cells were harvested in 5ml of the appropriate 
complete growth media and gently pipetted up and down before being pelleted 
by centrifugation at 250g for 5 minutes at room temperature in 15ml or 50ml 
centrifuge tubes (Falcon-BD, UK). Cell pellets were resuspended in the 
appropriate growth media and re-plated as required in new tissue culture plates. 
Cells were passaged every 2-3 days. Growth media was changed every 48 
hours when needed. 
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2.1.4 Cryo-conservation and recovery of cell lines 
Cells in a 10 cm petri dishes were detached when 80-85% confluent. Cells 
were washed in 1X PBS and incubated with 3ml of trypsin 
(0.25%)/EDTA(0.2g/l) solution to detach the cells. After 3-5 minutes, cells 
were harvested in 5ml of the appropriate complete growth media and recovered 
by centrifugation at 250g for 5 minutes at room temperature. Cell pellets were 
resuspended in 1ml of 90% FBS:10% DMSO (Sigma Aldrich, UK) freezing 
solution and the total volume transferred in cryovials (VWR) for cell storage in 
aliquots of 1ml per cryovial. Cells were wrapped in tissue paper and stored at -
80°C in a polystyrene box for a time minimum of 24 hours up to 1 month 
before being transferred into liquid nitrogen for long term storage. 
 
 
2.2 Molecular Biology 
 
2.2.1 Proteins 
2.2.1.1 Western blotting analysis 
2.2.1.1.1 Protein sample preparation from cell lysates 
Cell were plated in tissue culture treated 6 well plates. Cells were detached 
from 10 cm petri dishes when 80-85% confluent as described in chapter 2.1.3. 
The pellet was resuspended in 10 ml of growing media and an aliquot of 2 ml 
of the resuspended pellet was diluted in 10 ml of growing media. Then 2 ml of 
the diluted reuspension were added in each well of a 6-well plate. Alternatively 
1 ml of the diluted resupsension was added in each well of a 12-well plate. 
When necessary, the day after being plated, cells were cultured in serum free 
growth media for 24 hours before stimulation and then lysed. Cells were 
washed twice in 1X PBS and lysed in 200l of cold NP-40 lysis buffer (50mM 
Tris-pH 8.0; 50mM KCl, 1% (v/v) NP-40) containing 1X protease inhibitor 
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cocktail (Sigma-Aldrich, UK) and 1X phosphatase inhibitor cocktail II (Sigma-
Aldrich, UK). Scrapers were used to detach the cells from the plastic dish and 
destroy cellular integrity. Lysate was collected in 1,5 ml tubes (VWR, UK) and 
cleared from cell debris and cell membrane by centrifugation at 10,000g for 3 
minutes. The supernatant was transferred to a new 1.5 ml tube used for protein 
quantification and subsequent western blot analysis. Cell lysates were stored at 
-20°C or -80°C for long conservation. 
2.2.1.1.2 Bradford protein assay 
Protein concentration was determined by Bradford protein assay. Bovine 
Serum Albumin (BSA) (Sigma-Aldrich, UK) was used to establish a standard 
calibration curve for protein quantification. Table 2.2 shows a typical standard 
curve preparation. 1l of lysate was added to 199l of 1X Bradford solution 
(Bio-Rad, UK). The absorbance of the standards and of the samples was 
measured at 595 nm using a plate reader. A linear calibration curve was set 
using Microsoft Excel® plotting BSA concentration (X axis) and absorbance 
value (Y axis). The linear equation for the standard curve was calculated by the 
software. Standard curve with a minimum r
2
=0.97 was used to determine 
sample protein concentration. The unknown protein concentration of the 
lysates was calculated using the following formula: 
Abs=mx+b 
Abs=Absorbance; m=slope of the line; x=protein concentration; b=Y intercept 
Protein samples were diluted in 5X denaturing sample buffer (see Appendix 
1.1) and heated at 95°C for 5 minutes. The denatured protein samples were 
used for Polyacrylamyde Gel Electrophoresis (PAGE) and Western blot 
analysis. The denatured sample buffers were stored at 4°C or at -20 for short 
and long period storage respectively. 
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Table 2.2: BSA Standard curve protein concentration  
Biorad 
protein 
assay 
1X Bradford 
reactive 
BSA 200 g/ml 
(l) 
BSA (g/ml) 
 
 
Standard 
curve 
200 0 0 g/ml 
198 2 0.4 g/ml 
196 4 0.8 g/ml 
194 6 1.2 g/ml 
192 8 1.6 g/ml 
  
1X Bradford solution was prepared diluting 5X Bradford Bio-Rad protein 
assay solution (Bio-Rad Laboratories, UK) in ddH20.  
 
 
2.2.1.1.3 Polyacrylamyde Gel Electrophoresis (PAGE) and Western blot 
Two dedicated glass plates were assembled in a gel electrophoresis apparatus 
(Bio-Rad Laboratories, UK). A 10% resolving polyacrylamide gel solution was 
prepared and poured between the two glass plates, overlaid with 1.5ml of water 
and left at RT for 20-25 minutes to polymerize. Then, the water was removed 
and a 5% stacking solution was added on top of the previously set resolving gel 
and cast with 10 or 15 sample combs on top. Polymerization was allowed at 
RT for about 30 minutes (see appendix 1.2 and 1.3). 
After removing the comb, each well of the gel was washed with ddH2O. 
Previously denatured protein samples were loaded on the gel and gel 
electrophoresis performed in 1X running buffer (Appendix 1.4). A constant 
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voltage of 120V was used for gel-electrophoresis. Electro-blotting from the gel 
onto a Protran® nitrocellulose membrane filter (Whatman, UK) was performed 
in 1X transfer buffer (see appendix 1.5) using a dedicated apparatus (Bio-Rad 
Laboratories). Transfer was performed at constant current of 400mA for 1 hour 
and 30 minutes at RT in presence of a dedicated icepack within the tank. The 
correct protein transfer was assessed by staining with Ponceau solution 
(Applichem GmbH, UK). The solution was incubated for 2 minutes at RT. 
Membrane were washed in ddH2O in order to remove the excess of Ponceau 
solution and visualize protein staining. 
2.2.1.1.4 Immunoblotting and analysis 
Nitrocellulose membrane was incubated with a solution of 5% milk (w/v) 
(Invitrogen) in PBS-0.05%Tween-20 (v/v) for 30 minutes before being 
transferred in PBS-0.05%Tween-20 (v/v) solution containing the diluted 
primary antibody (table 2.3) and incubated at 4°C overnight in  agitation. The 
following day the membrane were washed 3X for 10 minutes in PBS-
0.05%Tween-20 (v/v) and incubated with agitation at RT for 1 hour with the 
appropriate peroxidase-conjugated secondary antibodies anti-mouse (GE 
Healthcare, UK) (1:8,000), anti-rabbit (Sigma-Aldrich, UK) (1:8,000) or anti-
goat (GE Healthcare, UK) (1:20,000) diluted in PBS-0.05%Tween-20 (v/v). 
Membranes were then washed 3X 5 minutes in PBS-0.05%Tween-20 (v/v) and 
1X 5 minutes in PBS before being incubated with ECL Plus Mix solution 
(Amersham Bioscience, UK) for 1 minute, sealed in a plastic sheet and 
exposed to chemiluminescence sensitive film (Kodak) in a dedicated cassette, 
usually from 15 seconds to 10 minutes.                    
 Table 2.3: List of Antibodies used for WB 
Antibody Company Catalog # Host Dilution 
PLC1 Santa Cruz SC-7290 Mouse 1:1000 
pPLC1 Cell signalling 2821 Rabbit 1:500 
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PDK1 Cell signalling  3062 Rabbit 1:500 
PLC2 Santa Cruz SC-5283 Mouse 1:500 
AKT 
1/2/3 
Santa Cruz Sc-8312 Rabbit 1:1000 
pAKT 
Ser473 
Santa Cruz Sc-7985 Rabbit 1:500 
pAKT 
Thr308 
Cell signalling 2965 Rabbit 1:500 
ERK1/2 Santa Cruz sc-
135900 
Goat 1:1000 
Anti-HA Sigma-Aldrich H3663 Mouse 1:500 
GAPDH Sigma-Aldrich G9545 Rabbit 1:2500 
 
2.2.1.2 Co-immunoprecipitation analysis 
2.2.1.2.1 Co-immunoprecipitation analysis by Millipore Catch and 
release KIT 2.0 (Millipore, US) 
Co-immunoprecipitation in overexpressing conditions was performed using 
HEK293 cells transfected with pOZ-PDK1 and PRK5-PLC1 constructs as 
indicated in “plasmid transfection” paragraph. Three six centimetre dishes 
were used for each co-immunoprecipitation. Cells were lysed using the NP-40 
lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% (v/v) NP-40) containing 
protease and phosphatase inhibitors. Protein lysates were cleared from cell 
debris by centrifugation step at 10,000 RPM for 3 minutes at 4°C. In parallel, 
spin columns from the kit were washed by adding 400l of 1X catch and 
release wash buffer and centrifuged for 30 seconds at 2,000g. Then 500 g of 
protein were loaded onto the spin columns together with 3g of primary 
antibody or 3g of IgG as negative control, and with 10l of antibody capture 
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affinity ligand. 1X wash buffer was added to provide a final volume of 500 
l. Columns were incubated at 4°C overnight. The day after spin columns 
were centrifuged for 30 seconds at 2,000g and the flow-through collected. 
This fraction was used later to check the immunoprecipitation efficiency by 
western blot analysis. Spin columns were washed 3 times with 1X washing 
buffer and spinned at 2,000g for 30 second for each wash. The 
immunoprecipitated complex was eluted in 70 l of 1X denaturing sample 
buffer by centrifugation at 2,000g for 1 minute. The eluted fraction was 
heated at 95°C for 5 minutes before western blot analysis.  
2.2.1.2.2 Endogenous co-immunoprecipitation analysis   
Endogenous co-immunoprecipitation assay was performed using three 
confluent 10 cm petri dishes of MDA-MB-231, MDA-MB-435 and A375M. 
Cells were lysed using the NP-40 lysis buffer (50mM Tris-pH 8.0, 50mM 
KCl, 1% (v/v) NP-40) containing protease and phosphatase inhibitors. In both 
cases 1 mg of the whole protein lysed was mixed with 3 g of anti-PLC1 
antibody (Santa Cruz Biotechnology Inc., US) and incubated on a rotating 
wheel overnight at 4°C to a final volume of 700 l in IP buffers. The 
following day the mix was centrifuged at 10,000g for 3 minutes and 
transferred to a new clean tube. The mixture was then incubated with 30 l of 
protein G Sepharose 4 fast flow (GE Healthcare, UK) and incubated on a 
rotating wheel at 4°C for 1 hour. Beads were centrifuged at 2,000g for 1 
minute. Then, supernatant was removed and the beads were washed three 
times with IP buffer on a rotating wheel at 4°C for 5 minutes. Then beads 
were resuspended in 50 l of 2X sample buffer and heated at 95°C for five 
minutes. The supernatant was analysed by SDS-PAGE electrophoresis and 
western blot.  
2.2.1.3 GST-Pull down assay 
Three sets of three 6-cm petri dishes, previously seeded with HEK293, were 
transfected respectively with PRK5-PCL1, pEBG2T-GST-PDK1 and 
pEBG2T-GST empty vector. 24 hours from transfection cells were lysed in 
lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% NP-40) containing protease 
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and phosphatases inhibitors. Lysates were cleared by centrifugation at 
10,000g for 3 minutes at 4°C. 500 g of HEK293 overexpressing GST-empty 
vector and 500 g of HEK293 lysate overexpressing GST-PDK1 were 
incubated separately with 20 l of G4510 glutathione-Sepharose-beads 
(Sigma-Aldrich) for 1 hour at 4°C. The beads were washed 3X in washing 
buffer for 5 minutes at 4°C. Beads were incubated with 500 g of protein 
lysate of HEK293 overexpressing PLC1 overnight on a rotating wheel at 
4°C in a total volume of 1 ml in IP buffer. The following day beads were 
harvested and washed 3X with IP washing buffer and the beads resuspended 
in 50 l of denaturing sample buffer and heated at 95°C for 5 minute (see 
appendix 1.1). Supernatant was analysed by SDS-PAGE electrophoresis and 
western blot. 
 
2.2.2 RNA-interference  
 
2.2.2.1 siRNA using Oligofectamine transfecting agent 
Transient knock down of target proteins was achieved using siRNA duplex 
technology. siRNAs were purchased from Dharmacon, USA (Appendix 2.2). 
Transfection of MDA-MB-231 and MDA-MB-435 was performed using 
Oligofectamine
TM
 (Invitrogen, UK) following the manufacturer’s instruction 
for transfection of adherent cells seeded in 6-well plates. 2X10
6
cells/well 
were seeded the day before transfection in complete growth media and 
incubated at 37°C/5% CO2. A mix (A) of 5l siRNA duplexes (stock solution 
of 20 M) and 180 l of serum-free, penicillin-streptomycin-free OptimemTM 
(Invitrogen, UK) was prepared. In parallel a mix (B) of 7.5l of 
Oligofectamine
TM
 and 7.5 l of serum-free, penicillin-streptomycin-free 
Optimem
TM
 (Invitrogen, UK) was prepared. The two mixes were incubated 
for 7 minutes at RT. Subsequently the content of the tubes was mixed and 
incubated 25 minutes RT resulting (total volume of 200 l). Cells were 
washed in 1X PBS solution and 800 l of OptimemTM plus the 200 l of 
transfecting mix were added to each well and incubated for 4 hours at 37°C 
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/5% CO2. At the end of the incubation time, 500 l of 30% FBS Optimem
TM
 
(v/v) were added to the 6 well and incubated overnight at 37°C/5%CO2. The 
following day cells were washed with 1X PBS solution and incubated with 
normal growth media for the indicated time before the experiment. Cells 
transfected with a pool of non-targeting siRNA (Applied Biosystem/Ambion 
Inc., USA) were used at the same final concentration as negative control in all 
the experiments. 
 
 
 
2.2.2.2 siRNA using Hiperfect reagent 
Transient knock-down of target proteins was achieved using siRNAs in 
A375M cell line. Cells were transfected using Hyperfect® transfecting agent 
(Qiagen Ltd, UK) following the protocol provided by the manufacturer, 
optimised for transfection of adherent cells in 6-well plate. 2X10
6 
cells were 
seeded in 6 well plates and grown in complete RPMI growth media at 
37°C/5%CO2. The day after, 100l of Optimem
TM
 were mixed with 7.5 l of 
20M siRNA stock solution and 18l of Hyperfect® in a tube and mixed by 
vortexing for 5 seconds. The mix was incubated for 10 minutes at RT and 
then added to the growth media in the 6-well plate. The cells were incubated 
with the transfection complex overnight at 37°C/5%CO2 and media was 
replaced the following day.  Cells transfected with a pool of non-targeting 
siRNA (Applied Biosystem/Ambion Inc., USA) were used at the same final 
concentration as negative controls in all the experiments. 
 
2.2.2.3 stable knock down using short hairpin RNA 
 
2.2.2.3.1 Stable knock-down of PLC1 using pSUPERTM.retro vector-
based shRNA  
MDA-MB-231, MDA-MB-435 and TSA cell lines stable knock-down for 
PLC1 were previously generated in the lab using the pSUPERTM.retro 
vector-based RNAi system (Oligoengine Inc. USA). A 19 nucleotide 
sequence derived from the mRNA PLC1 transcript were cloned in the vector 
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following the vector instruction. A 3 point-mutated non-targeting sequence 
was cloned in the vector and used as control for all the experiments (see table 
2.4) 
Table 2.4: The PLC1 targeting sequence cloned in pSUPER.retro vector 
together with the position in the cDNA is indicated. 3-point mutation of the 
control non-targeting sequence is indicated in RED.    
PLC1 targeting sequence: GAACAACCGGCTCTTCGTC 
Position in cDNA 2791nt of 5205 
3MUT control non-targeting sequence: GAACAACCGACGTTTCGTC  
 
 
 
2.2.2.3.2 Inducible knock-down of PLC1 using pSUPERIORTM  vector-
based shRNA  
Inducible downregulation of PLC1 was achieved using the (Oligoengine Inc. 
USA) vector-based system. MDA-MB-231 cells expressing the inducible 
downregulating system was previously generated in the lab. These cells 
express the tetracycline repressor encoded by the vector pCDNA
TM
6/TR 
(Invitrogen) and the pSUPERIOR vector-based RNA. The targeting sequence 
and the control non-targeting illustrated in table 2.4, were cloned in the 
pSUPERIOR.retro.puro as indicated by the manufacturer.   
 
2.2.2.3.3 Stable downregulation of PDK1 using pSUPER vector-based 
shRNA. 
Stable downregulation of PDK1 was achieved using the 
pSUPERIOR
TM
.retro.puro. The PDK1 targeting sequence was designed based 
on PDK1 targeting sequence used by Sahai et al., 2008. A Pair of forward and 
reverse oligonucleotides, which comprise identical motifs in an inverted 
orientation separated by a 9 nt spacer, were generated. The extremities were 
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designed in order to present BglII and HindIII sticky ends. A control non-
targeting sequence was designed by mutating 5 nucleotides in the sequence 
(see table 2.5). 5 g of vector were digested overnight with BglII and HindIII 
restriction enzymes (Fermentas, UK) according to the manufacturer’s 
instruction. The cut plasmid was run on 1% agarose gel and extracted from the 
gel using the Genejet
TM
 gel extraction kit (Fermentas, UK) following the 
manufacturer’s instruction.  
 
Table 2.5 The 21 target sequence in PDK1 mRNA molecule is indicated 
together with the position in the mRNA transcript. The target sequence is 
indicated in bold while the BglII and HindIII sites together with the 5-pointed 
mutation are indicated in grey. 
PDK1 targeting sequence: GACCAGAGGCCAAGAATTTTA 
Position in mRNA 1658 nucleotide  
Forward and reverse oligonucleotides designed to target PDK1 expression. 
 
Forward and revearse oligonucleotides designed with 5-point-mutation in 
order to generate a control non-targeting sequence. 
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 2.2.3 DNA 
 
2.2.3.1 Ligation and transformation 
Inserts were ligated in a previously digested vector mixing insert and 
linearized vector at a 3:1 molar ratio. 1 unit of T4 ligase (Fermentas, UK) was 
mixed with 50 ng of vector and the insert together with 2l of 10X T4 ligase 
buffer and made up to a final volume of 20 l. The ligation reaction was 
incubated at RT overnight. Control reactions were performed without the 
inserts. 
The generated constructs were transformed in DHstrain bacterial cells. 
Bacteria were thawed on ice for 20 minutes. 5 l of ligation mixture were 
added to the cells and incubated on ice for 20 minutes. Cells were heat-
shocked at 42°C for 60 seconds and held directly on ice for 30 seconds. 500 l 
of pre-warmed LB media was added to the bacteria and the mixture was 
incubated at 37°C for 1 hour in agitation at 200 rpm. Then cells were spun 
down at 500 g for 3 minutes and resuspended in 250 l of LB before being 
plated on LB-agar plates (LB media with 1,5% (w/v) bacteriological agar) 
containing 100 mg/ml ampicillin or 100 mg/ml Kanamycin according to the 
resistance conferred by the vector. The inoculated plates were incubated 
overnight at 37°C. 
 
2.2.3.2 DNA digestion 
Fastdigest® enzymes (Fermentas, UK) were used for all the restriction 
reactions. 1 g of vector was digested mixing 1 l of enzyme together with 2 
ml of 10X fastdigest® buffer in a final volume of 20 l. The Digestion 
reaction was performed for 30 minutes at 37°C. DNA digestion was assessed 
by agarose gel electrophoresis. 
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2.2.3.3 Plasmid preparation 
Plasmids were extracted and purified from bacteria using the spin miniprep kit 
(Qiagen, UK) for small-scale plasmid preparation, or the QIA filter plasmid 
maxi kit (Qiagen, UK) for the large-scale plasmid preparation.  
2.2.3.4 Miniprep 
For small-scale preparation, resistant colonies obtained from the inoculated 
plates were picked individually using sterile tips and grown overnight in 5 ml 
of LB media at 37°C with agitation (200 rpm) containing the appropriate 
antibiotic for selection. The DNA plasmid was then extracted following the 
manufacturer’s instructions.       
2.2.3.5 Maxiprep 
For large scale preparation 300 ml of LB media supplemented containing the 
appropriate antibiotic for selection were inoculated with 2 ml starter culture, 
prepared as indicated in “miniprep” section, and incubated with agitation (200 
rpm) overnight at 37°C. Plasmids were extracted according to the 
manufacturer’s instructions.  
2.2.3.6 Agarose-gel electrophoresis 
A 1% agarose (Sigma, Aldrich, UK) (v/w) solution in 1X TAE buffer (see 
appendix 1.6) was prepared heating the solution until the total amount of 
agarose was dissolved. The solution was cooled down at RT for 10 minutes. 
Ethidium bromide was added to a final concentration of 0.5 g/ml and the 
mixture was poured into a gel-casting tray, cast with sample combs and left to 
set at RT. The set gel was transferred on an electrophoresis apparatus filled 
with 1X TAE buffer. The samples were diluted in 5X loading buffer (New 
England Biolabs, UK) and loaded on the gel in parallel to 5 l of 1-KB ladder 
(Fermentas, UK) for size comparison. The gel was run at 100 V for 30-60 
minutes and DNA visualised under UV transillumination. 
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2.2.3.7 Plasmid transfection 
Transfection of mammalian cells was performed using Lipofectamine™ 
(Invitrogen, UK) following the manufacturer’s instructions. The amount of 
Lipofectamine™ and DNA was optimized according to the cell line used 
(Table 2.5). A “mix A” and a “mix B”, containing respectively 
Lipofectamine™, Optimem™ and DNA/ Optimem™ were prepared as 
illustrated in Table 2.6. The two mixes were incubated separately at RT for 15 
minutes before being mixed and left to incubate for further 15 minutes at RT. 
Cells were washed with 1X PBS and incubated with the mix plus serum free 
Optimem™ to the final volume indicated. After 4 hours, cells were washed in 
1X PBS and incubated in complete growth media for 24 hours or 48 hours 
depending on the experiment. 
Table 2.6: Transfection protocol optimized for HEK293 and MDA-MB-231 in 
different culture dishes/plate 
Cell line Plate Lipofectamine/Optimem 
(Mix A) 
DNA/Optimem 
(Mix B) 
Total 
Volume 
HEK293 6 cm  
dishes 
10 l/200 l 5 g/200 l 2 ml 
MDA-
MB-231 
12-well 
plate 
2 l/50 l 1 g/50 l 500 l 
6 cm 
dishes 
12 l/200 l 5g/200 l 2 ml 
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2.2.3.8 Polymerase chain reaction (PCR) 
25 ng of plasmid was used as template using the “Maxima® hot start PCR 
master mix 2X”. A typical PCR reaction is illustrated in table 2.7 and 2.8. 
Table 2.7: Typical PCR master mix 
 Sample Control 
Maxima® hot start PCR 
master mix 2X 
25 l 25 l 
Forward primer (100 mM) 0.5 l 0.5 l 
Reverse primer (100 mM) 0.5 l 0.5 l 
Template DNA 5 l - 
H2O 19 l 24 l 
Total Volume 50 50 
 
Table 2.8: Typical thermal-cycler program for PCR 
 Temperature (°C) Time Cycles 
Initial 
denaturation/enzyme 
activation 
95 4 min 1 
Denaturation 95 30 sec 35 
Annealing 57 30 sec 
Extension 72 40 sec 
Final extension 72 10 min 1 
Hold 4 Indefinite  
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2.2.4 RNA 
2.2.4.1 RNA extraction 
Total RNA was extracted from 2X10
5
 cells seeded on 6 wells multiplate using 
the RNeasy kit (Qiagen, UK) following the manufacturer’s instructions. 
 
2.2.4.2 RNA Reverse transcription 
Total RNA was retro-transcripted using the SuperScript II reverse transcriptase 
kit (Invitrogen, UK). 1 g of RNA was diluted in a mix containing oligod(T) 
and random primers (25mg/ml), dNTP mix (0.5 mM) to a final volume of 12 
l. The mix was heated to 65 degrees for 5 minutes in a PCR thermal-cycler 
block and quickly moved on ice. A mix of 1X first strand buffer, DTT (5mM) 
and RNase OUT (40 units) (Invitrogen, UK) was added and the mix was 
heated at 42°C for 2 minutes in a PCR thermal-cycler, where 200 units of 
SuperScript II reverse transcriptase were added to the reaction. The PCR 
thermal-cycler was programmed as follows:  
 
Table 2.9 RNA retrotranscription program indicated in manufacturer’s 
instruction 
 
SuperScript II 
thermal-cycler 
program 
Temperature (°C) Time (min) 
25 10 
42 50 
70 15 
4 (until tube collection) 
 
2.2.4.3 Real Time quantitative Polymerase Chain Reaction (RT-qPCR) 
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For quantitative PCR 100 ng of cDNA was mixed withv12.5 l of 2X 
Maxima® SYBR green/Fluorescein qPCR master mix (Fermentas), 2.5 l of 
10M stock solution of forward and reverse primers to a final volume of 25 l. 
The ABI 7500 Real-Time PCR system was programmed as indicated in Figure 
2.1. For each qPCR reaction a fragment from GAPDH cDNA was amplified as 
internal control. Relative quantification of gene was calculated using the 
relative ddCT analysis mode of the ABI 7500 Real-Time PCR system 
software. 
 
 
 
Figure 2.1: Thermal-Cycler protocol for RT-qPCR reaction using the 7500 
ABI 7500 Real-Time PCR system software 
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2.3 Imaging methods 
Zeiss LSM Meta 510 or Zeiss LSM 510 inverted equipped with 405 nm, 488 
nm, 543 nm , 594 nm lasers were used for all the fluorescence studies.   
 
2.3.1 Ruffling Assay 
 
Cells were seeded on coverslips (VWR, UK) (1x10
5
 per coverslip). Cells were 
starved overnight and then stimulated with 10% serum supplemented media or 
EGF (20ng/ml). After two washes in cold 1X PBS, cells were fixed in 4% 
paraformaldehyde for 30 minutes at room temperature. Cells were 
permeabilized in 1XPBS/0.25% Triton-X-100 for 2.5 minutes at RT. 
Unspecific staining was prevented blocking the coverslips  with a solution 1X 
PBS/0.1% BSA for 30 minutes at RT. Alexa Fluor 594-Phalloidin (Invitrogen, 
UK) was added at 1:1000 dilution in PBS and incubated for 1 hour at 37°C. 
Hoechst 33342 5µg/ml (Sigma-Aldrich, UK) was added for nuclei staining. 
Coverslips were mounted on glass slides using the anti-fade Vektashield 
(Vector Laboratories, UK) and incubated for 1 hour at 4°C.  Samples were 
analysed using Carl Zeiss™ confocal microscope LSM 510 Meta equipped 
with a 63X oil objective. DAPI was excited with laser 405nm wavelength 
while Alexa Fluor 594 dye was excited at 594nm and emission was measured 
at 620nm. All images were processed using LSM Image browser from Zeiss. 
 
 
2.3.2 Calcium measurement Assay 
   
The fluorescent calcium indicator, Fluo-4 AM (Invitrogen, UK), was used to 
measure changes in intracellular calcium. 4x10
5
 cells were seeded on a 
bottom-glassed chamber for confocal live microscopy (Labtech Ltd, UK). The 
following day, cells were starved in serum free medium overnight. In case of 
siRNA transfection, cells were transfected in a 6 well-plate (chapter 2.2.2.1, 
2.2.2.2) and 24 hours after transfection they were detached and seeded on the 
bottom-glassed chambers as described above. The following day each well 
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was incubated with 200 µl of HBSS (Invitrogen, UK), containing 0.5% BSA 
(Sigma-Aldrich, UK), 2mM CaCl2 (Sigma-Aldrich, UK), 4µM Fluo-4 for 45 
minutes at 37°C/10%CO2. After loading, cells were washed twice in HBSS 
0.5% BSA 2mM CaCl2 and left in the same solution for 30 minutes for de-
esterification of the Fluo-4-AM dye. Where indicated inhibitors were added 
during the de-esterification step for a total time of 30 minutes.  The samples 
were protected from light during all the passages. The samples were moved in 
the confocal facilities and analysed using the LSM 510 inverted confocal 
microscope equipped with a chamber for live imaging at 37°C supplied with 
5% CO2 using a 20X objective. ZEN Carl Zeiss software was used for 
acquisition. The confocal was set in a time lapse acquisition mode acquiring a 
picture every 1.27 seconds, recording the fluorescence emitted by the Fluo-4 
using a 505-545 nm pass-band filter. After recording basal fluorescent for 20 
seconds cells were then stimulated with EGF (20ng/ml) and fluorescent was 
measured for 10 minutes. Analysis of fluorescence intensity was performed 
with ZEN™ Carl Zeiss software. Specifically, thirty cells were gated and 
variation of fluorescence intensity was measured for each sample. The average 
of intensity per time point was calculated and a chart of fluorescence on time 
was generated.  
 
 
2.3.3 Incorporation of Fluorescein-conjugated InsP5 (2-FAM-InsP5) 
 
MDA-MB-231 cells were seeded on coverslips in 12-well dishes at 60% of 
confluence and pre-treated with the indicated inhibitors for 2 hours. Cells were 
incubated with 2-FAM-InsP5 (25 M) (provided by Professor Potter, Bath 
University, UK) or fluorescein (25 M) (Sigma-Aldrich) with or without the 
inhibitors for the indicated times. In the case of MDA-MB-231 transfected 
with siRNA targeting ABCC1 and ABCC5 and a scrambled non-targeting 
sequence, cells were seeded in a 12-well plate at a density of 50% of 
confluence, after 24 hours from transfection. Cells were then incubated with 2-
FAM-InsP5 or fluorescein for the indicated time points. In all cases cells were 
fixed in paraformaldehyde 4% (v/v) for 20 minutes and mounted on glass 
 
 
 
96 
 
slides. Fluorescence was measured by confocal analysis using an LSM 510 
meta exciting the dye with the 488 laser with a 505-515 nm filter. Cell 
fluorescence was measured using the Carl Zeiss LSM software. Intracellular 
fluorescence was measured gating 40 cells for each time point of the 
experiments and mean fluorescence calculated.       
  
2.3.4 Forster Resonance Energy Transfer by acceptor photo-bleaching 
Direct protein–protein interactions were visualized using FRET whereby 
energy from an excited donor is transferred to an acceptor in very close 
proximity. The measurement of the energy transfer was monitored by 
following the fluorescence emission of the donor–acceptor couple and gave a 
reasonable approximation of the proximity and interaction between the two 
molecules, assuming that the emission spectrum of the donor overlapped with 
the excitation spectrum of the acceptor. The efficiency of this process was 
used to estimate the proximity and thus the interaction between PLC1 and 
PDK1 in MDA-MB-231 cells in overexpressing conditions. 
Cells were seeded on coverslips in a 12-well plate at a density of 50% of 
confluence. Cells were co-transfected with PRK5-PLC1 and pOZ-PDK1 and 
after 24 hours from transfection cells were serum deprived overnight. The 
following day, cells were stimulated with a solution of DMEM + EGF (50 
ng/ml) at the indicated time points before being fixed in paraformaldehyde 4% 
(v/v) for 30 minutes at RT. Cells were permeabilized in 1X PBS/0.25% Triton-
X-100 for 2.5 minutes at RT. Unspecific staining was prevented by blocking 
the coverslips  with a solution 1X PBS/0.1% of BSA for 30 minutes at RT. 
Primary antibodies anti-mouse-PLC1,  (Santa Cruz Biotechnology, US) and 
anti-rabbit-PDK1 (Cell Signaling Technology Inc., USA) were diluted 1:50 in 
50 l/coverslip of 1X PBS/0.1% BSA. The day after cells were washed 3X in 
1X PBS/0.1% BSA and incubated with secondary antibodies anti-mouse-
Alexa488 (Invitrogen, UK) and anti-rabbit Alexa555 (Invitrogen, UK) (The 
spectra of the two secondary antibodies are showed in Figure 2.2). 
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Figure 2.2: Donor and acceptor spectra generated with Fluorescence spectra 
viewer tool (http://www.invitrogen.com/site/us/en/home/support/Research-
Tools/Fluorescence-SpectraViewer.html) 
 
Cells were then washed 3X with 1X PBS and mounted on glass coverslips 
using Vecktashield mounting media.  Spectral imaging analysis was performed 
on Carl Zeiss LSM 510 meta. Cells were imaged with excitation λ=488 nm 
and λ=543 laser line and emission spectra were collected respectively in two 
different channels of the PMT detector. Reference spectra were generated from 
coverslips incubated separately with the two Alexa-conjugated secondary 
antibodies alone in order to generate single positive samples and all data were 
corrected for crosstalk and background fluorescence. The FRET efficiency 
was measured by acceptor photo-bleaching according to the method by 
Guillaud et al., 2008 where the de-quenching of the donor emission is a direct 
measure of the FRET efficiency. Cells were imaged with λ=543 nm laser line 
to visualise PDK1 (acceptor) fluorescence and λ=488 nm laser line to visualize 
PLC1 (donor) fluorescence. A selected area of the cell was repeatedly 
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photobleached with λ = 543 nm laser line at full power for 1 minute and FRET 
efficiency was measured as the increase (or dequenching) of PLC1 
fluorescence after photo-bleaching in the selected area. All fluorescence 
measurements were performed in MetaMorph software (Moleculae Devices 
Inc., US). 
Two independent areas in the bleached zone and one area in the non-bleached 
zone were analysed in parallel to ensure that the FRET efficiency values were 
not artefacts due to the photo-bleaching protocol. FRET efficiency was 
calculated using the following equation:  
 
E=[1–(Donor.before–BCK.before)/(Donor.after–BCK.after)]x100 
 
Donor.before = fluorescence intensity of PLC1 before photobleaching  
BCK.before = background intensity before photobleaching  
Donor.after = fluorescence intensity of PLC1 after photobleaching  
BCK.after = background intensity after photobleaching. As a negative control, 
GFP was used as donor, was used to validate the system. 
 
 
 
 
2.3.5 Forster Resonance Energy Transfer by FACS 
MDA-MB-231 were transfected with pOZ-PDK1 and PRK5-PLC either 
individually or in combination. 48 hour after transfection cells where detached 
by incubating with 1X PBS + 0.2% EGTA (w/v) solution for 20 minutes. Cells 
were spin at 1,200 RPM for 5 minutes and resuspended in 1 ml of media 
serum free supplemented with EGF (50 ng/ml) for 5 and 10 minutes.  Cells 
where then fixed in 2% paraformaldehyde solution for 15 minutes. Cells were 
pelleted at 1,200 RPM for 5 minutes and permeabilized in 1XPBS/0.25% 
Triton-X-100 solution for 2.5 minutes at RT. Cells were centrifuged at 1,200 
RPM for 5 minutes and resuspended in 1X PBS/0.1% BSA blocking solution 
for 30 minutes at RT. Cells were then pelleted at 1,200 RPM for 5 minutes and 
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resuspended in 400 l blocking solution containing anti-PLC1 or anti-PDK1 
antibodies either individually or in combination (Table 2.10). Cells were 
incubated overnight at 4°C. The following day cells were centrifuged at 1,200 
RPM for 5 minutes and washed three times for 5 minutes in blocking solution 
before being resuspended in 500 l of blocking solution and read with a Canto 
II FACS (Becton, Dickinson BD; UK)  
Table 2.10: Plasmids, primary and secondary antibodies used for FRET 
experiments by FACS: 
Constructs Primary antibodies  
R=Rabbit; 
M=Mouse 
Secondary antibodies 
(Alexa-555/Alexa-488 
conjugated) 
pCDNA (Negative control) - Alexa 488 (anti-mouse)  
pCDNA (Negative control) - Alexa 555 (anti-mouse) 
pOZ-PDK1 (Single positive) anti-PDK1(R) Alexa-488 (anti-rabbit) 
pOZ-PDK1 (single positive) anti-PDK1(R) Alexa-555 (anti-rabbit) 
PRK5-PLCsingle positive) anti-PLC1(M) Alexa-488 (anti-mouse) 
PRK5-PLCsingle positive) anti-PLC1(M) Alexa-555 (anti-mouse) 
pEGFP/PRK5PLC1 anti-PLC1(M) Alexa-555 (anti-mouse) 
pEGFP/pOZ-PDK1 anti-PDK1(R) Alexa-555( Anti-rabbit) 
pOZ-PDK1/PRK5-PLC anti-PLC1(M) 
anti-PDK1(R) 
Alexa-488 (anti-rabbit) 
Alexa-555 (anti-mouse) 
pOZ-PDK1/PRK5-PLC anti-PLC1(M) 
anti-PDK1(R) 
Alexa-488 (anti-rabbit) 
Alexa-555 (anti-mouse) 
 
Cells were gated according to forward and sideward scatter (FSC/SSC). All 
samples were excited with 488 nm laser and emission measured at 555 nm. The 
single positive samples stained with Alexa-555 conjugated secondary antibodies 
allowed to measure the background emission of the dye when excited with the 
488 nm laser. The single positive samples stained with Alexa-488 conjugated 
secondary antibodies allowed removing of bleed-through fluorescence of the 
donor (Alexa-488) in the FRET channel by adjusting the photomultiplier tube 
(PMT) voltages and compensating for Alexa-488 and Alexa-555 dyes to 
specifically assess FRET in double positive cells. Cells co-transfected with 
pEGFP and PLC1 or PDK1 were used as negative controls of FRET. Data 
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were acquired using FACS Diva software (Becton, Dickinson BD; UK). Data 
were analysed with FlowJo Software (Treestar, US) with the help of Dr. Gary 
Warnes. 
 
 
2.4 Cell Biology 
2.4.1 Cell counting 
Cells were seeded in 12-well plates at a density of 1x10
5
. Cells were grown in 
10% FBS supplemented growth media or in serum-free media. When indicated 
cells were treated with inhibitors. In all the experiments described cells were 
washed with 1X PBS and detached by incubating with trypsin 
(0.25%)/EDTA(0g/l) (PAA, Austria) solution. Trypsin was neutralized by 
adding 1 volume of growth media supplemented with 10% FBS (v/v) and the 
cell suspension was transferred in 1.5 ml Eppendorf tube (VWR, UK). Cells 
were centrifuged at 4,000g for 5 minutes. The supernatant was then removed 
and the pellet was resuspended in 150 l of growth media. Cells were 
manually counted using a Burker chamber. 10 l of cell suspension were 
added into the Burker chamber. All fields delimited by the grid of the chamber 
were counted and cell number calculated according to the formula: 
   
         Cells number/ml=               *10,000 
 
2.4.2 Migration and invasion assay 
2.4.2.1 Cell migration assay 
MDA-MB-231, MDA-MB-435, TSA, 4T1 and A375M cell lines were cultured 
overnight in 6 wells multi-dishes and serum starved overnight before the 
experiment. Polycarbonate transwell insert 8.0 m diameter pores, 10mm 
diameter (Nunc, Thermo Scientific, UK) were coated overnight at 4°C with a 
solution of 10g/ml of Fibronectin (Sigma-Aldrich, UK) in 1X PBS. The 
following day the inserts were washed in PBS 1X for few seconds and 
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transferred in a blocking solution of DMEM or RPMI containing 0.5% BSA 
for 1 hour at 37°C. When indicated cells were pre-treated with inhibitors for 1 
hour before being trypsinized and pelleted. The pellet was resuspended in 2ml 
of RPMI or DMEM 0.5% BSA according to the cell type. Cells were counted 
and a suspension of 10,000 cells in 150l was homogenously added in the 
upper chamber. The lower chamber was filled with 500l of RPMI or DMEM 
0.5% BSA according to the cell type. Cells were allowed to migrate for 4 hours 
at 37°C 5% CO2. Before fixing, non-migrated cells were removed from the 
upper surface of the porous membrane with a cotton bud. Cells underneath 
were then fixed in 4% paraformaldehyde solution for 20 minutes and washed in 
3X in 1X PBS solution for 1 minute. Subsequently inserts were stained with 
0.1% crystal violet solution (v/w) for 10 minutes, then washed 3X with 1X 
PBS and dried. Cells were counted using a Leica phase-light microscope using 
a 10X magnitude objective. A minimum of five fields per transwell were 
counted and an average of migrated cells/field was calculated.      
 
2.4.2.2 Matrigel cell invasion assay 
 
MDA-MB-231, MBA-MB-435, TSA, 4T1, A375M cell lines were cultured 
overnight in 6 well multi-dishes and serum-starved overnight before the 
experiment. The following day Matrigel pre-coated insert (8.0 m diameter 
pores, 10mm diameter) were re-hydrated for 1 hour adding 500ul of RPMI or 
DMEM in the upper and lower compartment, according to the cell type to be 
seeded on the insert. When indicated, cells were pre-treated with inhibitors for 
the appropriated time before being detached from the 6-well dishes by 
trypsinisation. Cells were pelleted and resuspended in 2ml of 1%FBS DMEM 
or RPMI 1640 according to the cell type. Cells were counted and a suspension 
of 500l of media containing 10,000 cells (60,000 in the case of MDA-MB-
435) was seeded on the upper chamber of the insert. The lower chamber was 
filled with 500l of 10% FBS RPMI or DMEM media according to the cell 
type used. Cell invasion was allowed for 36 hours. After 36 hours the upper 
face of the porous membrane was delicately cleaned with a cotton bud in order 
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to remove the non-invading cells. The cells that successfully invade the 
Matrigel were fixed in 4% paraformaldehyde solution (w/v) for 25 minutes. 
Inserts were washed 3X for 1 minute using 1X PBS solution. Cells were 
stained with 0.1% crystal violet solution (v/w) for 10 minutes, then washed 3X 
with 1X PBS and the dried. Cells were counted using a Leica phase-light 
microscope using a 10X magnitude objective. A minimum of five fields was 
counted per insert. Each invasion experiment was performed in duplicate and 
the average of invading cells/fields was calculated. 
 
  
 
2.4.3 Inositol phosphate assay 
Cells were seeded on in 12-well plate at a density of 8x10
5 
cells per well. AG 
1-X8 analytical grade anion exchange resin (formate form, 200–400 mesh, 
BioRad, UK) was re-hydrated overnight in H2O. The following day cells were 
labeled with 0.5 Ci/well [3H]myo inositol (PerkinElmer, US)  in inositol free 
medium M199 (Sigma-Aldrich, UK). After 24 hours, cells were incubated in 
M199 containing 10 mM Hepes, pH 7.4 (Invitrogen, UK) and 20 mM LiCl 
(Sigma, UK) for 15 min before stimulation. A solution of M199 plus EGF (20 
ng/ml) was prepared and used to stimulate the cells at the indicated time points. 
Cells were then lysed with 1 ml of ice cold 0.1 M HCOOH. In parallel, 3 ml of 
the re-hydrated resin were added to each column and left to set for 5 minutes. 
Columns were washed with 10 ml of H20 before loading the cell lysate. Free 
inositol was eluted and collected by elution with 10 ml of H2O and 
radioactivity counted by liquid radioactivity counting. Columns were washed 
with 5 ml of H2O. Glycophosphatydylinositols (GPI) were eluted using 5 ml of 
“solution A” containing (5 mM Na2B4O7, 160 mM NH4HCOO), collected and 
radioactivity counted by liquid radioactivity counting. After washing with 5 ml 
of solution A, inositol phosphates were eluted with 2 ml of NH4HCOO
 
1M and 
radioactivity counted by liquid scintillation. Radioactivity measured in the 
inositol fraction was used to normalise the radioactivity content of the samples. 
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Inositol phosphate production was expressed as percentage of inositol 
phosphate produced compared to the control unstimulated sample. 
2.4.4 [
3
H]InsP5 incorporation assay 
MDA-MB-231 transfected with siRNA targeting ABCC1 and ABCC5 and a 
scrambled non-targeting sequence were seeded in a 12-well plate at a density 
of 50% of confluence 24 hours after transfection. In case of treatment with the 
ABCC1 inhibitor MK571 MDA-MB-231 were pre-treated with MK-571 
(40M) for 2 hours in 10% FBS growth media at 37°C/5% CO2. In the case of 
MDA-MB-231 transfected with siRNAs, cells were then incubated with 2 
l/well of [3H]InsP5 for 1 hour minutes. In the case of MDA-MB-231 pre-
treated with MK-571 cells were incubated with [
3
H]InsP5 (2l/well) for 2 
second as basal incorporation and for 15 and 30 minutes. Cells were washed 
3X with cold 1X PBS to remove the non-incorporated [
3
H]InsP5, then lysed on 
ice using 1 ml of HClO4 0.6M + 0.20 mg/ml Inositol Hexakisphosphate (IP6) 
solution and incubated on ice for 5 minutes. The whole lysate was diluted in 6 
ml of scintillation liquid and radioactivity assessed by radioactivity counting. 
Radioactivity counts were normalized for the protein concentration of a 
duplicate 12 plate-dishes seeded and treated in parallel with “cold” InsP5 as a 
duplicate. In the case of cells transfected with siRNAs incorporation was 
expressed as percentage of incorporation of scrambled after 1 hour of 
incorporation. In the case of cells treated with KM-571 incorporation was 
expressed as fold increase of basal incorporation. 
 
2.5 Statistical analysis 
Statistical analyses were carried out using the one-tailed, paired t-test using 
Microsoft Excel®. 
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Chapter 3 
PLC1 is essential for cancer cell 
migration and invasion
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3.1 Introduction 
PLC1 is activated by integrins engagement to the ECM and it also plays an 
important role in growth factor-induced cell motility, being activated by 
tyrosine kinase receptors for EGF, FGFs, NGF, VEGF, HGF and IGF-1 (Wells 
et al., 2002). Recent evidence produced by our group confirmed the pivotal 
role of PLC1 in malignant cell invasion and its role in metastasis development 
and progression (Sala et al., 2008).      
During metastasis, malignant cells are able to “escape” from the primary 
tumour through the circulatory or lymphatic system, invading distant healthy 
tissues to initiate a new malignant lesion. Cell motility is critical for this 
process to occur and the mechanisms involved in regulation of cell motility are 
the results of an intricate network of signals activated by different growth 
factors, chemo-attractant and ECM components in vivo. The first in vitro tool 
to study cell motility was built by Boyden, therefore it was called Boyden 
chamber and was initially used to study leukocyte chemotaxis. It consists of 
two medium-filled chamber separated by a microporous membrane (Falasca et 
al., 2011). Cells are seeded in the top compartment and allowed to migrate for 
an appropriate incubation time toward chemotactic agents present in the 
bottom chamber media, such as growth factors or ECM components used to 
coat the porous membrane. Since the cells migrate from the upper 
compartment to the lower one through a porous membrane, the Boyden 
chambers are also called transwell chambers. Once the cells pass through the 
membrane they remain adherent to it. For this reason the cells need to be fixed 
on the membrane and stained to allow quantification based on manual counting 
using a phase contrast microscope. 
 
In order to investigate the role of PLC1 in cell migration and 3D Matrigel 
invasion in cancer cell lines, I performed cell migration and cell invasion 
assays using different cancer cell lines (breast and melanoma cell lines) upon 
PLC1 inhibition by chemical and molecular biology approaches. Cytoskeleton 
remodelling was also analysed in those cell lines in order to investigate a 
potential role of PLC1 in this process. 
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3.2 Results 
     
Migration of breast cancer cell line MDA-MB-231 was analysed in vitro using 
the transwell assay. The transwell inserts used in this assay consist of a porous 
polycarbonate membrane with an average porous size of 8 m. The inserts 
were coated with fibronectin, an ECM component, used as chemo-attractant. 
Cells were seeded in the upper chamber of the insert and allowed to migrate 
for 4 hours before being fixed in paraformaldehyde and stained with crystal 
violet. Cell migration was calculated by manual cell counting using a 10x 
magnification of a phase contrast microscope.   
In order to determine the appropriate number of cells to be used in the assay, a 
preliminary experiment was performed using three different amounts of cells 
per transwell (5,000; 10,000; 20,000). Pictures in Figure 3.1A show 
representative fields of cell migrated on transwell insert. This experiment 
indicated that the optimal experimental condition to perform the assay was 
obtained when 10,000 cells were seeded on the inserts, which led to an average 
of 100 cells migrated through the porous membrane per fields, a reasonable 
number for the cell counting (Figure 3.1B). 
 
 
Figure legend next page 
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Figure 3.1: (A) Pictures of transwell inserts after fixing and staining with 
crystal violet. Representative fields of insert seeded with 5000 cells (left) and 
20000 cells (right). (B) Quantification of migrating cells by cell counting and 
expressed as number of migrated cells per field. The graph represents one 
experiment performed in duplicate in order to optimize the experimental 
conditions.  
 
3.2.1 PLC activity is essential for MDA-MB-231 fibronectin-induced 
migration  
In order to investigate the role of PLC1 in fibronectin-induced migration in 
MDA-MB-231 cells I decided to test the effect of the PLC inhibitor U73122 on 
cell migration. The inhibitor U73122 is a pan-PLC inhibitor that inhibits the 
lipase activity of all the PLC family components and has been show to inhibit 
cell motility (Jones et al., 2005). Since PLC1 is activated by fibronectin, the 
inhibitor was a useful tool to start investigating the involvement of PLC1 in 
fibronectin-induced migration. MDA-MB-231 were serum starved overnight 
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and pre-treated with U73122 (5μM) for 30 minutes before being plated on 
transwell inserts in the presence or absence of the inhibitor. Cells were allowed 
to migrate for 4 hours before being fixed. Migration of cells treated with the 
inhibitor was compared to control cells treated with the inactive analogue 
U73343. Migration of cells treated with the drug carrier (DMSO) alone was 
also determined. Cell migration was completely inhibited in MDA-MB-231 
treated with U73122 (p=0.001). No inhibition of cell migration was detected in 
cells treated with the inactive analogue U73343 compared to cells treated with 
vehicle alone. This data indicated that PLC activity is essential for fibronectin-
induced migration in MDA-MB-231 (Figure 3.2).          
 
Figure 3.2: Effect of PLC inhibition on fibronectin-induced cell migration. 
Migration is expressed as migrated cells per field. Migration of MDA-MB-231 
treated with U73122 was compared to cells treated with the inactive analogue 
U73343. Columns are the mean of 3 independent experiments performed in 
duplicate; bars S.E. *p=0.001  
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3.2.2 Effect of a PLC1 mutant form constitutively recruited to the plasma 
membrane on fibronectin-induced cell migration. 
PLC1 plays an important role in cellular spreading on Matrigel in endothelial 
and cancer cells (Jones et al., 2005; Jones et al., 2007). As shown in Figure 3.2, 
inhibition of PLC activity leads to impaired fibronectin-induced migration in 
MDA-MB-231. PLC1 has been demonstrated to be involved in focal adhesion 
formation during cell motility and it is recruited to the leading edge of the cells 
during wound healing assay and cell migration (Piccolo et al., 2002). Therefore 
PLC1 recruitment at the leading edge of the cells is crucial to regulate cell 
motility and it is probably involved in controlling directional motility.  
In order to assess the potential involvement of the PLC1 isoform in 
directional motility I decided to test the effect of overexpressing a 
constitutively membrane-recruited PLC1 mutant on fibronectin induced 
migration in MDA-MB-231. Since PLC1 is recruited to the plasma membrane 
at the leading edge, I hypothesised that a constitutively active form of PLC1 
recruited all along the plasma membrane could affect directionality during the 
migration process. For this purpose MDA-MB-231 cells expressing a 
palmitoylated form of PLC1 (MDA-MB-231 PALM-PLC1), kindly provided 
by Dr. Bonvini, were analysed on fibronectin-induced cell migration transwell 
assay.  
MDA-MB-231 cells expressing only the palmitoylation (MDA-MB-231 
PALM) sequence were used as internal control in the migration experiments. 
Data indicated a significant reduction of fibronectin-induced migration in 
MDA-MB-231 PALM-PLC1 compared to MDA-MB-231 PALM (Figure 
3.3), suggesting that overexpression of a mutant PLC1 constitutively 
associated to the plasma membrane affects the ability of cells to migrate 
towards fibronectin. These data further supported the hypothesis that 
recruitment of PLC1 to the leading edge of migrating cells is important for 
cell migration.    
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Figure 3.3 Cell migration in MDA-MB-231 expressing PALM-PLC1:   
Number of migrated MDA-MB-231 (Parental) or cells expressing a 
palmytoylated PLC1 (PALM PLC1), or the palmytoylation sequence alone 
(PALM) is expressed as percentage of migrated MDA-MB-231 expressing the 
empty vector as control. Columns are the mean of three different experiments 
each of them performed in duplicate; bars S.E. **p=0.005  
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3.2.3 Downregulation of PLC1 expression using a pSUPERIOR construct 
containing specific shRNA targeting PLC1. 
Since no PLC1 specific inhibitors are available, the best available molecular 
approach to assess the role of PLC1 activity in different cellular function was 
the generation of stable cell lines downregulated for PLC1 using short hairpin 
RNA (shRNA). pSUPERIOR.retro.puro vector containing unique 19 
nucleotides sequence complementary to the mRNA transcript of PLC1 was 
generated previously in the lab (Sala et al., 2008) (see chapter 2.2.2.3.1; 
2.2.2.3.2). The resulting transcript of the recombinant vector is predicted to 
fold back on itself to form a 19-base pair loop structure (shRNA) which is then 
cleaved in the cell to produce a functional siRNA. Three-point mutations in the 
19 nucleotides sequence were introduced to generate an appropriate 
pSUPERIOR.retro.puro vector control (3MUT) (Sala et al., 2008). MDA-MB-
435 and TSA cell lines were infected with pSUPERIOR.retro.puro 3MUT and 
pSUPERIOR.retro.puro shPLC1. Infected cells were kept in culture in the 
presence of puromycin. Western Blot (WB) analysis of cell extracts was 
performed to assess the expression level of PLC1 in cells expressing the 
targeting sequence shPLC1 and control cells 3MUT (Figure 3.4). Cells 
expressing the shPLC1 sequence showed a significant reduction in PLC1 
protein levels compared to the 3MUT control cells. 
 
Figure 3.4 WB analysis of stable protein downregulation of PLC1: PLC1 
protein level was assessed by WB in cell lysates of MDA-MB-435 and TSA 
cell lines expressing the specific shRNA targeting PLC1 (shPLC1) and 
compared to expression in cells expressing the non-targeting shRNA (3MUT). 
PLC1 expression was assessed by immunoblot using a specific anti-PLC1 
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antibody. Immunoblot for ERK2 was used as control for equal loading.  The 
position of the bands correspond to 155 KDa for PLC1 and 42 KDa for 
ERK2.  
3.2.4 Inducible downregulation of PLC1 expression using a pSUPERIOR 
construct 
The pSUPERIOR.retro.puro vector can be used as an inducible vector to 
produce siRNA in mammalian cells. The vector contains a tetracycline 
operator 2 (TetO2) derived from E. Coli in the H1 promoter. The TetO2 
sequence acts as binding site for a homodimer of Tet repressor that, if present, 
blocks the transcription of the shRNAs. Therefore a previous transfection with 
the tetracycline repressor expressing vector is necessary to allow the binding of 
the Tet repressor to the TetO2 operator. The tetracycline repressor binds with 
high affinity to the operator sequence in the absence of tetracycline. Upon 
addition, tetracycline binds to the Tet repressor causing conformational 
changes to the repressor that impair the operator-repressor binding, eventually 
resulting in the transcription of the shRNA duplex that, once processed from 
the RNAi machinery of the cell, provides functional siRNA (Figure 3.5). 
 
.  
Figure 3.5 Model of inducible protein downregulation using pSUPERIOR 
inducible system. Figure adapted from Santa Cruz Biotechnology 
(http://www.scbt.it/gene_silencers.html).  
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Therefore MDA-MB-231 cells were first transfected with a vector expressing 
the Tet repressor and selected to generate stable Tet repressor expressing 
clones. Subsequently, a selected clone was infected with the pSUPERIOR 
3MUT and pSUPERIOR shPLC1 in order to generate cells with an inducible 
downregulation of PLC1 and the respective control. These cells were 
previously generated in the lab (Sala et al., 2008). As shown in Figure 3.6, 
MDA-MB-231 pSUPERIOR 3MUT cells show comparable PLC1 expression 
in the presence or absence of tetracycline addition indicating that the 3MUT 
sequence has no effect on the expression levels of PLC1. On the contrary, 24 
hours of treatment with tetracycline of MDA-MB-231 pSUPERIOR shPLC1 
cells induces a clear downregulation of PLC1 protein expression. 
  
 
 
Figure 3.6 Inducible downregulation of PLC1: WB analysis of PLC1 
protein level in cells expressing the TET repressor and a non-targeting shRNA 
(3MUT) or the targeting shRNA (shPLC1) in the presence or absence of 
tetracycline. ERK2 immunoblot was used as an equal loading control.    
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3.2.5 Cell invasion assay in breast cancer cells stably downregulated for 
PLC1 expression 
The experimental conditions used in the transwell assays are very different 
from the physiological conditions encountered by cancer cells during the 
metastatic process. ECM and the basal membranes of organs represent the 
main barriers that cancer cells need to cross in order to locally invade the 
tissue of origin or to initiate a secondary tumour in a distant organ. 
The Matrigel cell invasion assay more closely mimics the physiological 
conditions encountered by the cancer cells during ECM invasion. Matrigel is a 
mixture of ECM components produced by the Engelbreth-Holm-Swarm (EHS) 
murine sarcoma that has been used to study cell morphology on ECM 
components and the three-dimensional architecture in normal and malignant 
cell lines. The main components of Matrigel are laminin, collagen IV, entactin 
and perlecan; growth factors are minor components. In particular Matrigel 
exists in a growth factor rich composition, or in growth factor reduced 
composition. Matrigel can be applied on the inserts in its cold liquid form over 
transwell inserts and allowed to polymerise to form a gel with a defined three 
dimensional structure. 
The effect of PLC1 downregulation on three-dimensional invasion was 
investigated previously in the lab using MDA-MB-231 stably downregulated 
for PLC1 expression (Sala et al., 2008). I decided to perform Matrigel 
invasion experiments using other breast cancer cell models such as MDA-MB-
435 and TSA stably downregulated for PLC1 expression. This allowed me to 
investigate the role of PLC1 in 3D invasion in different breast cancer cell 
lines. MDA-MB-435 and TSA expressing shRNA targeting PLC1 expression 
(shPLC1) or the 3MUT shRNA (sh3MUT) cloned in the 
pSUPERIOR.retro.puro were used for the assay. Cells were seeded on inserts 
pre-coated with Matrigel growth factor-reduced and fixed after the appropriate 
invasion time (see chapter 2.4.2.2). I observed that downregulation of PLC1 
completely inhibited Matrigel invasion in MDA-MB-435 (p<0.05) and in TSA 
(p<0.01) compared to the respective controls. These data indicate that PLC1 
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is required for 3D-Matrigel invasion in the breast cancer cell lines analysed 
and that its downregulation severely impairs the cellular movements through 
the 3D-structure of the Matrigel (Figure 3.7).  
 
 
Figure 3.7 Analysis of Matrigel invasion in breast cancer cell lines: 10,000 
cells were seeded on Matrigel and allowed to invade for 36 hours. Cells that 
have invaded were fixed, stained with crystal violet and counted. 
Quantification of Matrigel cell invasion is expressed as percentage of invading 
cells.  Columns are the mean of three independent experiments each of them 
performed in duplicate; bars S.E. *p<0.05; ** p<0.01  
 
 
 
 
 
 
* ** 
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3.2.6 Cell invasion assay in melanoma cells transiently downregulated for 
PLC1 expression 
In order to determine whether PLC1 has a role in invasion of different cancer 
cells, the effect of PLC1 downregulation in the highly invasive melanoma cell 
line A375M was investigated. Since A375M cells stably downregulated for 
PLC1 expression were not available, I decided to downregulate PLC1 
transiently using specific PLC1-targeting siRNA. A375M were transfected 
with Hiperfect transfecting reagent (Qiagen) (see chapter 2.2.2.2). 
Optimisation of the protocol transfection was necessary in order to setup the 
experimental conditions. Once the protocol was optimised, the invasion on 
Matrigel of A375M transfected with siRNA for PLC1 or a non-targeting 
sequence (Scrambled) was determined. WB analysis of lysates of transfected 
cells was performed in parallel to each invasion experiment at the end of the 
assay to evaluate the effective downregulation of PLC1 protein expression as 
shown in Figure 3.8A.  
Analysis of cells that have invaded demonstrated that downregulation of 
PLC1 protein expression strongly inhibits Matrigel invasion in A375M 
(p=0.001). These data confirm the importance of PLC1 in 3D cellular 
invasion and show that PLC1 is important for cell invasion not only in breast 
cancer cell lines but also in other models such as melanoma (Figure 3.8B). 
 
 
Figure legend next page... 
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Figure 3.8 (A) PLC1 transient downregulation in A375M assessed by WB 
using specific PLC1 antibody. (B) Matrigel cell invasion assay comparing 
A375M siPLC1 and A375 scrambled invasion rate. Cells were starved 
overnight 24 hours after transfection and then seeded on Matrigel-coated 
transwell for 36 hours before being fixed and stained. Columns are the mean of 
three different experiments performed in duplicate; bars S.E. *P=0.001  
 
3.2.7 Analysis of cytoskeleton remodelling in MDA-MB-435 
As described in chapter 1.3.4, PLC1 is involved in cytoskeleton remodelling 
and its inhibition induces a rounded morphology in endothelial and cancer cell 
lines which fail to form cell protrusion and to undergo cell spreading in 
response to integrin engagement (Jones et al., 2005). Previous experiments 
performed in the lab showed that EGF-induced membrane ruffles are inhibited 
in MDA-MB-231 cells downregulated for PLC1 (Sala et al., 2008). Therefore 
I decided to investigate the effect of PLC1 downregulation on cytoskeleton 
remodelling in other breast cancer cell lines. The effect of PLC1 
downregulation on cytoskeleton remodelling was investigated using 
immunofluorescence staining of actin with Alexa
®
Fluor 594 phalloidin. 
Phalloidin is a molecule with high affinity for actin, belonging to the family of 
* 
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phallotoxins, which stabilizes F-actin preventing actin depolymerisation. 
Phalloidin-conjugated with the Alexa® Fluor 594 dye allows fluorescent 
visualization of actin cytoskeleton by excitation at 543 nm wavelength. MDA-
MB-435 cells were serum starved overnight and then stimulated with EGF or 
media supplemented with 10% serum for 6 minutes before being fixed and 
examined with a confocal microscope. Serum and EGF stimulation induces 
formation of membrane ruffles and cytoskeleton protrusion (white arrows in 
Figure 3.9A) in both MDA-MB-435 3MUT and MDA-MB-435 shPLC1.  
However downregulation of PLC1 significantly reduced the percentage of cell 
processing membrane ruffles or cellular protrusion (Figure 3.9B). These data 
indicate that PLCis required for polymerization of new actin filaments 
underneath the plasma membrane, which is essential for membrane ruffling 
formation and growth factor-induced cytoskeleton remodelling. 
 
 
Figure legend next page... 
MDA-MB-435 
A 
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Figure 3.9: PLC1 is important for cytoskeleton remodelling: (A) 
Phalloidin staining of actin cytoskeleton in unstimulated and EGF- or Serum-
stimulated MDA-MB-435. Arrows indicate membrane ruffles. (B) 
Quantification of membrane ruffles was performed on 4 independent 
experiments. At least 100 cells per experiment were counted and classified 
according to the presence or absence of membrane ruffles. Columns represent 
the average of four independent experiments ±SEM. Bar=10 m,*p=0.05, 
**p=0.01.  
 
3.2.8 Analysis of cytoskeleton remodelling in TSA murine breast cancer 
cell line     
To determine whether PLC1 has a role in actin remodelling in other breast 
cancer cell lines, actin cytoskeleton staining was performed in TSA cells. Data 
revealed that serum-induced and EGF-induced membrane ruffle formation was 
strongly inhibited in TSA shPLC1 compared to control TSA 3MUT (Figure 
3.10). Inhibition of membrane ruffle formation was more evident in this cell 
line than in the MDA-MB-435 (Figure 3.9A) but data in both cell lines 
demonstrated the role of PLC1 in EGF- and serum-induced actin remodelling. 
B 
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Figure 3.10 (A) Phalloidin staining of actin cytoskeleton in unstimulated and 
EGF- or Serum-stimulated TSA. Arrows indicate membrane ruffles 
Bar=10m. (B) Quantification of membrane ruffling was performed in 4 
A
B 
B 
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different experiments in duplicate. At least 100 cells per experiments were 
counted and classified according to the presence or absence of membrane 
ruffles. Columns represent the average of four independent experiments. bars 
S.E., *p=0.05.  
 
3.3 Discussion 
The tumour is the second cause of death in adults. Surgical excision of the 
primary tumour can result in good prognosis. However, cancer cells can 
acquire metastatic capacity leading to the spreading of tumour in distant tissues 
often resulting in a poor prognosis. Metastatic tumours are often resistant to 
chemotherapy and non-responsive to treatment and therefore the metastatic 
stage in cancer disease represents the most serious condition. Cancer cells able 
to metastasise are the result of a selective process where cells with high ability 
to migrate and to invade the ECM are selected. Understanding the mechanism 
by which they migrate and can invade is therefore a key goal in cancer 
research. It has been widely accepted that PLC is involved in cell migration 
and cell invasion in vitro and in vivo. Previous works investigated how 
integrins (Tvorogov et al. 2004) and EGF stimulate PLC-mediated cell 
migration and invasion in different normal and cancer cell lines. Furthermore 
the use of specific siRNA targeting PLC1 expression underlined the 
importance of this specific isoform in cell spreading on different substrates 
such as fibronectin and Matrigel. The EGFR-PLC1 pathway plays an 
important role in cell motility and cancer invasion (Chen et al., 1994; Kassis et 
al., 1999). Indeed EGFR and ERB2 receptors have been linked to increased 
invasivity and poor prognosis in breast cancer patients, and inhibition of PLC 
using the pan-PLC inhibitor U73122 or EGFR inhibitor decreased breast 
cancer cell migration in vitro (Kassis et al., 1999) as confirmed in my 
experimental system (Figure 3.2).  
Furthermore PLC1 is highly expressed in colon cancer, breast cancer and 
highly metastatic colorectal tumour cell lines (Nomoto et al., 1995; Smith et 
al., 1998). Especially, high levels of PLC were found in breast carcinoma 
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metastases compared to primary tumour (Sala et al, 2008), indicating that this 
enzyme is important for the metastatic process.  Expression of a dominant-
negative mutant of PLC1 in de novo-occurring carcinomas of the mammary 
or prostate gland mice models diminished lungs metastasis (Shepard et al., 
2007). These data pointed at PLC as an important regulator of metastasis 
dissemination and suggested PLC as a potential therapeutic target to prevent 
metastasis formation. However it should be mentioned that all these studies 
were obtained using generic PLC inhibitors or a dominant negative mutant. My 
results were obtained using specific siRNA or shRNA that allowed the 
transient or stable downregulation of PLC1 expression in a panel of metastatic 
breast cancer cell lines and one cell line of a highly metastatic melanoma. The 
experiments described in this chapter were published in a Cancer Research 
paper together with parallel experiments performed by co-authors (Sala et al., 
2008).  Downregulation of PLC1 inhibited Matrigel cell invasion in vitro in 
all the cell lines, indicating that this enzyme has a role in cell motility and 
invasion in different cell lines (Figure 3.7; 3.8). It has been already shown that 
PLC1 is recruited to the leading edge of migrating cells in a PI3K dependent 
manner (Falasca et al., 1998; Piccolo et al., 2002) and that it is involved in 
integrin-induced cytoskeleton remodelling downstream of FAK activation 
(Zhang et al., 1999), which results in directional migration. In line with this, 
data in Figure 3.3 shows that the expression of a mutant PLC1 constitutively 
associated to the plasma membrane inhibits the fibronectin- induced cell 
migration, likely through a loss of cell directionality caused by lack of 
polarization of PLC1. Data in the literature have also demonstrated an 
important role of PLC1 in integrin-induced cell spreading and cytoskeleton 
remodelling. Mouse embryonic fibroblast (MEF) cells knocked-down for 
PLC1 showed rounded morphology and diminished RAC1 activation upon 
integrin engagement which is essential for membrane ruffles formation (Choi 
et al., 2007). Consistent with this we also reported a role of PLC1 in EGF-
induced Rac1 activation (Sala et al., 2008).  Similarly, I observed that 
downregulation of PLC1 in MDA-MB-435 and TSA breast cancer cells 
impaired ruffles formation upon EGF or serum stimulation (Figure 3.9-3.10), 
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indicating that PLC1 plays an essential role in cytoskeleton remodelling 
which is essential for protrusion formation in cancer cell lines in turn necessary 
to regulate cell motility.  Taken together these studies highlighted PLC1 as a 
key molecular enzyme involved in cell motility in normal and in cancer cells. 
Interestingly PLC1 has been found overexpressed in different cancer type like 
prostate and breast cancer. Furthermore we reported that PLC1 was 
overexpressed in 50% of metastasis form breast cancer patients (Sala et al., 
2008). Data showed in this chapter showed that PLC1 isoform is essential for 
cell invasion of breast cancer and melanoma cells on Matrigel. These data 
supported the hypothesis that PLC1 might have a role in the metastatic 
process. Indeed, based on these data, we performed in vivo metastasis assay 
using MDA-MB-231 cells expressing the stable and inducible system in order 
to downregulate PLC1 protein expression (Sala et al., 2008) and we 
demonstrated that PLC1 is important for both development and progression of 
metastasis (chapter 1.4). 
 
Summary 
Taken together these data demonstrated the main role of PLC1 in cell 
migration and in particular in cancer cell invasion in vitro. Furthermore data 
showed that PLC1 has a main role in growth factor-induced cytoskeleton 
remodelling, which may explain the eventual inhibition of cell motility. These 
data, published in a Cancer Research paper, demonstrated the role of PLC1 in 
metastasis and highlighted PLC1 as a potential target for anti-metastatic drug 
development. 
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Chapter 4 
PLC1 is the main PLC isoform 
involved in EGF- and FGF- induced 
calcium release and InsP3 production 
in  
MDA-MB-231 and endothelial cells 
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4.1 Introduction 
The results described in chapter 3 demonstrated the essential role of PLC1 on 
cell migration, invasion and cytoskeleton remodelling. These data, together 
with our data indicating the key role in metastasis development and 
progression (Sala et al., 2008), suggested that targeting PLC1 may represent a 
novel key anti-metastatic strategy. In order to investigate the potential effect of 
PLC1 inhibition it was first necessary to find an unequivocal read out of the 
enzymatic activity of PLC1. PLCγ1 is activated by different growth factor 
like EGF, FGF and PDGF (Kim et al., 1990; Kim et al., 1991). Once activated 
PLC1 hydrolyzes PtdIns(4,5)P2 leading to accumulation Ins(1,4,5)P3 and 
diacylglycerol that in turn induce calcium release from internal stores and the 
activation of some protein kinase C (PKC) isoforms, respectively. Following 
the initial calcium release from the internal stores and plasma membrane 
depolarisation, store operating channels (SOC) situated on the plasma 
membrane allow the influx of calcium ions from the extracellular compartment 
providing a more sustained signal (Patterson et al., 2005M; Heo et al., 2006). 
Analysis of cytoplasmic calcium variation provides an indirect read-out of IP3 
production which is dependent from PLC activity. Molecular probes are 
available to measure calcium concentration in a fluorescence assay. In 
particular the fluorescent calcium probe Fluo-4 AM is extensively used to 
measure variation in the cytoplasm calcium levels on time. This is obtained 
using a confocal time lapse analysis exciting the probe with a 488 nm 
wavelength laser and measuring the emission at 515 nm.  
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4.2 Results 
4.2.1 Effect of PLC1 downregulation on EGF-induced calcium release in 
MDA-MB-231  
EGFR and HerB family receptors are often overexpressed in breast cancer and 
EGF stimulates activation of PLC1 in different types of cancer (Thomas et al., 
2003; Price et al., 1999). Based on this, the effect of PLC1 downregulation on 
calcium variation upon EGF stimulation was determined in MDA-MB-231 
cells.  
As shown in Figure 4.1, calcium measurements were performed in MDA-MB-
231 cells expressing the inducible system, described in chapter 3.2.4, in the 
absence (PLC1 expressed) or presence (PLC1 downregulated) of 
tetracycline. Cells were stimulated with EGF (50 ng/ml) after a pre-acquisition 
of 1 minute and the fluorescence was monitored for 8 minutes. ATP was added 
at the end of the experiment as positive control in order to determinate cell 
viability. MDA-MB-231 not treated with tetracycline (-TET) responded in a 
fast-response-manner to EGF stimulation. In contrast MDA-MB-231 
downregulated for PLC1 (+TET) did not show any fluorescence variations 
after EGF stimulation. The calcium response induced by ATP was comparable 
in both MDA-MB-231 (-TET) and MDA-MB-231 shPLC1 (+TET) indicating 
that cells were equally viable for the duration of the analysis. This data 
indicated that PLC1 is essential for EGF-induced calcium mobilisation in 
MDA-MB-231 and suggested that other PLC members are not involved in 
EGF-induced calcium release in this cell line. 
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Figure 4.1: PLC1 is essential for EGF-induced calcium mobilisation: 
Calcium mobilisation assay upon EGF stimulation: (A) Calcium increase in 
EGF-stimulated-MDA-MB-231 when PLC1 is expressed. Arrows indicate the 
MDA-MB-231 shPLC1 (-TET) 
MDA-MB-231 shPLC1 (+TET) 
 
 
 
128 
 
time point of EGF or ATP treatment. (B) Calcium increase in EGF-stimulated-
MDA-MB-231 when PLC1 expression is downregulated by tetracycline 
treatment is not expressed following the induction of transcription of the 
specific shRNA. Arrows indicate the time point of EGF or ATP treatment. 
Graph is the average of three independent experiments.  
 
4.2.2 Effect of PCL1 downregulation on EGF-dependent Inositol 
Phosphates accumulation 
 
In order to validate the calcium measurement data obtained in MDA-MB-231 
expressing the inducible system targeting PLC1, I used a complementary 
approach to assess PLC1 activity. As described in introductory chapter 4.1 the 
hydrolysis of PtdIns(4,5)P2 by PLC produces the second messengers 
Ins(1,4,5)P3 and DAG. Measurement of inositol phosphates production 
represents a direct read-out of PLC activity upon cellular stimulation. The 
assay specifically used in this set of experiments measures the production of all 
inositol phosphates species. However, since the inositol phosphates variation is 
mainly due to the Ins(1,4,5)P3 production generated by PLC activation and its 
degradation products, the assay is a direct read-out of PLC activation.  
MDA-MB-231 cells expressing the inducible system were divided in two 
groups. One group was treated with tetracycline 24 hours before the labelling 
to induce PLC1 downregulation (+TET), whereas the second group was not 
treated with tetracycline and used as control (-TET). This second group 
therefore expressed PLC1 since the silencing system was not induced. Cells 
were then labelled using 
3
H-myo-inositol for 24 hours in inositol free, serum 
free media and then stimulated with EGF at different time points. Cells were 
lysed, inositol phosphates were separated by anion exchange chromatography 
and the total amount was assessed by liquid radioactivity counting. 
Downregulation of PLC1 (MDA-MB-231 shPLC1 +TET) strongly inhibited 
the EGF-induced inositol phosphates production at all time points compared to 
the control MDA-MB-231 sh PLC1 –TET (Figure 4.2). Taken together 
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calcium measurement assay and inositol phosphates production assay indicate 
that EGF stimulation specifically activates the PLC1 isoform in MDA-MB-
231 excluding any significant involvement of other PLC isoforms.  
 
Figure 4.2 Inositol phosphate assay: MDA-MB-231 shPLC1 (-TET) and 
MDA-MB-231 shPLC1 (+TET) were stimulated with 50 ng/ml EGF for 
1,3,5,7,10 minutes. Inositol phosphates accumulation was expressed as 
percentage of the respective basal. Graphs are the average of 4 independent 
experiments; bars S.E; *P<0.05  
 
 
4.3 Discussion 
In this chapter I described two assays used to analyse PLC1 activity: the 
calcium mobilisation assay and the inositol phosphates assay. The calcium 
assay using the confocal microscope in a time lapse mode was rigorously 
optimised since it is composed of a step of incorporation of the Fluo-4-AM 
probe, followed by a de-esterification step. The optimal concentration of Fluo-
4 to be used was determined empirically evaluating the number of fluorescent 
 
 
 
130 
 
cells after 1 hour of incubation with a solution 2mM and 4mM of Fluo-4. Only 
cells incubated with 4M Fluo-4 showed detectable fluorescence. The cells 
were incubated in presence or absence of calcium at 2mM concentration. The 
absence of calcium caused cell detachment from the bottom glassed plate, 
indicating that calcium was essential for cell adhesion in MDA-MB-231. 
Because of this all subsequent calcium measurement were performed in the 
presence of extracellular calcium, therefore the analysed calcium variations 
were due to the overall flux of calcium across the membranes (internal store 
and extracellular Ca
2+
 influx). The inositol phosphate assay was used to 
validate data obtained by calcium release, since this method measures directly 
the production of inositol phosphates. Data obtained analysing the intracellular 
calcium mobilisation and the inositol phosphate production showed that down 
regulation of PLC1 completely inhibits EGF-induced calcium release in 
MDA-MB-231. As described in paragraph 1.2.5, PLC can also be activated 
by EGF. However the fact that PLC is mainly expressed in tissues such brain, 
colon and lungs and together with results obtained from calcium and inositol 
phosphates measurements rules out any contribution of this PLC isoform to 
the EGF-induced signalling in this particular model. Therefore PLC1 appears 
to be the only member of the PLC family necessary for EGF induced-calcium 
mobilisation in MDA-MB-231.  
Summary 
Calcium release assay revealed that PLC1 is the only PLC isoform involved 
in the EGF-induced signalling in MDA-MB-231 
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4.4 PLC1 siRNA interference inhibits FGF-2 induced calcium release in 
HUVEC cells 
4.4.1 Calcium release assay upon FGF-2 addition 
Angiogenesis is involved in different processes such as development, wound 
healing and tissue regeneration. It plays also an important role in disease such 
as arteriosclerosis and tumour growth. This process involves endothelial cells 
which are able to organise three dimensional capillary structures. Different 
growth factors play an important role in angiogenesis. The most investigated 
growth factor, the vascular endothelial growth factor (VEGF), has been related 
to pathological angiogenesis and has been the targeted for development of 
anti-angiogenic agents. The fibroblast growth factor family (FGF) is 
composed of 22 different factors. In particular it has been reported that FGF-2 
is upregulated in different cancers. FGF induces activation of PI3K/AKT 
pathway, Src family tyrosine kinases and Ras pathway and it has been shown 
to activate PLC1. It was previously observed in my laboratory that 
downregulation of PLC1 strongly reduces the FGF-induced inositol 
phosphates accumulation in Human umbilical vein cells (HUVEC) (Maffucci 
et al., 2009). To further investigate whether FGF-2 was able to activate 
PLC1, I decided to analyse FGF-2-induced calcium mobilisation. The assay 
was first optimized for this cell line. Cells were labelled with FLUO-4 and 
stimulated with FGF-2 using the two different concentrations (50ng/ml and 
100ng/ml) in order to find the optimal concentration. Changes in fluorescence 
were measured for 20 minutes.  The first concentration failed to induce any 
detectable intracellular calcium release whereas stimulation with 100ng/ml 
FGF-2 induced a spiked-shape response as indicated in Figure 4.3. Cell 
viability was assessed at the end of the acquisition time measuring the calcium 
release upon ATP stimulation. 
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Figure 4.3 Intracellular calcium increase in serum starved HUVEC was 
determined as described in the Materials and Methods section. Cells were 
stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times 
(arrows). Data are mean of values obtained from 4 independent experiments. 
 
4.4.2 PI3K is required for FGF-2-induced calcium release 
To gain further insight into the mechanism of FGF-induced activation of 
PLC1, I decided to investigate the potential role of PI3K in this process in 
HUVEC cells. As described in chapter 1.3.2 PI3K activation is essential for 
PLC1 translocation to the plasma membrane (Falasca et al., 1998). Therefore, 
I decided to investigate the effect of the reversible PI3K inhibitor LY294002 
on intracellular calcium mobilisation. HUVEC cells were serum starved 
overnight and pretreated with LY294002 (10 M) and FGF-induced calcium 
mobilisation was measured by confocal analysis. HUVEC cells treated with 
vehicle alone were used as control. Cell viability was assessed by ATP 
stimulation at the end of the assay. Data in Figure 4.4 shows that the FGF-2-
induced calcium mobilisation was completely inhibited in HUVEC cells 
treated with LY294002 compared to control cells. These data indicate that 
PI3K is important also in FGF-2 induced PLC1 activation in endothelial cells.  
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Figure 4.4: PI3K is required for FGF-2-induced calcium release. FGF-2-
induced calcium release in serum starved HUVEC untreated (blue line) or 
treated (pink line) with LY294002 (10 M). Data are mean of values obtained 
from 2 independent experiments. 
 
4.4.3 Effect of PLC1 and PLC2 downregulation on endothelial cell 
proliferation  
Previous experiments performed by others in my laboratory showed that 
downregulation of PLC1 inhibited inositol phosphates accumulation in 
endothelial cells. To investigate a potential aspecific effect of PLC1-targeting 
siRNA on PLC2 expression, I decide to investigate PLC2 levels in HUVEC 
cells transfected with siRNA targeting PLC1. In parallel, siRNA targeting 
PLC2 were used to evaluate the effect of PLC2 dowregulation in endothelial 
cells. Data in figure 4.5A-B show western blot analysis of HUVEC cells 
transfected with siRNA targeting PLC1 or PLC2 or with scrambled siRNA 
as control. Data showed that PLC1 was completely downregulated in cells 
transfected with siRNA targeting PLC1, while PLC2 levels were not 
affected. Similarly, transfection with siRNA targeting PLC2 had no effect on 
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PLC1 expression indicating that the siRNA sequences used were isoform 
specific. In order to investigate the role of the PLC1 and PLC2 on cell 
proliferation in endothelial cells, cell counting experiments were performed 
after 24 hours and 48 hours from transfection. Data in Figure 4.5C show that 
downregulation of PLC1 had no effect on cell proliferation. On the contrary, 
HUVEC transfected with siRNA targeting PLC2 showed a significant 
decrease in cell proliferation compared to control cells or cells transfected with 
siRNA targeting PLC1. These data indicated that PLC1 and PLC2 play 
different roles in endothelial cells, with a main role of PLC2 in cell 
proliferation. 
 
 
 
 
. 
 
 
 
 
 
Figure 4.5: PLC2 but not PLC1 affects cell proliferation in HUVEC 
cells: A,B) Western blot analysis for PLC1 and PLC2 expression in HUVEC 
cells transfected with scramble, PLC1 or PLC2 siRNA. C) Cell counting of 
HUVEC transfected with scrambled, PLC1 or PLC2 siRNA after 24 and 48 
hours of transfection. Data are expressed as percentage of scrambled cells and 
are mean ±SEM of values from 6 independent experiments. 
 
4.5 Discussion 
 
In this chapter I described experiments performed to understand the 
contribution of PLC1 signalling in endothelial cells (HUVEC). The 
mechanism of FGF-2-induced activation of PLC1 has been controversial. 
A 
B 
C 
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Some studies reported a positive regulation of PLC1 phosphorylation by 
FGF-2 (Burgess et al., 1990), while other reported that FGF-2 is not able to 
phosphorylate PLC1 (McLaughlin et al., 2001). To investigate the FGF-2 
induced PLC1 activation, I decided to measure the intracellular calcium 
mobilisation upon FGF-2 stimulation. FGF-2 stimulation induced an instant 
calcium increase in HUVEC cells. Furthermore, parallel experiments in my 
laboratory showed that downregulation of PLC1 inhibited inositol phosphates 
accumulation upon FGF-2 stimulation (Maffucci et al., 2009). Together these 
data demonstrated the main role of PLC1 in the FGF-2 response in 
endothelial cells.  It was reported that PI3K activation is essential for PLC1 
activation upon growth factor stimulation in cancer cells (Falasca et al., 1998; 
Piccolo et al., 2002). I therefore decided to investigate the potential role of 
PI3K in FGF-2-induced PLC1 activation. My data showed that treatment with 
PI3K inhibitors (LY294002 and Wortmannin) inhibited PLC1 activation. In 
particular LY294002 treatment inhibited intracellular calcium mobilization 
and experiments performed in my laboratory by others showed that treatment 
with wortmannin inhibited inostitol phosphates accumulation in cells 
stimulated with FGF-2. Therefore this data demonstrated that PI3K is essential 
for the FGF-2-induced PLC1 activation. Since PLC2 is mainly expressed in 
the hematopoietic tissue, I investigated the effect of PLC1 and PLC2 
downregulation on cell viability. The effect on cell proliferation observed in 
HUVEC cells downregulated for PLC2, but not in cells transfected with 
PLC1 siRNA, shows that PLC1 and PLC2 had different functions in 
endothelial cells. These results are in line with different reports that showed 
the differential and not overlapping role of the PLC1 isoforms in the 
immunitary system (Regunathan et al., 2006).  
Summary 
Taken together these data demonstrate that FGF-2 induces PLC1 activation in 
a PI3K-dependent mechanism and identified the critical role of PLC1 in cell 
migration and tubulogenesis in endothelial cells and highlighted the non-
overlapping functions of PLC1 and PLC2 (Maffucci et al., 2009).
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Chapter 5 
Effect of Ins(1,3,4,5,6)P5 and 2-O-Bn-
InsP5 on cell migration, cell invasion 
and on PLC1 activity
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5.1 Introduction 
 
Inositol 1,3,4,5,6 pentakisphosphates (InsP5) has been shown to possess anti 
angiogenetic properties and to induce apoptosis in ovarian cancer, lung and 
breast cancer cell lines (Piccolo et al., 2004; Maffucci et al., 2005). This 
compound is able to inhibit activation of the PI3K/AKT pathway activation 
preventing AKT phosphorylation (see introduction chapter 1.8). Since AKT 
PH domain not only binds phosphoinositides but also inositol phosphates such 
as InsP4, it has been hypothesised that InsP5 prevents AKT plasma membrane 
recruitment by binding to the AKT PH domain and therefore competing with 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 for the PH domain binding. As described in 
the introductory chapter 1.2.4, PLC1 possesses a PH domain reported to be 
important for its enzymatic activation. The PH domain of PLC1 recruits the 
enzyme to the plasma membrane in an essential step for its enzymatic 
activation, interacting with PtdIns(3,4,5)P3 produced by PI3K. Therefore I 
hypothesized that InsP5 could prevent PLC1 activation by competing with 
PLC1 PH domain binding to PtdIns(3,4,5)P3 and therefore preventing its 
activation. As described in introduction chapter 1.3.4, PLC1 is involved in 
controlling cell migration and cytoskeleton remodelling and its 
pharmacological inhibition could block these processes. Therefore I decided to 
test the effects of InsP5 on cell migration and Matrigel cell invasion on a panel 
of cancer cell lines.   
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5.2 Results 
5.2.1 InsP5 inhibits fibronectin-induced migration in MDA-MB-231 
 
In order to determine the effect of InsP5 on fibronectin-induced cell migration 
of MDA-MB-231, I performed migration assay using transwell inserts 
previously coated with fibronectin. MDA-MB-231 cells were serum starved 
overnight and then pre-treated with InsP5 (50 M) for 30 minutes. Since InsP5 
is dissolved in H2O, MDA-MB-231 cells treated with the same volume of H2O 
were used as control. Cells were then seeded on the inserts and allowed to 
migrate for 4 hours before being fixed and counted. Data revealed that InsP5 
inhibits MDA-MB-231 fibronectin-induced migration by 60% indicating that 
InsP5 inhibits the integrin-activated migration in this breast cancer cell line 
(Figure 5.1).   
 
 
 
Figure 5.1 InsP5 inhibits fibronectin-induced migration: Quantification of 
fibronectin-induced migration of MDA-MB-231 cells treated with InP5 
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(50M) compared to control cells treated with vehicle alone. Data are means 
±SEM of values obtained from three independent experiments. *p<0.01 
 
5.2.2 InsP5 inhibits cell invasion on Matrigel of MDA-MB-231 
 
To investigate the effects of InsP5 on cancer cell invasion, Matrigel cell 
invasion assay was performed. MDA-MB-231 cells were serum deprived 
overnight and treated with the inhibitor for 30 minutes before being seeded on 
the transwell inserts pre-coated with Matrigel. Cells were allowed to invade 
the Matrigel for 36 hours before being fixed. InsP5 was maintained for the 
duration of the invasion experiment. MDA-MB-231 cells treated with H20 
were used as control. Data revealed that InsP5 inhibits invasion of MDA-MB-
231 cells on Matrigel by 38% compared to the control, indicating that InsP5 is 
not only able to reduce cell migration but also to inhibit 3D-Matrigel cell 
invasion (Figure 5.2). 
 
Figure 5.2 InsP5 inhibits Matrigel invasion: Quantification of 3D-Matrigel 
invasion of MDA-MB-231 cells treated with InP5 (50M) compared to control 
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cells expressed as percentage of control cells which invaded the Matrigel. Data 
are means ±S.E.M of values obtained from 3 independent experiments. 
*p=0.01 
 
5.2.3 Effect of InsP5 on cell survival and proliferation in MDA-MB-231 
Breast cancer cells 
Since InsP5 inhibits migration and invasion in MDA-MB-231, I decided to 
investigate the effect of the compound on cell proliferation and cell survival 
since these processes may affect cell motility. Furthermore it has been 
previously shown that InsP5 induces apoptosis in ovarian, lung cancer and 
some breast cancer cell lines (Piccolo et al., 2004). A potential pro-apoptotic 
effect in MDA-MB-231 could also result in the inhibition of cell invasion rate 
on Matrigel. In order to determine any potential effect of InsP5 on cell 
proliferation and cell survival, I performed cell counting experiments in 
MDA-MB-231 after 72 hours of treatment with InsP5 in serum free and in 
serum conditions. Cells treated with H20 were used as control. 15,000 cells 
per-well were seeded, treated with InsP5 or carrier alone and counted after 72 
hours treatment. Data shown in Figure 5.3 indicate that InsP5 had no effect on 
MDA-MB-231 proliferation, in cells treated with InsP5 in 10% serum for 72 
hours of treatment. Similarly, no effect on cell survival was detected in cells 
treated with InsP5 in serum free condition. These data indicate that InsP5 does 
not affect cell proliferation and cell survival in MDA-MB-231 and that the 
effect seen on cell invasion is not dependent on changes in the proliferation or 
survival.  
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Figure 5.3: Cell counting of MDA-MB-231 after 72 hours of treatment with 
InsP5 (50M) in media supplemented with 10% serum or serum deprived 
media conditions. Data are means ±SEM of values obtained from 3 
independent experiments in duplicate. No significant difference was observed. 
 
 
5.2.4 InsP5 inhibits Matrigel cell invasion in human and murine breast 
cancer cell lines 
My previous experiments performed using MDA-MB-231 indicated that InsP5 
inhibits migration and invasion. I therefore decided to evaluate the effect of 
InsP5 treatment on different cancer cell lines. I performed cell invasion assays 
on Matrigel using the human breast cancer cell line MDA-MB-435 and two 
singenic mouse models of breast cancer cell lines (TSA and 4T1). InsP5 was 
maintained for the duration of the invasion experiment. Cells treated with H20 
for each cell line were used as internal controls.  Data in Figure 5.4 show that 
InsP5 decreased the percentage of cells that had invaded by 35% in MDA-MB-
435 and TSA, compared to the respective control. Interestingly, 4T1 cells were 
more sensitive to the treatment with InsP5 compared to the other cell lines 
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used, showing an inhibition of invasion of 76%. Overall these data 
demonstrated that InsP5 inhibits invasion of a panel of breast cancer cell lines. 
 
 
Figure 5.4: InsP5 inhibits cell invasion on Matrigel of MDA-MB-435, 4T1 
and TSA treated with InsP5. Invasion was expressed as percentage of cells 
treated with the vehicle alone which invaded the Matrigel (control). Data are 
means ±SEM of values obtained from 3 independent experiments in duplicate. 
*p=0.05; **p=0.005 
 
 
5.2.5 InsP5 does not affect cell proliferation and cell survival of MDA-MB-
435, 4T1 and TSA. 
In order to evaluate any potential pro-apoptotic effect of InsP5 on MDA-MB-
435, 4T1 and TSA cell lines, I analysed cell proliferation and cell survival on 
these cell lines, as previously described. Cell counting experiments were 
performed on cells treated with InsP5 in 10% serum media and on cells treated 
with InsP5 in serum free condition. Cells treated with vehicle (H2O) alone 
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B 
were used as controls for the experiments. Data in Figure 5.5 show that InsP5 
did not affect proliferation and survival in MDA-MB-435 and TSA (panel 
A,B). Similarly, no effect on proliferation of TSA was observed in cells kept 
in 10% serum upon InsP5 (panel C, D). On the contrary the number of 4T1 
cells after 48 hours or 72 hours treatment with InsP5 in serum free condition 
was clearly reduced, suggesting an effect of the inositol phosphate on cell 
survival in this particular cell type. Nevertheless, since Matrigel invasion 
assays were performed in the presence of serum and InsP5 does not affect cell 
proliferation in the presence of serum, we can conclude that the inhibition of 
invasion detected in the presence of InsP5 is exclusively due to an impaired 
cell migration.  
 
   
 
  
Figure 5.5: Effect of InsP5 on cell proliferation/survival: Cell counting 
experiment assessing cell proliferation (10% serum) and survival (Serum free 
A 
C D
D 
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condition) in, MDA-MB.435 (A), TSA (B) and 4T1 (C,D) after 72 hours of 
treatment with 50 M InsP5. Data are means ±SEM of values obtained from 3 
independent experiments in duplicate. 
 
5.2.6 InsP5 inhibits internal calcium release In MDA-MB-231 and MDA-
MB-435 cell lines. 
Our data so far indicated that InsP5 inhibits cancer cell invasion primarily 
through inhibition of cell migration. Since we have shown that PLC1 has a 
key role in regulating cell migration, I hypothesised that InsP5 could affect 
PLC1 activity. Therefore to test this hypothesis, a calcium release assay was 
performed using MDA-MB-231 and MDA-MB-435 treated with InsP5 and 
stimulated with EGF, since I previously demonstrated that this process is 
completely dependent on PLC1 in MDA-MB-231 (Figure 4.1). Cells were 
pre-treated with InsP5 and intracellular calcium variation was assessed with 
confocal microscope analysis, as before. Data in Figure 5.6A show the 
calcium response in control MDA-MB-231, treated with vehicle alone. EGF 
stimulation induced a rapid increase in fluorescence generating an initial Ca
2+
 
spike immediately after stimulation followed by calcium oscillations. In 
contrast, cells treated with InsP5 showed a significant decrease of the initial 
spike and calcium oscillation, indicating that InsP5 inhibits PLC1 activity 
(Figure 5.6B). Cell viability was assessed at the end of the assay by ATP 
stimulation (Figure 5.6C). Fold increase in fluorescence was calculated 
comparing the difference in fluorescence between basal and the highest 
fluorescence induced by EGF in three different experiments (Figure 5.6D) and 
confirming the strong inhibition upon InsP5 treatment. Similarly, EGF induced 
a rapid increase in calcium in MDA-MB-435 (Figure 5.7A) which was 
completely inhibited in cells treated with InsP5 (Figure 5.7B), indicating that 
InsP5 inhibits EGF-induced intracellular calcium mobilization in different cell 
types. Fold increase in fluorescence was calculated as previously indicated 
(Figure 5.7D). Similarly, cell viability was assessed at the end of the assay by 
ATP stimulation (Figure 5.7C) 
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Figure 5.6 Effect of InsP5 on EGF-induced intracellular calcium 
mobilisation in MDA-MB-231: A, B) Representative experiment of EGF-
induced intracellular calcium mobilisation in untreated MDA-MB-231 and 
MDA-MB-231 treated with InsP5 (50 M). C) Representative ATP-induced 
intracellular calcium mobilisation.  D) Quantification of intracellular calcium 
increase.  Columns are the mean of three indipendent experiments; Bars S.E 
*P=0.01 
D
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Figure 5.7: Effect of InsP5 on EGF-induced intracellular calcium 
mobilisation in MDA-MB-435: A,B) Representative experiment of EGF-
induced intracellular calcium mobilisation in untreated MDA-MB-435  and 
MDA-MB-435 treated with InsP5 (50 M). C) Representative ATP-
induced intracellular calcium mobilisation. D) Quantification of 
intracellular calcium increase.  Columns are the mean of three indipendent 
experiments; Bars S.E *p=0.001 
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5.3 Discussion 
Taken together these experiments demonstrated that InsP5 is able to inhibit 
cell migration and Matrigel cell invasion in vitro in different metastatic cell 
lines. Furthermore Figure 5.6 and 5,7 showed that InsP5 inhibits the EGF-
induced intracellular calcium mobilization in breast cancer cell lines. Since, 
as shown in chapter 4.2.1 and 4.2.2 the EGF-induced calcium mobilization 
is completely dependent on PLC1 activity, it is possible to conclude that 
InsP5 inhibits PLC1 activity. Due to the key role of PLC1 in cell motility, 
cytoskeleton remodelling and cell metastasis (Sala et al., 2008), it is 
tempting to speculate that InsP5 may have anti-metastatic properties in vivo, 
since this compound is able to inhibit cell migration and invasion in vitro 
(Figure 5.1, 5.2, 5.4). 
 
 
5.4 2-O-Bn-InsP5 – a new synthetic compound based on InsP5 structure  
In the last years my lab has been focussed on finding alternative 
compounds based on InsP5 structure, in collaboration with Professor Potter 
at the University of Bath. X-Ray crystallography data revealed that Akt PH 
domain possesses a tyrosine residue near the 6-OH of bound of 
Ins(1,3,4,5)P4 that might interact with an aromatic group. Therefore InsP5 
analogues were designed not to alter the symmetry of the parental 
molecule. As described previously in the introduction chapter 1.8, 2-O-Bn-
InsP5 was more potent in inhibiting AKT phosphorylation and it was 
effective in cell lines resistant to InsP5 treatment, indicating a more potent 
action of this synthetic InsP5 derivative compared to its natural parental 
molecule.  
Thus, I decided to test whether 2-O-Bn-InsP5 was able to inhibit PLC1. 
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5.4.1 2-O-Bn-InsP5 inhibits fibronectin-induced cell migration in MDA-
MB-231 
Data presented in chapter 5.1 shows that InsP5 inhibits MDA-MB-231 
fibronectin-induced migration. Based on this, I decided to investigate the 
effect of 2-O-Bn-InsP5 on cell migration. Fibronectin-induced cell 
migration was measured in the same experimental conditions described in 
chapter 5.1. Cells were serum starved overnight and pre-treated with 2-O-
Bn-InsP5 (50M) for 30 minutes before being plated on fibronectin-coated 
transwell inserts and allowed to migrate for 4 hours and then fixed in 
presence of the compound. Cells treated with vehicle alone were used as 
control. Data in Figure 5.8 shows that 2-O-Bn-InsP5 completely blocked 
fibronectin-induced cell migration in MDA-MB-231 and that 2-O-Bn-InsP5 
has a more potent effect in inhibiting cell migration compared to the 
parental molecule (InsP5) which inhibits fibronectin-induced migration by 
60% (Figure 5.1). 
 
Figure 5.8: 2-O-Bn-InsP5 blocks fibronectin-induced migration: 
fibronectin-induced migration of MDA-MB-231 cells treated with 2-O-Bn-
InsP5 (50M) compared to control cells treated with vehicle alone. Data are 
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means ±SEM of values obtained from 3 independent experiments. 
**p=0.003  
5.4.2 2-O-Bn-InsP5 inhibits cell migration in a dose-dependent manner 
Considering that 2-O-Bn-InsP5 show an inhibition of 90% in cell migration, 
I decided to test different concentrations of inhibitor on fibronectin-induced 
cell migration, to find the lower effective concentration. Experiments were 
performed using MDA-MB-231 treated with 2-O-Bn-InsP5 at 5, 10, 25, 50 
μM. Cells treated with vehicle alone were used as control As shown in 
Figure 5.9 cells treated with 2-O-Bn-InsP5 10μM show already an inhibition 
of 80% compared to the control. These data demonstrate that 2-O-Bn-InsP5 
inhibit in a dose response manner and is already effective at the 
concentration of 10μM. Taken together these data showed that the synthetic 
InsP5-derivative compound, 2-O-Bn-InsP5, is more potent in inhibiting cell 
migration compared to the mother molecule. 
 
Figure 5.9: 2-O-Bn-InsP5 inhibits cell migration in a dose-dependent 
manner: MDA-MB-231 were pre-treated with 2-O-Bn-InsP5 at different 
concentration (5, 10, 25, 50 μM). Control cells were pre-treated with H20 as 
control. Data are means ±SEM of values obtained from 3 independent 
experiments. 
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5.4.3 2-O-Bn-InsP5 inhibits cell invasion on Matrigel in different human 
and murine breast cancer cell lines 
Data previously described showed that 2-O-Bn-InsP5 inhibits fibronectin-
induced cell migration in MDA-MB-231 more potently compared to InsP5. 
Therefore I decided to investigate the effect of 2-O-Bn-InsP5 on cancer cell 
invasion on Matrigel. Invasion assays were performed using MDA-MB-
231, MDA-MB-435, TSA and 4T1 cell lines. The same experimental 
conditions described in chapter 5.2.3 and 5.2.4 were used. Briefly, cells 
were serum starved and pre-treated with 2-O-Bn-InsP5 for 30 minutes 
before being seeded on Matrigel-coated transwell inserts and allowed to 
invade for 36 hours before being fixed. The compound was maintained for 
the duration of the invasion experiment. Cells treated with H20 were used as 
control. Data in Figure 5.10 show that 2-O-Bn-InsP5 strongly inhibits 
invasion on Matrigel in all the cell lines tested. In particular a 52.7%, 
63.8%, 73.9%, 87.9% of inhibition was observed respectively in TSA, 
MDA-MB-435, MDA-MB-231 ad 4T1. As indicated in Table 5.1, it is 
worth noticing that in each cell line 2-O-Bn-InsP5 inhibited cell invasion on 
Matrigel more potently than InsP5. Taken together these data suggested that 
2-O-Bn-InsP5 is able to inhibit cancer cell invasion even more efficiently 
than the parental molecule.   
 
 
 
 
Table 5.1: Percentage of MDA-MB-231, MDA-MB-435, 4T1, TSA treated 
with InsP5 50M or 2-O-Bn-InsP5 50M that have invaded after 36 hours  
*p<0.05,**p<0.005. Matrigel invasion expressed as percentage of control 
cells that had invaded the Matrigel layer (average of 3 independent 
experiments).   
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Figure 5.10: 2-O-Bn-InsP5 inhibits cell invasion on Matrigel: Cell 
invasion assay on Matrigel, expressed as percentage of cells that had 
invaded, assessed in the indicated cell lines treated with 2-O-Bn-InsP5. 
Invasion was compared to control cells treated with H20. Data are means 
±SEM of values obtained from 3 independent experiments. **p=0.005 
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5.4.4 2-O-Bn-InsP5 does not affect cell proliferation and cell survival in 
MDA-MB-435, 4T1 and TSA cell lines. 
As discussed before for InsP5, the effect of 2-O-Bn-InsP5 on cell invasion 
prompted us to evaluate a potential effect on cell proliferation and cell 
survival. Cell counting assay was performed on MDA-MB-231, MDA-MB-
435, 4T1 and TSA after 72 hours of treatment with 2-O-Bn-InsP5. Cells 
were treated with 2-O-Bn-InsP5 in 10% serum supplemented media 
condition to measure changes in proliferation and in serum free condition to 
evaluate effects on cell survival. Cells treated with H20 were used as 
control. Data in Figure 5.11A,B,E reveals that, similarly to InsP5 treatment¸ 
2-O-Bn-InsP5 treatment had no effect on cell proliferation and cell survival 
in MDA-MB-231, MDA-MB-435 and TSA. Similarly, no change was 
observed in cell proliferation in 4T1 treated with 2-O-Bn-InsP5 (Figure 
5.11C). However, a decreased number of 4T1 cells was observed when 
treated in serum free condition (Figure 5.11D), indicating an effect on cell 
survival promoted by 2-O-Bn-InsP5 treatment. Since the Matrigel cell 
invasion assay was performed in serum condition, I concluded that the 
effect seen upon 2-O-Bn-InsP5 treatment on cell invasion was not due to 
effects on cell growth but to a decreased ability of the cells to invade.  
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Figure 5.11: Cell proliferation and cell survival upon 2-O-Bn-InsP5 
treatment: Cell counting performed on MDA-MB-231 (A), MDA-MB-
435 (B), 4T1 (C,D) and TSA (E) treated with 2-O-Bn-InsP5 (50M) in 
10% serum or serum free condition. Cell counting was performed after 72 
hours (48 hours and 72 hours in 4T1). Data are mean ±SEM of three 
independent experiments. 
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5.4.5 2-O-Bn-InsP5 inhibits calcium release response in MDA-MB-231 
and MDA-MB-435 upon EGF stimulation.  
 
To determine whether the effect of 2-O-Bn-InsP5 on cell invasion is also 
due to inhibition of PLC1, as for InsP5, I decided to perform calcium 
release assay experiments on MDA-MB-231 and MDA-MB-435 treated 
with 2-O-Bn-InsP5 and then stimulated with EGF. All experiments were 
performed following the same experimental conditions used to test the 
effect of InsP5 described in chapter 5.2.6. Data in Figure 5.12 show that 2-
O-Bn-InsP5 completely inhibits the EGF-induced intracellular calcium 
variation in MDA-MB-231 (A) and MDA-MB-435 (B). These data indicate 
that 2-O-Bn-InsP5 completely blocks PLC1 activity upon EGF stimulation 
in both cell lines. Furthermore data indicates that the inhibitory effect of 2-
O-Bn-InsP5 is more potent compared to InsP5 (Chapter 5.2.6). 
 
          Figure legend next page 
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Figure 5.12 Effects of 2-O-Bn-InsP5 on intracellular calcium 
mobilisation. A) EGF-induced intracellular calcium mobilisation in MDA-
MB-231 untreated (left) or treated with 50 M 2-O-Bn-InsP5 (right). 
Quantification of intracellular calcium increase (bottom).  Columns are the 
mean of three indipendent experiments; Bars S.E *p=0.002 B) Calcium 
release assay in MDA-MB-435 untreated (left) or treated with 50 M 2-O-
Bn-InsP5 (right). Quantification of intracellular calcium increase (bottom).  
Columns are the mean ±SEM of four indipendent experiments; *p=0.001. 
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5.4.6 2-O-Bn-InsP5 inhibits PLC1 tyrosine phosphorylation upon EGF 
stimulation 
As discussed in chapter 1.3, different steps are involved in PLC1 activation. 
The recruitment to the plasma membrane is essential for PLC1 activation. 
Furthermore tyrosine phosphorylation of PLC1 is essential for its enzymatic 
activation. Since 2-O-Bn-InsP5 showed the highest inhibitory effects on cell 
motility, Matrigel cell invasion and EGF-induced PLC1-mediated 
intracellular calcium release, I decided to focus on the mechanism through 
which 2-O-Bn-InsP5 inhibits PLC1 activity. Therefore I decided to 
investigate the potential effect of 2-O-Bn-InsP5 treatment on PLC1 tyrosine 
phosphorylation. In particular I decided to investigate the phosphorylation of 
the residue Y783 which is essential for PLC1 enzymatic activity (Sekiya et 
al, 2004).  
MDA-MB-231 cells were serum starved overnight and then pre-treated with 2-
O-Bn-InsP5 for 30 minutes. Cells were then stimulated with EGF for 3 and 10 
minutes and lysed for protein extraction. MDA-MB-231 cells treated with 
H2O were used as control. Western blot analysis was performed and 
phosphorylation of PLC1 at Y783 residue was assessed using a specific 
antibody. Western blot analysis generated two bands corresponding to the 
phosphorylated form of PLC1 as indicated by the manufacturer. GAPDH 
levels were measured in order to evaluate protein equal loading. A 
representative blot is shown in Figure 5.13. 2-O-Bn-InsP5 strongly inhibits 
PLC1 phosphorylation upon EGF stimulation compared to untreated cells. 
These data indicates that 2-O-Bn-InsP5 can inhibit PLC1 activation by 
blocking its tyrosine phosphorylation. Therefore the ability of 2-O-Bn-InsP5 to 
inhibit PLC1 phosphorylation provides a molecular mechanism for the 
reduced Matrigel invasion detected in cancer cell lines treated with 2-O-Bn-
InsP5, and possibly InsP5, explaining the decreased activity of the enzyme 
observed by the intracellular calcium mobilization assay. 
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Figure 5.13: PLC1 phosphorylation is inhibited by 2-O-Bn-InsP5 
treatment: Western blot analysis of PLC1 phosphorylation at its residue 
Y783 in MDA-MB-231 untreated or pre-treated with 2-O-Bn-InsP5 for 30 
minutes before stimulation with 50 ng/ml EGF for 3 and 10 minutes. Blot 
representative of 4 independent experiments.   
 
 5.5 Discussion  
As discussed in the introductory chapters increasing evidence showed that the 
inositol phosphates might compete with the binding of phosphoinositides to 
PH domains possessed by key proteins involved in cell proliferation, cell 
survival and motility such as AKT, preventing their activation. My laboratory 
has been focussed on developing inositol phosphates-based compounds and 
investigating their effects on the PI3K/AKT pathway. Data showed in chapter 
3, together with data published in our recent report (Sala et al., 2008) 
demonstrate the pivotal role of PLC1 in cell migration and invasion and, 
more importantly, the requirement of PLC1 for metastases development and 
progression. In an effort to identify potential specific PLC1 inhibitors, I 
decided to investigate the effect on PLC1 activation of inositol phosphates 
treatment, hypothesising that they might compete with the PtdIns(3,4,5)P3 for 
the binding of PLC1 PH domain, blocking the PI3K-dependent plasma 
membrane recruitment of PLC1 necessary for the activation of the enzyme. 
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This model was already demonstrated for AKT inhibition promoted by InsP5 
(Piccolo et al., 2004; Maffucci et al., 2005). I therefore investigated the effect 
of InsP5 treatment on cell migration in MDA-MB-231 and cell invasion in a 
broader number of breast cancer cell lines (MDA-MB-231, MDA-MB-435, 
TSA, 4T1). Data showed a significant inhibition of cell invasion on Matrigel 
in all the cancer cell lines analysed (Figure 5.1, 5.2, 5.4). Noteworthy no 
difference in cell proliferation or cell survival (except 4T1 cell line) was 
observed in cells treated with InsP5, excluding therefore the possibility that the 
effect on cell migration and invasion was due to decreased cell viability 
(Figure 5.3, 5.5).  
 It has to be noted that InsP5 induced apoptosis mostly in cell lines with high 
level of AKT activation while it had low or no effect in cell lines with normal 
level of activation of PI3K/AKT pathway (Piccolo et al., 2004). MDA-MB-
231 for example shows low level of AKT activation and treatment with InsP5 
has no effect on cell proliferation and survival. On the contrary SKOV3 
possesses elevated levels of AKT activation and treatment with 
Ins(1,3,4,5,6)P5 affects cell proliferation and cell survival (Piccolo et al., 
2004). To investigate the potential inhibition of PLC1 by InsP5 treatment, I 
performed calcium mobilisation assays upon EGF stimulation in MDA-MB-
231 and MDA-MB-435. EGF-induced calcium mobilisation was inhibited in 
cells upon treatment with InsP5 compared to untreated cells (Figure 5.6, 5.7). 
No difference in ATP-induced calcium mobilisation was observed upon InsP5 
treatment compared to the control. Since the EGF-induced calcium migration 
in MDA-MB-231 is completely dependent on PLC1 (Figure 4.1, 4.2), these 
data strongly suggested that InsP5 inhibits PLC1 activation directly or 
undirectly.  
The effect of InsP5 treatment on cell migration and invasion prompted my 
group, in collaboration with Professor Potter (University of Bath) to develop 
novel molecules based on InsP5 structure in the effort to improve its potency 
and specificity. The derivative 2-O-Bn-InsP5 showed enhanced inhibitory 
properties towards AKT. Invasion assay on Matrigel showed that 2-O-Bn-
InsP5 was more efficient in inhibiting invasion compared to InsP5 (Figure 5.8, 
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5.9, 5.10) without affecting cell proliferation and cell survival (Figure 5.11). 
Intracellular calcium mobilisation showed that 2-O-Bn-InsP5 completely 
blocked intracellular calcium release, indicating that this InsP5 derivative was 
a more potent inhibitor towards PLC1 compared to the parental molecule 
(Figure 5.12). Since PLC1 phosphorylation status is essential for PLC1 
activity, I investigated whether 2-O-Bn-InsP5 was able to inhibit the 
phosphorylation status of PLC1. Analysis of EGF-induced tyrosine 
phosphorylation of PLC1 showed that 2-O-Bn-InsP5 inhibited PLC1 
phosphorylation at its residue Y783, which strictly correlates with the 
enzymatic activity (Figure 5.13). Taken together these data demonstrated that 
the inhibitor prevents PLC1 phosphorylation and the following activation of 
PLC1. However the mechanism by which 2-O-Bn-InsP5 and InsP5 inhibit 
PLC1 is not well understood and different hypotheses must be further 
investigated. For example it cannot be excluded that the inhibitors compete 
with EGF binding to the EGFR, resulting in an inhibition of the downstream 
pathway. 
 In an effort to determine specificity and targets of these two compounds, an in 
vitro kinase screening was performed on InsP5 and 2-O-Bn-InsP5 (Falasca et 
al., 2010). The screening was performed by Select Screen™ Kinase Profiling 
Service supplied by Invitrogen. InsP5 and 2-O-Bn-InsP5 were tested in vitro on 
over 60 different kinases in order to assess their specificity and their inhibitory 
activity. 2-O-Bn-InsP5 inhibits PDK1 activity with an IC50 of 26.5 nM towards 
PDK1. Both compounds showed no effect on AKT1 and AKT2 kinase 
activity. These results suggested a potential link between PDK1 and PLC1 in 
a mechanism that could involve PDK1 in PLC1 phosphorylation directly or 
indirectly. However since PDK1 is a serine/threonine kinase, a direct 
involvement is unlikely. A recent report showed that PDK1 is involved in 
ROCK1 regulation in a kinase-independent mechanism which involves the 
direct interaction of PDK1 with ROCK1 at the plasma membrane (Sahai et al., 
2008) promoting ROCK1 activity. Therefore a similar mechanism might be 
involved in PLC1 regulation. This hypothesis was the basis for the 
experiments described in chapter 7.  
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Summary 
Ins(1,3,4,5,6)P5 and 2-O-Bn-InsP5 show inhibiting PLC1 activity. This was 
assessed by calcium release assay and inositol phosphates incorporation in 
MDA-MB-231. Moreover 2-O-Bn-InsP5 inhibits PLC1 Y783 
phosphorylation. Both compounds, but more 2-O-Bn-InsP5, inhibit cell 
migration and cancer cell invasion.   
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Chapter 6 
Potential involvement of ABC 
transporters on inositol 
polyphosphates transmembrane 
transport 
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6.1 InsP5 internalisation 
My data so far demonstrated that 2-O-Bn-InsP5 is able to inhibit PLC1 
phosphorylation at residue Y783 and to inhibit its enzymatic activity. Furthermore 
InsP5 and 2-O-Bn-InsP5 block cell migration and invasion in the panel of breast 
cancer cell lines tested, indicating that they may have anti-metastatic properties in 
vivo. The mechanism by which inositol polyphosphates are transported across the 
membrane has not been characterised. It has to be noticed that Ins(1,3,4,5,6)P5 
possesses five phosphates groups that confer a high negative charge to the 
compound. Therefore it is unlikely that Ins(1,3,4,5,6)P5 can be transported by 
passive diffusion across the plasma membrane. It has been demonstrated that 
Ins(1,3,4,5)P4 and Ins(1,3,4,5,6)P5 are internalized by cancer cells (Razzini et al., 
2000; Maffucci et al., 2005), and preliminary data produced by my group shows 
that inositol polyphosphates uptake is inhibited at 4°C suggesting an active 
transport mechanism. In order to investigate inositol polyphosphates uptake I used 
the 2-fluorescein-conjugated-InsP5 (2-FAM-InsP5) which was synthetized by our 
collaborator Professor Potter at the University of Bath. The fluorescein-conjugated 
compound gave the opportunity to follow its incorporation over time and visualise 
the dynamic of its incorporation inside the cells.  
 
6.1.1 Time-course of InsP5 uptake 
MDA-MB-231 were seeded on coverslips and incubated with 25 M FAM-InsP5 
prepared in DMEM supplemented with 10% serum for the indicated time points. 
As controls MDA-MB-231 were incubated with 25M fluorescein for the indicated 
time and then fixed. Fluorescence intensity was measured using confocal 
microscopy. Figure 6.1A shows that 2-FAM-InsP5 entered the cells and it was 
already detectable intracellularly after 5 minutes. In contrast, control cells treated 
with fluorescein did not show intracellular fluorescence at any of the indicated 
time-points (Figure 6.1B). These results indicate that InsP5 is able to enter MDA-
MB-231 cells, despite its polar nature, as already demonstrated for the ovarian 
cancer cell line SKOV-3 and for the Small Cell Lung Cancer cell line (Maffucci et 
al., 2005; Razzini et al., 2000). 
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Figure 6.1 Incorporation of 2-FAM-InsP5 A) MDA-MB-231 were seeded on 
converslips in a 12-well plate and incubated with 2-FAM-InsP5 (25 M) for the 
indicated times before being fixed. B) MDA-MB-231 cells were incubated with 25 
M florescein as appropriate control for the 2-FAM-InsP5 uptake. 
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6.1.2 Probenecid and Glibenclamide inhibit 2-FAM-InsP5 uptake 
In 2009 Nagy et al. identified in Arabidopsis a membrane transporter belonging to 
the ATP-binding-cassette (ABC) transporter, involved in the inositol 
hexakisphosphates transport. The ABC transporters are involved in the trafficking 
of many substances and several lines of evidence established their role in cancer 
drug resistance. Indeed the multidrug resistance in tumour is associated with 
overexpression of certain ABC transporters which, for this reason, are called 
Multidrug Resistance (MDR) protein or Multidrug Resistance Proteins (MRP) 
(Glavinas et al., 2004). In particular ABCC1/MRP1, ABCB1/MDR1 and ABCG2 
are the transporters mainly involved in the drug resistance process. It has been 
recently reported that that inositol hexakisphosphate is actively exported from the 
cytoplasm to the vacuole by the ABCC5 transporter (Nagy et al., 2009). In order to 
assess the possibility that ABC transporters may also be involved in inositol 
polyphosphates uptake in mammalian cells, I decided to test the effect of 
probenecid and glibenclamide, which are two inhibitors of ABC transporters, on 
inositol phosphates uptake. MDA-MB-231 cells were treated with the inhibitors in 
a dose dependent manner in order to find highest non-toxic concentration (table 
6.1). Treatment with probenecid 5mM and 10mM and glibenclamide 600 and 
1.5mM were toxic, resulting in cell death within one hour from the beginning of the 
treatment. Therefore hereafter the first effective non-toxic concentration was used 
for all the experiments. In particular cells were treated with probenecid 1mM and 
glibenclamide 150M. MDA-MB-231 were pre-treated for 1 hour with probenecid 
and glibenclamide and then incubated with 2-FAM-InsP5 for the indicated times in 
presence of the inhibitors before being fixed and fluorescence analysed by confocal 
microscopy. Figure 6.2 shows that treatment of MDA-MB-231 with both inhibitors 
reduced 2-FAM-InsP5 intake for 5 and 10 minutes. This data indicated that 
transporters belonging to the ABC family could be involved in the uptake of InsP5 
in mammalian cells similarly to what was reported in Arabidopsis. 
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Table 6.1: 
Concentration Tested 
Probenecid 500M 1mM 3mM 5mM 10mM 
Glibenclamide 75M 150M 450M 600M 1.5mM 
 
 
Figure 6.2: Time course of 2-FAM-InsP5 uptake in untreated cells and in MDA-
MB-231 treated with probenecid and glibenclamide. On the right a representative 
bright-field picture of untreated and treated cells is presented.  
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 6.1.3 ABCC1 transporter is involved in 2-FAM-InsP5 uptake 
The ABC transporters are a family of trans-membrane transporters involved in 
export of different substances. Mice deficient in ABCG2, ABCB1 or ABCC1 are 
viable and fertile but are more sensitive to cytotoxic drugs, consistent with the role 
of ABC transporters in protecting cells from toxins (Wijnholds et al., 1998; Dean et 
al., 2005). At present no evidence shows that in mammalian cells ABC transporters 
are involved in the import process, but they have been characterised for their main 
role in drug export and multidrug resistance. The finding that ABC inhibition by 
probenecid and glibenclamide is able to block the uptake of 2-FAM-InsP5 (Figure 
6.2) showed that this class of transporter may be involved also in the import 
process of InsP5, supporting the hypothesis that ABC transporter may be involved 
in the import of certain substances rather than export alone.  
In order to further investigate the role of ABC transporters in inositol 
polyphosphates intake, I decided to investigate the role of the ABCC family 
members.  In particular ABCC1 has been found upregulated in a variety of solid 
tumour such as lung, breast and prostate and it constitutes a negative prognostic 
marker for early stage breast cancer (Kartenbeck et al., 1996; Rudas et al., 2003).  
The first approach was to use the ABCC1 specific inhibitor MK-571. MDA-MB1-
231 cells were pre-treated with 40 M MK-571 for 1 hour before being incubated 
with 2-FAM-InsP5 for the indicated minutes. Figure 6.3A shows images of a 
representative experiment of four experiments. Decreased fluorescence was 
observed at 10, 15 and 30 minutes of 2-FAM-InsP5 incorporation in cells treated 
with MK-571 compared to untreated cells, indicating that ABCC1 transported is 
involved in FAM-InsP5 uptake. However it is worth noticing that cells treated with 
MK-571 inhibitor were able to uptake 2-FAM-InsP5, although with a slower 
kinetic, indicating that ABCC1 is not the only transporter involved in the 2-FAM-
InsP5 intake (Figure 6.3B). 
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 Figure legend next page 
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Figure 6.3: 2-FAM-InsP5 is inhibited by MK-571: A) Images of MDA-MB-231 
untreated or pre-treated with 40 M MK-571 and incubated with 2-FAM-InsP5 at 
indicated time points. B) Quantification of 4 independent experiments. Graphs are 
means values ±S.E; *P<0.05 
 
6.1.4 ABCC1 is potentially involved in 
3
H-InsP5 uptake. 
In order to validate the data obtained using 2-FAM-InsP5 uptake, incorporation 
experiments of 
3
H-labelled InsP5 were performed. MDA-MB-231 were seeded on a 
12 well plate and left untreated or pre-treated with 40 M MK-571 for 1 hour and 
then incubated with 50M of “cold” InsP5 supplemented with 
3
H-InsP5 (4,000 
cpm/well) provided by our collaborator (Adolfo Saiardi, UCL). The amount of 
incorporated radioactivity was determined by liquid scintillation counting. The 
uptake of 
3
H-InsP5 was significantly decreased in cells pre-treated with the ABCC1 
inhibitor compared to control cells (Figure 6.4). These data confirmed the results 
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obtained following the incorporation of the 2-FAM-InsP5 and suggest that ABCC1 
transporter is involved in the InsP5 uptake. 
 
 
 
Figure 6.4: 
3
H-InsP5 incorporation is inhibited by MK-571: 
3
H-InsP5 
incorporation in MDA-MB-231 untreated (blue line) or treated with the ABCC1 
inhibitor MK-571 (red line). Graphs are the mean of 3 independent experiments; 
bars S.E.M; *P<0.05 
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6.1.5 Downregulation of ABCC1, but not ABCC5, inhibits InsP5 uptake in 
MDA-MB-231 
In order to further investigate the role of ABCC1 in InsP5 transport, I decided to 
determine the effect of ABCC1 downregulation using specific siRNA in MDA-
MB-231. The effect of ABCC5 downregulation (another member of the ABCC 
family) on 2-FAM-InsP5 and 
3
H-InsP5 uptake was also investigated in order to 
assess the potential involvement of other family members in the uptake process.  
MDA-MB-231 cells were transfected with siRNAs targeting ABCC1 or ABCC5 
respectively. As controls, MDA-MB-231 transfected with a scrambled sequence 
were used. After 72 hours from transfection, cells were incubated with 2-FAM-
InsP5 for the indicated times before being fixed. Intracellular cell fluorescence was 
analysed in three independent experiments. Decreased fluorescence was observed 
in MDA-MB-231 transfected with siRNA targeting ABCC1 compared to cells 
transfected with scrambled siRNA. In particular a decrease of 50% was observed 
after 10 minutes of 2-FAM-InsP5 incorporation. Representative images are showed 
in Figure 6.5A,B. MDA-MB-231 transfected with siRNA targeting ABCC5 
transporter expression showed no difference in 2-FAM-InsP5 incorporation 
compared to control (Figure 6.5C). These data suggest that ABCC1 is required for 
inositol pentakisphophate transport and that its downregulation significantly 
decreases uptake of extracellular inositol pentakisphosphate (Figure 6.5D). 
Furthermore data suggest that ABCC1 may have a specific role in inositol 
pentakisphosphate active transport, since siRNA for ABCC5 does not affect its 
cellular intake.  
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Figure 6.5: Effect of siRNAs  targeting ABCC1 or ABCC5 on 2-FAM-InsP5 
uptake: Representative images of MDA-MB-231 transfected respectively with  
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scrambled siRNA (A), siRNA targeting ABCC1 (B) or siRNA targeting ABCC5 
(C) incubated with 2-FAM-InsP5 for 1, 5 and 10 minutes. Statistical analysis (D) 
was performed measuring fluorescence of 30 cells per sample for each time point. 
Plots are the mean of three independent experiments; bars S.E.M;*p<0.05 
 
 
6.1.6 Downregulation of ABCC1 expression inhibits 
3
H-InsP5 uptake 
I then analysed the effect of ABCC1 downregulation on 
3
H-InsP5 incorporation in 
MDA-MB-231. Incorporation of 
3
H-InsP5 was assessed in parallel in MDA-MB-
231 transfected with siRNA targeting the ABCC5 transporter. MDA-MB-231 
transfected with a scrambled siRNA sequence were used as control. MDA-MB-231 
were incubated for 1 hour with 50 M “cold” InsP5 and 
3
H-InsP5 (5000cpm/l), 
then lysed and analysed by liquid scintillation counting. Cells downregulated for 
ABCC1 showed a significant decrease in 
3
H-InsP5 incorporation compared to 
scrambled cells. On the contrary ABCC5 knock down did not show any effect on 
the uptake process (Figure 6.6). These data confirmed the observation obtained by 
confocal fluorescence analysis suggesting the specific role of ABCC1 in InsP5 
uptake. 
 
 Figure legend next page 
 
 
 
174 
 
Figure 6.6: Effect of siRNAs targeting ABCC1 or ABCC5 on 
3
H-InsP5 uptake 
3
H-InsP5 incorporation analysis in MDA-MB-231 transfected with scrambled 
siRNA, ABCC1 siRNA or ABCC5 siRNA and incubated with 
3
H-InsP5 for 1 hour. 
Columns represent the mean average incorporation of 4 independent experiments, 
expressed as percentage of 3H-InsP5 incorporation of scrambled cell lines; bars 
S.E.M; *p<0.05      
    
 
6.1.7 Downregulation of ABCC1 and ABCC5 protein levels in MDA-MB-231 
Downregulation of ABCC1 and ABCC5 in MDA-MB-231 levels was checked by 
Real-Time PCR after 72 hours from transfection. A scrambled non-targeting 
sequence was used as control. Figure 6.7 shows more than 80% decrease of 
ABCC1 and ABCC5 mRNA levels in cells transfected with the respective siRNA 
when compared with expression of control scrambled cells. Furthermore, no 
decrease in ABCC5 mRNA levels was detected in cells transfected with siRNA 
targeting ABCC1 and vice versa, indicating that the sequences used are specific for 
each transporter and are able to downregulate them with high efficiency. 
 
Figure 6.7: Quantification of ABCC1 and ABCC5 expression: RT-PCR analysis 
of ABCC1 and ABCC5 mRNA levels in cells transfected with siRNA for ABCC1 
and ABCC5 and control scrambled siRNA. Relative gene expression was 
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calculated using scrambled samples as calibrators and actin as a housekeeping gene. 
Columns are the mean ±SEM of three independent experiments 
 
6.2 Discussion 
Data presented in this chapter aimed to investigate the potential role of ABC 
transporters belonging to the ABCC family in inositol phosphate active transport in 
mammalian cells. My group showed that cancer cells uptake inositol 
polyphosphates (Razzini et al., 2000). Furthermore preliminary data show that 
inositol polyphosphates uptake is inhibited by incubating the cells at 4°C. However 
it is currently unknown which transporters are involved in this process. Although 
ABC transporters in mammals are involved in drug export and their overexpression 
confers drug resistance to cancer cells, it has been shown that ABCC family 
members are involved in the vacuole export of inositol pentakisphosphate (Nagy et 
al., 2009) in Arabidopsis. Furthermore evidence suggests that ABC transporters are 
involved in the import of anion abscisic acid into cells in plantae. Another report 
suggests the involvement of ABC transporters in the import of auxin (Terasaka K., 
et al., 2005). In principle there is no evidence suggesting that ABC transporters 
should not be involved in import/export process rather then export alone. Starting 
from this evidence, I decided to investigate the role of ABC transporters in inositol 
pentakisphosphates in cancer cells. Treatment of MDA-MB-231with two generic 
ABC transporter inhibitors (probenecid and glibenclamide) inhibited 2-FAM-InsP5 
incorporation, indicating that ABC transporters may be involved in Ins(1,3,4,5,6)P5 
uptake (Figure 6.2). In particular treatment with MK-571, a specific inhibitor of 
ABCC1, inhibited uptake of 2-FAM-InsP5 and of 
3
H-InsP5 (Figure 6.3, 6.4). Similar 
results were obtained using siRNA targeting ABCC1 (Figure 6.5). It has to be 
noted that neither MK-571 treatment nor downregulation of ABCC1 completely 
inhibited InsP5 uptake indicating that ABCC1 is not the only ABC transporter 
involved in this process. However downregulation of ABCC5 had no effect on 
InsP5 uptake indicating that the inhibition observed upon ABCC1 inhibition may be 
specific and not all the ABCC family members are involved in this process. 
Although a more complete screening is required to assess the role of the ABC 
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family members in inositol phosphates uptake, my data indicate for the first time 
that in mammalian cells ABC transporters may be involved in inositol phosphate 
uptake and therefore suggest a potential involvement of ABC transporters also in 
cellular import. These data may also have important relevance in cancer therapy. 
Indeed ABC transporters have been found overexpressed in several cancers 
including pancreatic cancer (Konig et al., 2005; Hagmann et al., 2009). This family 
of proteins has an established role in chemoresistance or multidrug resistance. 
Work in my laboratory has recently unravelled a novel involvement of these 
proteins in cancer progression. Indeed it has been reported that ABCC1 transporter 
is involved in an autocrine loop by which cancer cells can stimulate their 
proliferation (Pineiro et al., 2010). In particular the phospholipid 
lysophosphatidylinositol (LPI) is synthesized by cancer cells, through the action of 
the enzyme phospholipase A2 (PLA2), and exported by ABCC1. Once released, 
LPI can bind its receptor GPR55 (G-protein coupled receptor 55) and activate 
signalling pathways involved in cell proliferation (Pineiro et al., 2010). Inhibition 
of this ABC transporter-mediated autocrine loop can represent a novel strategy to 
block cancer cell proliferation. Indeed, blockage of activation of GPR55 or activity 
of the LPI transporter ABCC1 inhibits survival and proliferation of prostate and 
ovarian cancer cell lines. However, according to the data shown in this chapter, the 
overexpression of ABCC1 might increase the intracellular uptake of exogenous 
inositol phosphates such as InsP5 or potential synthetic derivatives, resulting in 
increased sensitivity and cell death.  
Summary 
Data shown in this chapter indicates for the first time a potential involvement of 
ABC transporters and in particular of ABCC1 transporter in inositol phosphate 
uptake in mammalian cells. Taken together this data show a potential novel role for 
ABCC transporters in active cellular import and suggest a novel way of thinking 
ABC transporters, not only as transporter involved in drug resistance or autocrine 
loop but also as potentially marker to identify tumour responsiveness to specific 
anti-cancer treatment, such as inositol phosphates. 
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Chapter 7 
PDK1-dependent PLC1 activation 
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7.1 Transient downregulation of PDK1 in MDA-MB-231, MDA-MB-435 
and A375M 
Results described in chapter 5.4.5 and 5.4.6 showed that 2-O-Bn-InsP5 
treatment is able to block PLC1 activity (Figure 5.13) and that it inhibits 
PLC1 phosphorylation at the residue Y783. Furthermore kinase profile assays 
provided in vitro evidence that 2-O-Bn-InsP5 specifically inhibits PDK1. These 
data suggested that PDK1 might have a novel role on PLC1 regulation and 
activation. In order to investigate this hypothesis I decided to investigate the 
potential effect of PDK1 downregulation on PLC1 activity.  
 
7.1.1 PDK1 protein downregulation in MDA-MB-231, MDA-MB-435 and 
A375M 
Transient downregulation of PDK1 was achieved using specific siRNA 
targeting PDK1. MDA-MB-231, MDA-MB-435 cells were transfected with 
Oligofectamine transfecting agent, while A375M were transfected using 
Hyperfect transfecting agent. In order to test the efficiency of PDK1 silencing, 
MDA-MB-231 lysates obtained after 48 hours and 72 hours from transfection 
were analysed by western blot analysis using a specific PDK1 antibody (Figure 
7.1A). Efficiency of downregulation in A375M and MDA-MB-435 was 
assessed after 72 hours from transfection. Cells transfected with non-targeting 
siRNA were used as control. Western Blots in Figure 7.1B,C showed a reduced 
PDK1 expression after 48 hours compared to scrambled cells in MDA-MB-
435 and A375M. PDK1 protein expression was downregulated after 72 hours 
from transfection in all the three cell lines, indicating that 72 hours are required 
for the efficient downregulation of this enzyme in all the three cell lines 
investigated.   
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Figure 7.1: Transient downregulation of PDK1: Expression levels of PDK1 
after 48 and 72 hours from transfection with specific siRNA targeting PDK1 
in MDA-MB-231 and after 72 hours in A375M and MDA-MB-435 cells. 
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7.1.2 Transient downregulation of PDK1 protein expression inhibits 
calcium release upon EGF stimulation 
The observation that 2-O-Bn-InsP5 inhibits PLC1 activity (as assessed by 
EGF-induced calcium release) and that kinase profiling analysis revealed that 
2-O-Bn-InsP5 is a specific PDK1 inhibitor, prompted me to investigate 
whether PDK1 had a role in PLC1 activation. Therefore I decided to 
determine the effect of PDK1 downregulation on PLC1 activity in MDA-
MB-231 and A375M using the intracellular calcium measurement assay upon 
EGF stimulation. As indicated in chapter 7.1, the most efficient 
downregulation was obtained after 72 hours of transfection with the specific 
siRNAs. Therefore the calcium measurement was performed after 72 hours 
from transfection. MDA-MB-231 and A375M siPDK1 were serum-starved 
overnight and loaded with Fluo-4-AM before analysis of calcium mobilisation 
induced by EGF stimulation. MDA-MB-231 and A375M transfected with a 
scrambled sequence were used as controls. The chart shown in Figure 7.2 
indicates that EGF stimulation induced a fast response in MDA-MB-231 and 
A375M scrambled cells, leading to the peaks in the calcium pattern. Cell 
viability was assessed adding ATP to the cells towards the end of the assay, 
which generated peak at the end of the chart. Strikingly, EGF-induced calcium 
mobilisation was completely abrogated in MDA-MB-231 and A375M 
transfected with siRNA targeting PDK1.  ATP-induced calcium mobilisation 
was comparable in cells transfected with scrambled or PDK1 specific siRNA, 
indicating no significant difference in cell viability. These data revealed for 
the first time a role of PDK1 in PLC1 activation.  
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Figure 7.2 PDK1 downregulation inhibits EGF-induced calcium release: 
Calcium release assay performed on MDA-MB-231 and A375M transfected 
with siRNA specific for PDK1 or with a non-targeting sequence. Arrows 
indicate the time point of EGF and ATP stimulation. The chart is the mean of 
4 independent experiments.     
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7.1.3 Matrigel cell invasion is inhibited in Breast cancer and Melanoma 
cell lines upon PDK1 downregulation. 
As described in the introductory chapter 1.7, PDK1 is a key enzyme involved 
in promoting cell invasion. Calcium measurement showed that siRNA for 
PDK1 inhibits PLC1 activity as assessed by intracellular calcium 
mobilisation upon EGF stimulation in MDA-MB-231. Since both enzymes 
play an important role in cell invasion, I decided to investigate the effects of 
PDK1 downregulation on cell invasion on Matrigel using different invasive 
cancer cell types. MDA-MB-231, MDA-MB-435 and A375M were 
transfected with scrambled siRNA and siRNA for PDK1 and 72 hours after 
transfection cells were plated on Matrigel pre-coated transwells and allowed to 
invade for 36 hours. An aliquot of cells was seeded in parallel on 6-well plates 
to perform western blot analysis at the end of the invasion assay. Cells 
transfected with a scrambled siRNA sequence were used as control. Cell 
invasion on Matrigel was inhibited in all three cell lines upon downregulation 
of PDK1 compared to their respective control. In particular invasion was 
inhibited by 50% and 52% in MDA-MB-231 and MDA-MB-435 upon PDK1 
knock down respectively compared to MDA-MB-231 and MDA-MB-435 
scrambled cells (Figure 7.3). A375M showed the highest inhibition with a 
decrease in cell invasion of 70% compared to scrambled cells, indicating that 
PDK1 plays an important role in Matrigel cell invasion in several cancer 
types, and the inhibition is independent of the cell type used (Figure 7.3). 
These data showed that PDK1 is an essential enzyme for promoting cancer 
cell invasion, consistent with data in the literature (Primo et al., 2007; Pinner 
and Sahai, 2008; Finlay et al., 2009). 
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Figure 7.3 Cell invasion on Matrigel of MDA-MB-231, MDA-MB-435 and 
A375M downregulated for PDK1 expression: Invasion assay was performed 
after 72 hours from siRNA transfection and lasted 36 hours. Columns are 
mean of three independent experiments. Bars S.E; *p<0.05;***p<0.001 
 
7.2 Generation of MDA-MB-231 stably downregulated for PDK1 
expression 
 
In order to further investigate the effect of PDK1 protein downregulation on 
PLC1 activation, I decided to generate stable MDA-MB-231 downregulated 
for PDK1. The rationale for this decision was the limitation of the transient 
transfection using siRNAs. Transient transfection interfering efficiency is 
variable among the different experiments. Furthermore transient interfering 
does not provide a homogenous population of cell downregulated for the 
targeted protein. In order to overcome these limitations I generated MDA-MB-
231 cells expressing shRNA targeting PDK1 using specific targeting 
sequences cloned in the vector pSUPERIOR.retro.puro. Cells expressing the 
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construct were selected. This method allowed the selection of a more 
homogeneous population of cells downregulated for PDK1 expression.     
The pSUPERIOR vector was used in concert with a pair of custom 
oligonucleotides that contained a unique 22-nt sequence derived from the 
mRNA transcript of PDK1 in order to induce gene suppression. The target 
sequence corresponds to the sense strand of the pSUPERIOR-generated 
siRNA, which corresponds to the complementary sequence within the mRNA. 
The forward and reverse oligonucleotides were annealed and cloned into the 
vector, between the unique BglII and HindIII enzyme sites. This strategy 
positions the forward oligonucleotides at the correct position downstream 
from the H1 promoter’s TATA box to generate the desired siRNA duplex.  
 
 
7.2.1 Design of 22-nucleotide targeting sequence cloned in 
pSUPERIOR.retro.puro vector 
 
The sequence of the targeting oligonucleotides includes the unique 22-
nucleotide targeting sequence in both sense and antisense orientation, 
separated by a 9-nt spacer sequence. The 5’ end corresponds to the BglII site, 
while the 3’ end contains the HindIII corresponding nucleotides. The resulting 
transcript of the recombinant vector is predicted to fold back on itself to form 
a 22–base pair stem-loop structure. 
The 22-nucleotide targeting sequence was designed based on the sequence 
published by Sahai et al, 2008 used for siRNA (Figure 7.4). The sequence was 
modified in the last nucleotide in order to remove the fifth T that would be 
otherwise recognized as a stop by RNA polymerase III aborting the 
transcription of the shRNA. A 5 point mutated sequence was generated and 
cloned in the pSUPERIOR.retro.puro vector as closest control. The 5’ end 
presents the BglII restriction site, while the 3’ end contains the HindIII 
corresponding nucleotides (Figure 7.4). 
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shPDK1 targeting sequence: 
 
 
5MUT sequence 
 
Figure 7.4: Short hairpin constructs: Cloning of shPDK1 targeting sequence 
(panel above) and 5 point mutated non-targeting sequence (panel below) in 
pSUPERIOR.retro.puro vector. 
 
 
In order to insert the custom-designed oligonucleotides in the 
pSUPERIOR.retro.puro vector, I performed serial digestions of the 
pSUPERIOR.retro.puro vector with Hind III and BglII restriction enzymes. 
The serial digestions were performed separately in order to be certain of the 
restriction activity of each enzyme. After each digestion, plasmids were loaded 
on 1% agarose gel and analysed by electrophoresis.  
The vector was first digested with Hind III overnight. Figure 7.5 shows the 
uncut plasmid on the left and the vector upon overnight digestion on the right. 
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Figure 7.5: pSUPERIOR.retro.puro not digested and digested with 
HindIII restriction enzyme. 
The digested vector was purified and digested a second time with restriction 
enzyme BglII, in order to create complementary extremities for the insertion 
of the annealed custom oligonucleotides. As a control the parental uncut 
vector was digested with BglII alone in order to verify the activity of the 
restriction enzyme. Figure 7.6 shows that the vector was successfully double 
digested with HindIII and BglII as indicated by the second band at 1kb in the 
third lane on the right at 6.3kb and at 1Kb. 
 
Figure 7.6: Digestion of the previously HindIII-digested 
pSUPERIOR.retro.puro using the restriction enzyme BglII (right lane). BglII 
activity was tested on uncut vector (middle lane). 
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7.2.2 Colony-PCR screening  
In order to insert the 5Mut and the shPDK1 oligonucleotides in the vector, 
ligase reaction was performed overnight. Competent Top10™ bacterial cells 
(Invitrogen, UK) were transformed with the plasmids upon ligation. 20 
Positive bacterial colonies for the 5MUT and 20 positive bacterial colonies for 
shPDK1 were picked up and screened by PCR. Primers provided by the 
manufacturer for PCR screening of positive colonies were used in order to 
screen the effective integration of the customer oligos in the double-cut 
plasmids. Positive colonies were predicted to give an amplification product of 
482 bp. Figure 7.7 shows the amplification product of the 40 different 
colonies. Among the different positive colonies I choose the colonies listed in 
table 7.1 to proceed for plasmid purification and cell transfection. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Colony PCR screening: Screening of positive colonies shows an 
amplicon at the predicted size of 483bp.  
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Table 7.1: List of colonies chosen for plasmid purification and following 
transfection for generation of cells stably downregulated for PDK1 and 
respective control.  
 
 
7.2.3 Clones selection 
MDA-MB-231 cells were transfected with plasmid constructs listed in table 
7.1 and plated in selection media containing 1g/ml puromycin after 48 hours 
after transfection. Five days later two clones from each transfection were 
picked up and plated in separate plate dishes and allowed to grow. Protein 
lysates obtained from the different clones were analysed for PDK1 protein 
expression levels by western blot using a specific PDK1 antibody. Only two 
clones (construct 39, clone number 1 and construct 39, clone number 2) 
showed a clear reduction in PDK1 expression, and will be referred to as 
shPDK1 Clone 1 and Clone 2.  Construct 2 clone 1 and construct 8 clone 1 
were chosen as scrambled and maintained in culture and will be referred to as 
5MUT clone 1 and clone 2 (Figure 7.8A). Figure 7.8B shows a further western 
blot analysis of MDA-MB-231 5MUT clones and MDA shPDK1 clones after 
different passages in culture.  
Colony number Sequence 
2 5MUT 
8 5MUT 
25 shPDK1 
26 shPDK1 
27 shPDK1 
39 shPDK1 
40 shPDK1 
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Figure 7.8: Stable downregulation of PDK1. A) Western blot analysis of 
PDK1 levels on the different clones at passage 1. B) Representative Western 
blot analysis of PDK1 after two cell passages in culture. 
 
 
 
 
 
  
 
 
 
190 
 
7.3 Effect of PDK1 protein downregulation on Inositol phosphates 
production 
 
Intracellular calcium analysis experiments showed that transient protein 
downregulation of PDK1 using siRNA interfering inhibits intracellular 
calcium mobilisation upon EGF stimulation in MDA-MB-231 (chapter 7.1.2). 
In order to validate these results, I decided to investigate the inositol 
phosphate production in MDA-MB-231 shPDK1 “MDA-MB-231 shPDK1”. 
MDA-MB-231 5MUT cells were used as control for the experiments. 
Experiments were performed using the two clones previously selected in order 
to avoid any clone-specific effect in the analysis. 
Cells were labelled with a 
3
H-myo-inositol for 24 hours in inositol free, serum 
free media and then stimulated with EGF at different time points. Cells were 
lysed, and total inositol phosphates were separated by anion exchange 
chromatography and the total amount assessed by liquid radioactivity 
counting. Accumulation of inositol phosphates was inhibited in both clones 
MDA-MB-231 shPDK1 compared to MDA-MB-231 5MUT (Figure 7.9A). 
This data were consistent with results obtained in the calcium mobilization 
assay and identify PDK1 as a new key protein in regulating PLC1 activity. 
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Figure 7.9: Inositol phosphates levels in MDA-MB-231 stably 
downregulated for PDK1: Inositol phosphates accumulation in MDA-MB-
231 5MUT and shPDK1 previously incubated in 
3
H-myo-inositol for 24 hours 
in inositol free, serum free media and then stimulated with 50ng/ml EGF for 
the indicated times before being lysed and analysed by liquid radioactivity 
counting. Data are means ±.SEM of 4 independent experiments.; *p<0.05 
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7.4 The PDK1-dependent PLC1 regulation 
7.4.1 Analysis of PLC1 protein level in MDA-MB-231 downregulated for 
PDK1 
In order to understand the mechanism of PDK1-dependent regulation of 
PLC1 activity, I first determined whether downregulation of PDK1 affected 
PLC1 protein expression in MDA-MB-231. This experiment aimed to 
investigate any potential effect of the absence of PDK1 on PLC1 protein 
level due to changes at transcription level or protein stability. After 48 hours 
from transfection with specific PDK1-targeting siRNA or scrambled siRNA, 
cells were starved overnight and then stimulated with EGF at different times. 
Since PDK1 phosphorylates AKT at threonine 308 (Thr 308), I decided to 
check AKT phosphorylation to validate the efficiency of PDK1 
downregulation. Western blot analysis showed that the decreased levels of 
PDK1 expression in MDA-MB-231 was mirrored by the inhibition of the 
EGF-induced threonine phosphorylation of AKT in “MDA-MB-231 siPDK1” 
compared to scrambled cells (Figure 7.10). No change in PLC1 expression 
was observed between MDA-MB-231 siPDK1 and control cells, indicating 
that PDK1 protein downregulation does not affect PLC1 expression and that 
the inhibition of PLC1 previously observed is due to an impaired PLC1 
activation. 
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.  
Figure 7.10: PLC1 expression in cells downregulated for PDK1:Western 
blot analysis of MDA-MB-231 transfected with scrambled siRNA or siRNA 
targeting PDK1 (siPDK1). Cells were treated with EGF for the indicated times 
72h after transfection. Lysates were analysed using specific antibodies for the 
specified proteins. Blot representative of two independent experiments. 
 
 
7.4.2 Effect of downregulation of PDK1 on tyrosine phosphorylation of 
PLC1 in MDA-MB-231  
To gain further insight into the mechanism of PDK1-dependent PLC1 
activation, I decided to investigate any potential effect of PDK1 
downregulation on PLC1 post-translational modifications. As described in 
chapter 1.3.1, PLC1 phosphorylation is required for its enzymatic activation. 
In particular phosphorylation of tyrosine 783 (Y783) correlates with PLC1 
activation. MDA-MB-231 transfected with a control scrambled siRNA or 
siRNA targeting PDK1 were starved overnight 48 hours after transfection and 
then stimulated with EGF for 3 and 10 minutes. Western blot analysis showed 
that tyrosine phosphorylation of PLC1 was inhibited after 10 minutes of EGF 
stimulation in MDA-MB-231 compared to scrambled cells (Figure 7.11A). No 
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changes were observed after a short stimulation of 3 minutes, probably due to 
the not complete downregulation of PDK1. The efficiency of transfection was 
assessed using a specific PDK1 antibody to test protein expression levels of 
PDK1 in MDA-MB-231 and scrambled cells. These data indicate that 
downregulation of PDK1 inhibits the EGF-induced tyrosine phosphorylation 
of PLC1 at its residue Y783. Furthermore this data reveal a novel role for 
PDK1 in the regulation of PLC1 activity through modulation of its tyrosine 
phosphorylation. In order to validate the data obtained using transient siRNA 
similar experiments were performed in MDA-MB-231 stably downregulated 
for PDK1 expression. Cells were serum starved over-night, stimulated with 
EGF for 3 and 10 minutes before being lysed. Phosphorylation of PLC1 was 
strongly inhibited in cells expressing the shRNA targeting PDK1 compared to 
control cells (Figure 7.11B) at all time points of EGF stimulation. The 
discrepancy in the results obtained by transient and stable PDK1 
downregulation may be explained by the partial silencing of PDK1 using 
transient RNA interfering. On the contrary, a more efficient PDK1 
downregulation was achieved in MDA-MB-231 expressing the shRNA 
targeting PDK1, which showed a complete inhibition of PLC1 
phosphorylation.     
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Figure 7.11: Western blot analysis of MDA-MB-231 downregulated for 
PDK1 (siPDK1 or shPDK1): A) Cells were treated with EGF 72 hours after 
transfection and overnight serum starvation. Phosphorylation of tyrosine 783 
of PLC1 was assessed after 3 and 10 minutes of EGF stimulation 
(Representative Western blot of two independent experiments). B) MDA-MB-
231 sh5MUT and MDA-MB-231 shPDK1 were treated with EGF for the 
indicated times and phosphorylation of PLC1 analysed. Lysates were 
analysed using specific antibodies for the specified proteins. Representative 
Western blot of 3 independent experiments. 
B 
A 
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7.5 Investigation of the mechanism of PDK1-mediated PLC1 activation 
 
In order to further investigate the mechanism through which PDK1 regulates 
PLC1 I decided to investigate the hypothesis that the two enzymes could 
interact. To test this hypothesis I used different complementary approaches. 
First I tested whether the two proteins, either endogenous or over-expressed 
could co-immunoprecipitate. 
 
7.5.1 Overexpression of PLC1 and PDK1 in HEK293 cells 
To optimise the protocol of co-immunoprecipitation experiment, I first 
decided to perform the experiment using overexpressed PDK1 and PLC1. In 
these experiments HEK293 cells were chosen because of their high 
transfection efficiency. Cells were transfected using Lipofectamine 
(Invitrogen, UK) according to the manufacturer’s instructions. 48 hours after 
transfection, proteins lysates were collected and expression of exogenous 
PLC1 and PDK1 assessed by western blot. HEK293 showed a high rate of 
transfection using both plasmids. Western blot analysis showed an increased 
expression of PLC1 in overexpressing HEK293 cells (HEK293-PLC1) 
compared to HEK293 transfected with the empty vector (HEK293). PLC1 
was detected using specific anti-PLC1 antibody (Figure 7.12A). 
The pOZ-PDK1 construct expresses an HA-FLAG tagged fusion protein. The 
HA and FLAG are two epitopes tags recognised by specific antibodies. 
Because of these flags the overexpressed PDK1 was predicted to be shifted 
compared to the wild type protein when run on acrylamide gel and then 
analysed by western blot.  
Indeed Western blot analysis of HEK293 overexpressing PDK1 (HEK293-
pOZ-PDK1) showed a high expression of the tagged PDK1 compared to 
control cells. Endogenous and exogenous PDK1 protein levels were assessed 
using a specific anti PDK1 and anti HA-antibody (Figure 7.12 B,C).  
A 
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Figure 7.12: Overexpression of PLC1 and HA-Flag-PDK1 in HEK293 
cells: A) Western blot analysis of HEK293 overexpressing PLC1 48 hours 
after transfection detected by a PLC1 specific antibody; B) Western analysis 
using the anti-PDK1 antibody of HEK293 expressing the HA-PDK1 tagged 
protein detected two bands which corresponded to the endogenous PDK1 
(lower band) and to the recombinant protein HA-PDK1 (upper band); C) The 
overexpressed HA-PDK1 was detected using an anti-HA antibody in HEK293      
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7.5.2 Investigation of potential PLC1-PDK1 through co-
immunoprecipitation analysis. 
Once optimized the protocol of overexpression, co-immunoprecipitation 
experiments were performed using HEK293 cells overexpressing both PLC1 
and the tagged fusion protein HA-FLAG-PDK1.  Cells were transfected and 
48 hours after transfection cells were lysed and immunoprecipitation 
experiments were performed using the Catch and release 2.0® kit (Millipore, 
US) (chapter 2.2.1.2.1). This kit allows reducing troubleshooting in setting 
experimental conditions, since the IgG affinity beads are already in a column 
in a fixed amount decided by the manufacturer. I decided to perform 
immunoprecipitation experiments using the anti PLC1 antibody (Santa Cruz 
Biotechnology, USA)  validated for immunoprecipitation analysis according 
to the manufacturer’s datasheet. Immunoprecipitation with mouse IgG was 
performed in parallel as control. For each sample the lysates that did not bind 
to the PLC1 antibody-bead complex (unbound) was collected and loaded as a 
control. The immune-complex was detached from the beads using denaturing 
loading buffer after three washes, and loaded for western blot analysis (IP). 
Western blot analysis revealed an efficient immunoprecipitation of PLC1 in 
these experimental conditions. Furthermore the control IgG were unable to 
immunoprecipitate PLC1 (Figure 7.13). More importantly, a specific band 
recognised by the PDK1 antibody was detected in the PLC1-IP at the 
molecular weight of the HA-Flag-PDK1 fused protein. No PDK1 band was 
detectable in IgG-IP fraction indicating that the band was specific (Figure 
7.13).   
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Figure 7.13: Co-IP analysis of PDK1/ PLC1 upon overexpression: Co-IP 
analysis of overexpressed PDK1 and PLC1 using anti-PLC1 or mouse-IgG 
to immunoprecipitate. Immunocomplexes were analysed for the presence of 
PDK1 and PLC1. Representative western blot of two independent 
experiments.  
Data shown in Figure 7.13 suggested that a specific protein-protein interaction 
occurs between PLC1 and PDK1. However low amount of PDK1 was 
immunoprecipitated using the PLC1 antibody. Furthermore no endogenous 
PDK1 was detected in these experimental conditions indicating that the 
protocol needed to be further optimised. Using different amounts of protein 
lysates and antibody did not improve the co-immunoprecipitation rates, 
suggesting that conditions of lysis and wash buffers need to be optimised. It 
has to be noticed that the PDK1 band showed in IP-PLC1 samples presents a 
slight shift compared to the fusion protein of the unbound-PLC1, suggesting a 
potential post-translational modification of the protein. Further investigation 
could highlight a potential post-translational modification of PDK1 involved 
in the novel PDK1-PLC1 interaction and in PLC1 regulation. 
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7.5.3 GST pull-down experiments 
The second approach that I decided to use in order to investigate a potential 
PLC1-PDK1 protein-protein interaction was the GST-pull down assay. This 
second approach is a complementary method to investigate protein-protein 
interactions in overexpressing conditions. The assay allows the pull-down of 
interacting protein without the use of specific antibodies. In this assay one of 
the two proteins whose interaction has to be tested is cloned in a Glutathione-
S-Transferase (GST) expressing vector and the resulting GST-fused protein is 
immobilised on Glutathione agarose beads. Lysate containing the second 
protein of the potential interaction is loaded on the beads, and this allows the 
two proteins to interact. Finally the immobilised protein and the potential 
associated protein(s) can then be dissociated from the beads. Any potential 
interaction can then be analysed by western blot.   
For these experiments, a pEBG2T vector expressing the coding sequence of 
PDK1 fused with GST at N-terminal (GST-PDK1) was used. This vector 
allowed the expression of GST-fusion protein directly in mammalian cells 
HEK293. Lysates from HEK293 overexpressing the empty vector pEBG2T-
GST (GST) were used as control. The GST-PDK1 fusion protein presents a 
shift of ~26 KDa compared to the wild type protein. Figure 7.14 shows the 
western blot analysis of lysates from HEK293 overexpressing 
PLC1(HEK293-PLC1) and HEK293 overexpressing GST-PDK1 (HEK293-
GST-PDK1). GST-PDK1 was efficiently overexpressed in HEK293 and 
recognised by a PDK1 specific antibody as a band at 85 KDa. In parallel 
HEK293-PLC1 showed increased levels of PLC1 compared to HEK293-
GST-PDK1 used as control for PLC1 expression in this particular case.  
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Figure 7.14: Overexpression of PLC1 and GST-PDK1 analysed by western 
blot using specific antibodies for PLC1 and PDK1. Note that addition of GST 
to PDK1 generates a band of ˜85KDa. 
 
7.5.4 GST pull down analysis of PDK1-PLC1 interaction 
The GST pull down assay was performed using protein lysates from HEK293-
GST and HEK293-GST-PDK1. Lysate from HEK293-GST was used as 
negative control for the experiments, since the GST alone should not interact 
with PLC1. Briefly, lysates from HEK293-GST and HEK293-GST-PDK1 
were incubated with the agarose-glutathione beads for 1 hour and then 
incubated overnight with lysed collected from HEK293 overexpressing 
PLC1. Beads were then washed and proteins bound to the agarose beads were 
harvested in denaturing condition and analyzed by western blot analysis. 
Figure 7.15 shows a representative western blot of experiments performed 
using lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% NP-40) for collecting 
cell lysates and for the washing steps. A band recognised by PLC1 antibody 
was detected when lysates HEK293-PLC1 were incubated with GST-PDK1 
previously immobilised on the agarose beads. However a small band 
recognised by PLC1 antibody was detected also in the negative control 
(HEK-GST). The limited amount of PLC1 interacting with PDK1, together 
with the signal detected in the control suggested me that the technique was not 
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optimised. Nevertheless the result was encouraging to further optimise the 
assay.    
 
Figure 7.15: GST pull down: Western blot analysis of GST pull down assay 
of HEK293 overexpressing GST or GST-PDK1 incubated with lysate from 
HEK293 overexpressing PLC1. PLC1 and PDK1 were detected using 
specific antibodies. Representative western blot of 2 experiments. 
 
In an effort to find the optimal condition to detect the interaction, I decided to 
test different buffers for the incubation step. Three different buffers were 
prepared changing the ionic and detergent concentration (Table 7.2). The aim 
of this optimisation protocol was to preserve the PLC1-PDK1 interaction and 
remove the aspecific binding observed in the control. 
Table 7.2: 
 Buffer 1 
 
Buffer 2 Buffer 3 
Tris pH 8.0 
 
50 mM 50 mM 50 mM 
NaCl 
 
300 mM 150 mM 50mM 
NP-40 
 
0.1% 1% 2% 
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HEK293-GST and HEK293-GST-PDK1 were lysed in lysis buffer (50mM 
Tris-pH 8.0, 50mM KCl, 1% NP-40) and incubated with agarose-glutathione 
beads for 2 hours using one of the buffers listed in table 7.2. After three 
washes, performed in the chosen buffer, lysate from HEK293-PLC1 was 
incubated overnight with the beads-bound GST-fused protein, in the 
corresponding buffer. Complexes were eluted in denaturing conditions after 
three washes and analysed by western blot. As shown in Figure 7.16 PLC1 
was not detected in the complex when the incubation was carried out in buffer 
1 (lanes 2-3). On the contrary, a clear band was detected when HEK293-
PLC1 lysate was incubated with GST-PDK1 using the buffer 2 (lanes 3-4) 
and buffer 3 (lane 5-6), indicating that PLC1-PDK1 complex was preserved 
in these conditions. Moreover a very low aspecific signal was detected 
following incubation with GST alone. Coomassie brilliant blue staining was 
performed in order to evaluate proteins levels in the different samples. The 
arrows indicate GST-PDK1 and GST. The staining revealed no major 
difference in protein levels among the different samples. Taken together these 
data demonstrated that PLC1 can associate with PDK1, at least in vitro.  
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Figure 7.16: GST Pull-down optimisation protocol: WB analysis of GST 
pull down assay in cells expressing GST or GST-PDK1 and lysed with three 
different buffers (see table 3) (upper panel). Loading control was assessed by 
Coomassie staining of a gel run in parallel (lower panel). Representative 
Western blot of three independent experiments. 
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7.5.5 Co-immunoprecipitation analysis of endogenous PLC1 and PDK1 
in MDA-MB-231 
Co-immunoprecipitation and GST pull down experiments demonstrated for 
the first time that PLC1 can interact with PDK1 when overexpressed. To 
investigate the PDK1-PLC1 interaction at endogenous level, I decided to 
perform co-immunoprecipitation experiments of endogenous proteins from 
lysates of MDA-MB-231 stimulated with EGF and in full serum condition. 
Experimental conditions optimised in the pull-down assay were used. To this 
end, MDA-MB-231 were serum starved overnight and left untreated (control) 
or stimulated with EGF for 10 minutes. Alternatively, cells maintained in 10% 
serum supplied media were used. PLC1 and PDK1 were co-
immunoprecipitated using the PLC1 antibody and immunocomplexes 
fractions assessed by western blot for PLC1 and PDK1. As shown in Figure 
7.17, PDK1 was specifically immunoprecipitated by the anti-PLC1 in lysates 
from EGF-stimulated cells compared to non-stimulated cells or to cells 
maintained in serum condition. These data demonstrated that EGF induces 
association of PLC1 and PDK1. Data are consistent with previous results 
showing a reduced tyrosine phosphorylation of PLC1 after EGF stimulation 
in cells downregulated for PDK1 or treated with 2-O-Bn-InsP, suggesting that 
the interaction between PLC1 and PDK1 is necessary for PLC1 
phosphorylation and the subsequent activation.  
 
Figure 7.17 Co-immunoprecipitation of endogenous PDK1 and PLC1: 
MDA-MB-231 were left untreated or stimulated with EGF for 10 minutes or 
maintained in serum-supplemented media. Co-IP and western blot analysis 
 
 
 
206 
 
were performed using anti- PLC1 and anti-PDK1 antibodies. Representative 
Western blot of three independent experiments.  
 
To further investigate the novel identified complex between PLC1 and 
PDK1, I decided to perform co-immunoprecipitation experiments in MDA-
MB-435 downregulated for PLC1 expression (MDA-MB-435 shPLC1) and 
the respective control (MDA-MB-435 sh3MUT). The rationale was to 
investigate the potential PLC1/PDK1 complex in a second cell line and also 
to validate the specificity of the co-immunoprecipitation assay. Indeed, in 
principle, the co-immunoprecipitation analysis performed using the PLC1 
antibody in cells lacking PLC1 should monitor potential aspecific 
immunoprecipitation. Cells were serum starved overnight and left untreated or 
stimulated with EGF for 10 minutes or with media containing 10% serum 
supplied media before being lysed. Immunoprecipitation assay was performed 
in the conditions previously described. Lysates were incubated with PLC1 
antibody and immunoprecipitated fractions assessed by western blot for 
PLC1 and PDK1. Figure 7.18 shows that PLCwas efficiently 
immunoprecipitated in MDA-MB-435 3MUT whereas no PLC1 (or reduced 
PLC1) was immunoprecipitated in MDA-MB-435 downregulated for PLC1 
expression. These data demonstrate that PDK1 specifically interact with 
PLC1 and rule out any potential aspecific co-immunoprecipitation.  
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Figure 7.18: Co-immunoprecipitation of PDK1 and PLC1 in MDA-MB-
435: MDA-MB-435 3MUT and MDA-MB-435 shPLC1 were left untreated 
or stimulated with EGF for 10 minutes or maintained in serum-supplemented 
media. Co-IP and western blot analysis are performed using anti- PLC1 and 
anti-PDK1 antibodies. Representative Western blot of three independent 
experiments.  
 
7.5.6 FRET analysis of PLCPDK1 protein interaction by confocal 
imaging 
To understand the dynamic of the interaction between PDK1 and PLC1, I 
decided to use the Fluorescence Resonance Energy Transfer (FRET) assay as 
described in chapter 2.3.4, in order to analyse the formation of the complex 
spatially and temporally. To this end MDA-MB-231 were co-transfected with 
plasmids to over-express both PLC1 and PDK1. As controls, MDA-MB-231 
expressing a GFP-containing vector together with PLC1 plasmid and MDA-
MB-231 expressing GFP-containing vector together with the pOZ-PDK1 
plasmid were used. No FRET signal was expected to be detected in the control 
cells since no interaction occurs between GFP and PLC1 and between GFP 
and PDK1. Cells were starved overnight 24 hours after transfection and then 
left untreated or stimulated with EGF at different time points before being 
fixed. Immunofluorescence staining was performed using PLC1 and PDK1 
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specific antibodies (chapter 2.3.4) followed by FRET analysis. An increase in 
fluorescence in the donor channel was detected after acceptor’s photo-
bleaching. Donor fluorescence was measured at the level of membrane 
protrusions (when present after EGF stimulation) and also in more 
cytoplasmic regions. The rationale was that since PLC1 translocates to the 
plasma-membrane after EGF stimulation and also it is localised at the leading-
edge of motile cells, the PDK1-PLC1 complex could be enriched in the EGF-
induced cell protrusions. Donor fluorescence was measured also in more 
central cytoplasmic regions. Images in Figure 7.19 show the fluorescence 
intensity of the donor before and after the photo-bleaching for each time point 
in specific chosen regions. The merged channel shows where the acceptor was 
photo-bleached. The lines indicate representative regions where donor 
fluorescence change was measured and value collected for statistical analysis. 
In particular the chart in figure 7.20 shows the donor fluorescence (green line) 
before and after photobleaching of the acceptor (red line) of representative 
regions at all time points. FRET occurred after 1 minute and 3 minutes of EGF 
stimulation, since at these time-points acceptor’s drop of fluorescence was 
coupled with an increased donor’s fluorescence. As indicated in Figure 7.21, 
photo-bleaching of the donor caused a significant increase of fluorescence in 
the donor channel after 3 minutes of stimulation with EGF, indicative of 
FRET. No changes in donor fluorescence were revealed in the internal 
cytoplasmic region after acceptor photo-bleaching, and no FRET was detected 
when PLC1 or PDK1 were overexpressed together with a GFP-containing 
vector,  indicating that PLC1 and PDK1 associated after EGF stimulation, in 
well-defined region corresponding to cellular protrusions induced by EGF.  
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Figure 7.19: FRET images of MDA-MB-231 expressing exogenous PLC1 and PDK1: Donor pre-bleach and post-bleach 
fluorescence was measured in MDA-MB-231 overexpressing PLC1 and PDK1 after 1,3,5 and 10 minutes of stimulation with 
EGF in the areas indicated by the red line in each figure.  
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Figure 7.20:. Graphs representing donor and acceptor fluorescence measured 
at each time points along the red line indicated in the corresponding figures 
showed in figure 7.19. Increased donor fluorescence after bleaching indicated 
FRET occurring in the measured area. Unstimulated MDA-MB-231 
overexpressing PLC1 and PDK1 were used as control.   
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Figure 7.21: Quantification of FRET in MDA-MB-231:   Chart indicates 
percentage of FRET in MDA-MB-231 expressing exogenous PLC1 and 
PDK1 at the indicate times of EGF stimulation. Percentage of FRET was 
calculated in three independent experiments measuring donor fluorescence of 
10 cells per experiment before and after acceptor bleaching. Percentage of 
FRET in cells co-expressing PLC1 and GFP or PDK1 and GFP was used as 
basal FRET signal.  Columns are the means ±SEM of percentage of FRET 
measured at protrusion level or in more central cytosolic regions.  
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7.5.7 FRET analysis of PLCPDK1 protein interaction by FACS 
analysis 
To confirm the FRET data obtained by confocal analysis, I decided to 
perform FRET experiments using a different methodological approach. 
The FRET analysis described in chapter 7.5.6 was based on the increased 
fluorescence of the donor after photo-bleaching of the acceptor as read-out 
of occurring FRET. The methodology used to detect FRET using FACS 
analysis relies on increased fluorescence of the acceptor following donor 
excitation, without direct excitation of the acceptor itself. FRET occurs 
when donor’s and acceptor’s distance is less than 10 nm, resulting in 
increased fluorescence emission of the acceptor. Therefore the potential 
increase of acceptor fluorescence over background is due to FRET between 
donor and acceptor.  
MDA-MB-231 cells were co-transfected with plasmids overexpressing 
PLC1 and PDK1. Cells were serum starved over night before being 
stimulated with 50ng/ml EGF. Background fluorescence of acceptor alone 
was measured as control. Furthermore acceptor fluorescence was measured 
in MDA-MB-231 expressing a GFP-containing vector together with 
PLC1 plasmid or pOZ-PDK1 plasmid, in order to calibrate the 
background fluorescence of the acceptor. Furthermore MDA-MB-231 cells 
were transfected with PLC1 or pOZ-PDK1 plasmid and labelled with 
donor or acceptor dye-conjugated antibodies. These measurements allowed 
the calibration of the instrument in order to avoid false-positive FRET 
signal from cross-talk artefacts. The acceptor emission profiles of untreated 
and EGF stimulated cells were compared to the acceptor profile obtained 
in cells stained for PDK1 and PLC1 respectively. As indicated in figure 
7.22A unstimulated cells show an emission profile superimposable to the 
single positive sample. Cells stimulated with EGF present a shift in the 
acceptor emission profile indicating increased acceptor fluorescence 
subsequent to EGF stimulation. Analysis  of the acceptor emission profiles 
shows that a slight increase in the acceptor fluorescence was detected in 
unstimulated MDA-MB-231 overexpressing PLC1 and PDK1 compared 
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to background level, although not statistically significant. On the contrary 
stimulation with EGF induced 30% increase of acceptor fluorescence 
(Figure 7.22B,C).  These data indicate that EGF stimulation induces a 
fluorescence increase of the acceptor due to FRET occurring between 
PLC1 and PDK1, demonstrating that PLC1 and PDK1 interaction is 
induced by EGF stimulation. 
 
.     
 
 
Figure 7.22: Quantification of FRET by FACS analysis: A) The data 
display acceptor fluorescence of control and unstimulated cells (left) and 
control and EGF-stimulated cells (right) after correction of spectral bleeding 
of donor into the FRET (550 nm) channel. B) Fluorescence intensity over 
A 
B
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time of acquisition of control, unstimulated and EGF stimulated cells. C) 
Quantification of fluorescence in the FRET channels in MDA-MB-231 
transfected with PLC1 or pOZ-PDK1 plasmid and labeled with acceptor-
dye-conjugated antibody, or expressing a GFP-containing vector (donor) 
together with PLC1 plasmid or pOZ-PDK1 plasmid labelled with acceptor-
dye-conjugated antibody. FRET was quantified also in MDA-MB-231 co-
expressing PLC1 and PDK1 untreated or stimulated with EGF. Graph is 
the average ±SEM of three independent experiments.  
 
7.6 Discussion 
In order to test the hypothesis of a novel role of PDK1 in PLC1 regulation I 
decided first to investigate the role of PDK1 on PLC1 activation by 
measuring intracellular calcium and inositol phosphate accumulation upon 
EGF stimulation. Transient transfection of siRNAs is a powerful tool to 
downregulate the expression of targeted proteins. However, the results might 
be affected by intrinsic variability of the efficiency of transfection among 
different experiments and by a partial knock down. Therefore I decided to 
generate MDA-MB-231 expressing shRNA specific for downregulation of 
PDK1. The specific targeting sequence was cloned in the 
pSUPERIOR.retro.puro, which allows stable downregulation of the protein or 
inducible downregulation of the targeted protein if expressed in cells 
expressing the TET repressor. As described in the introductive chapter 1.7.2 
increasing lines of evidence showed that PDK1 plays a main role in cell 
migration and invasion in normal and cancer cell lines. My data showed that 
transient downregulation of PDK1 inhibited cell invasion on Matrigel in 
MDA-MB-231, MDA-MB-435 and A375M indicating that PDK1 plays an 
important role in cell invasion in the cell systems used (Figure 7.3). 
Interestingly transient downregulation of PDK1 inhibited EGF-induced 
calcium mobilisation in MDA-MB-231 and A375M (Figure 7.2). 
Furthermore inositol phosphates accumulation assay was inhibited in two 
clones of MDA-MB-231 expressing shRNA targeting PDK1 (Figure 7.9). 
Since the EGF-induced calcium release is entirely dependent on PLC1 in 
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this cellular system, these data demonstrated that PDK1 is involved in PLC1 
activity. Furthermore downregulation of PDK1 inhibited PLC1 
phosphorylation in MDA-MB-231 which explains the inhibition of PLC1 
activity (Figure 7.11). These data were consistent with the inhibition of 
PLC1 phosphorylation observed in cells treated with 2-O-Bn-InsP5 upon 
EGF stimulation. These data therefore identified a novel role of PDK1 in 
PLC1 regulation and a common mechanism of regulation of cancer 
progression and metastasis development. Considering the importance of 
PLC1 in metastasis development and progression, the inhibiting effect of 2-
O-Bn-InsP5 on PLC1 activity and on cell invasion strongly suggests that this 
inhibitor might have anti-metastatic effects in vivo. PDK1 represents a good 
target in cancer and since it is involved in the regulation of proteins that have 
an important role in cancer cell biology such as AKT, S6K1, SGK1-3 and 
PKC. However for this reason PDK1 inhibition could result in side effects. 
Interestingly data in literature showed that hypomorphic mice did not show 
any specific phenotype but, when crossed with PTEN heterozygote mice are 
protected against tumour development (Bayascas et al., 2005). Therefore 
pharmacological PDK1 inhibition could result in primary tumour growth 
inhibition and more importantly in anti-metastatic effect. 
Co-immunoprecipitation, GST pull-down and FRET analysis showed that 
PLC1 and PDK1 form a complex upon EGF stimulation, with an increased 
association upon growth factor stimulation. In particular confocal-based 
FRET analysis showed a significant increased association upon stimulation 
with EGF for 3 minutes in cell protrusion while FACS-based FRET analysis 
showed increased association upon EGF stimulation for 10 minutes. The 
different time response to EGF might be explained by the different conditions 
used for cell stimulation. Indeed for confocal-based FRET analysis adherent 
cells were stimulated at the different time points while for FACS-based FRET 
analysis cells were first detached and then stimulated with EGF in order to 
allow cell fixation for FACS analysis. Consistent with confocal-based FRET, 
co-immunoprecipitation analysis showed an increased association after 3 
minutes stimulation with EGF. Taken together these data revealed a novel 
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protein-protein interaction between PLC1 and PDK1 essential for PLC1 
activation and for cell motility.  
Summary 
Data shown in this chapter reveal a novel role of PDK1 in PLC1 activation, 
and demonstrated that PDK1 is essential in PLC1 activation. In particular 
PLC1 and PDK1 interact upon EGF stimulation and FRET analysis revealed 
that this association is increased at protrusion level. Furthermore, inhibition 
of PDK1 blocks PLC1 activation and inhibits PLC1 tyrosine 
phosphorylation. 
 
 
 
219 
 
 
 
 
 
 
 
Chapter 8 
Concluding discussion and future 
studies 
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8.1 Discussion 
The aim of my work was to investigate the role of PLC1 in cancer cell 
motility, with a particular interest in cancer cell migration and invasion, and 
the investigation of potential inhibitors that might prevent its activation. 
PLC1 has been extensively investigated in the literature and increasing lines 
of evidence suggested its role in cancer cell motility (Turner et al., 1997; 
Jonest et al., 2005; Shepard et al., 2007). Many previous reports used pan-
PLC inhibitors or expression of a dominant negative mutants to understand 
the role of PLC in cancer, especially in tumour local invasion and 
metastases. Our recent report demonstrated that PLC1 is overexpressed in 
lymph node metastases from breast cancer patients (Sala et al., 2008) and is 
required for metastasis development and progression.  
The experiments performed in this thesis improved the understanding of the 
role of PLC1 in cancer cell motility and invasion in vitro. In particular I 
investigated the role of PLC1 in breast cancer and melanoma cancer cell 
migration and invasion in vitro using specific siRNA and shRNA to inhibit 
PLC1. This approach minimised aspecific effects compared to previous 
reports that used expression of dominant negative mutant to investigate 
PLC1 role in cancer. In accordance with previous observation using 
dominant negative mutant, my data showed that downregulation of PLC1 in 
vitro inhibited cancer cell migration and cell invasion in vitro and its 
downregulation affected membrane ruffles formation and growth factor-
induced cytoskeleton remodelling. Failure in cytoskeleton remodelling is 
probably the main reason for the inhibition observed in cell migration and cell 
invasion. These in vitro data were the basis for experimental metastasis using 
MDA-MB-231 performed by my group. These experiments demonstrated that 
PLC1 is required for metastasis development and progression and identified 
PLC1 as a novel therapeutic target. Over the last 20 years successful 
strategies have been developed to treat different types of cancer, although 
cancer remains the second cause of death in adults. However no significant 
improvement has been achieved in treatment of metastasis, which most of the 
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time results in resistance to all the available treatment and represents the first 
cause of death in cancer patients. At present no antimetastatic drugs are 
available. Several papers produced by my laboratory demonstrated that 
inositol phosphates can be used to inhibit AKT by impairing the AKT 
PH/PtdIns(3,4,5)P3 interaction, competing with PtdIns(3,4,5)P3 for the PH 
domain binding (Piccolo et al., 2004; Maffucci et al., 2005). Similarly, since 
PLC1 possesses a PH domain responsible for its membrane recruitment, 
blocking the PH domain interaction with its substrate could be a good strategy 
to impair the activation of this enzyme. Considering that PH domains can 
bind different inositol phosphates with a different range of affinity ( Kavran et 
al., 1998; Maffucci and Falasca, 2001; Lemmon 2008), the hypothesis of 
finding inositol phosphates able to compete with the physiological substrate 
impairing the membrane recruitment, is extremely interesting. 
For these reasons, in order to find specific inhibitors for PLCγ1, I tested the 
inositol pentakisphosphate InsP(1,3,4,5,6)P5 and its derivative compound 2-O-
Bn-InsP5 on PLCγ1 activity. My data showed that 2-O-Bn-InsP5, and less 
potently InsP(1,3,4,5,6)P5, inhibit PLC1 activity upon EGF stimulation and 
that in MDA-MB-231, PLC1 is the only PLC isoform involved in EGF 
signalling. The effect observed in cancer cell migration and invasion, together 
with the potent PLC1 inhibition upon treatment with 2-O-Bn-InsP5, indicated 
that this compound might inhibit PLC1 in vivo and might have anti-metastatic 
activity. We recently reported that 2-O-Bn-InsP5 is a specific and potent 
inhibitor for PDK1 with antitumor effect (Falasca et al., 2010). Therefore 
considering the role of PDK1 in cell migration and invasion and the effect 
observed upon 2-O-Bn-InsP5 treatment in cancer cell migration and invasion 
and on PLC1 activation, I investigated a potential role of PDK1 in PLC1 
activation. Strikingly, my data demonstrated a novel PDK1-dependent 
mechanism of PLC1 activation. Indeed transient or stable downregulation of 
PDK1 inhibited calcium mobilisation, inositol phosphates accumulation and 
PLC1 phosphorylation in Y783 upon EGF stimulation. Similarly, 2-O-Bn-
InsP5 treatment inhibited PLC1 tyrosine phosphorylation and PLC1 activity. 
Therefore these data demonstrated that PDK1 is essential for PLC1 
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phosphorylation, which is an essential step for PLC1 activation. However my 
data did not explain the mechanism by which PDK1 is involved in PLC1 
phosphorylation. Indeed PDK1 is a threonine/serine kinase and therefore it is 
unlikely that the enzyme direct phosphorylates of PLC1. To further gain 
insight into the novel identified PDK1-dependent mechanism, I decided to 
investigate the existence of a protein-protein complex between PLC1 and 
PDK1 which might be important for PLC1 activation independently of PDK1 
kinase activity. Indeed a report showed that PDK1 association to ROCK1 
regulates ROCK1 activity independently from PDK1 kinase activity (Pinner 
and Sahai, 2008). My data demonstrated not only the existence of a complex 
between PLC1 and PDK1 but also that this interaction is modulated upon 
EGF stimulation in breast cancer cells with an increased association in cellular 
protrusion. My work therefore identified a novel PDK1/PLC1 pathway, 
linking two major proteins involved in the regulation of cell motility and 
reported to play a major role in metastases. Moreover it improves the 
understanding of the molecular mechanism involved in the regulation of 
PLC1 in cancer. These data shows that the PDK1/PLC1 is pharmacologically 
targetable and its inhibition may have antimetastatic effect in vivo.  In 
particular these data indicate that 2-O-Bn-InsP5 inhibits the PDK1/PLC1 
pathway and is a promising anticancer and potential antimetastatic drug. My 
data strengthened the idea of PDK1 as a promising therapeutic target and 
suggest a major role of PDK1 in controlling metastasis development and 
progression by promoting PLC1 activation. Indeed PDK1 is overexpressed in 
breast cancer and increased copy number correlates with upstream lesion such 
as PTEN loss, PK3CA mutation and EGFR amplification which result in 
increased tumour growth, increased cell motility and poor prognosis (Maurer et 
al., 2009). In this scenario the novel PDK1/PLC1 might play an important role 
and could be an important therapeutic target for metastasis.  
Data showed in this thesis highlighted the potential therapeutic properties of 
inositol phosphates compounds such as Ins(1,3,4,5,6)P5 and 2-O-Bn-InsP5. 
However it is currently unknown how inositol phosphates are transported 
through the membrane. Recent evidence identified the role of ABCC family 
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members in inositol phosphates export, but no data are available in 
mammalian cells. My data showed for the first time that ABC transporters are 
involved in Ins(1,3,4,5,6)P5 uptake in mammalian cells. In particular ABCC1 
inhibition reduced Ins(1,3,4,5,6)P5 uptake in breast cancer cells. The ABC 
transporters have a main role in chemoresistance and multidrug resistance. It 
was reported by my group that ABCC1 transporter promotes an autocrine 
loop by which cancer cells can stimulate their proliferation (Pineiro et al., 
2010). Therefore this report suggests ABCC1 as a potential target to block 
cancer cell proliferation. However, according to the data showed in this 
thesis, the overexpression of ABCC1 might increase the intracellular uptake 
of exogenous inositol phosphates such as Ins(1,3,4,5,6)P5 or potential 
synthetic derivative and could correlate with increased sensitivity showed by 
different cancer cell lines to inositol phosphates treatment. Therefore 
enhanced expression of ABCC1 might be used as potentially marker to 
identify tumour responsiveness to specific anti-cancer treatment, such as 
inositol phosphates. 
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8.2 Future work 
Several questions, arisen form the experiments showed in this thesis, remain 
pending.  
Further work will focus on: 
PDK1/PLC1 
Investigation of the mechanism by which PDK1 regulates PLC1 
activity. Further experiments should investigate whether kinase activity 
of PDK1 is required for PLC1 activation or it is dispensable.   
 
2-O-Bn-InsP5 in metastases 
In vitro data showed that 2-O-Bn-InsP5 inhibits PLC1 activity and cancer 
cell invasion. Further in vivo work is required to investigate the role in 
metastases development and progression and to investigate the 
pharmacokinetic of this compound. 
ABC transporter and Inositol phosphates active transport 
Further work is required to investigate the role of ABC transporter family 
members. In particular, modulation of expression of different ABC 
transporters, especially ABCC and ABCG family members by overexpression 
or siRNAs could the contribution of ABC transporter in inositol phosphate 
intake. Furthermore, screening of ABCC and ABCG transporter expression in 
cancer cell could correlate their expression with increased sensitivity to 
Inositol phosphates treatment.  
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1.1 5X denaturing sample buffer (per 16 ml) 
6.8 ml of ddH2O 
2 ml of 0.5M tris-HCl pH 6.8 
4 ml of Glycerol 87% 
1.6 ml of SDS 20% 
1.6 ml of bromophenol blue 
  
 
1.2 10% separating gel solution (per 5 ml) 
1.7 ml of Acrylamide mix [Protogel 30% (w/v) acrylamide: 0.8% (w/v) stock 
solution (37.5:1)] 
1.9 ml of ddH2O 
1.3 ml of 1.5M Tris, pH 8.8 
0.05 ml of 10% SDS 
0.05 ml of 10% APS 
0.02  of TEMED 
 
 
1.3 5% stacking gel solution (per 1 ml) 
0.17 ml of Acrylamide mix [Protogel 30% (w/v) acrylamide: 0.8% (w/v) stock 
solution (37.5:1)] 
0.68 ml of ddH2O 
0.13 ml of 1.0M Tris, pH 6.8 
0.01 ml of 10% SDS 
0.01 ml of 10% APS 
0.01 ml of TEMED 
 
 
1.4 1X running buffer 
25 mM tris, pH 8.9 
192 mM glycine 
0.2% SDS 
 
 
1.5 1X Transfer buffer 
25 mM Tris, pH 8.3 
192 mM Glycine 
 
 
1.6 1X TAE buffer 
96.8 g Tris 
22.84 mL Acetic Acid 
14.88 g EDTA 
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2. Map of pSUPERIOR.retro.puro used for generation of PDK1 targeting 
shRNA 
 
2.2
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2.1 Plasmids: 
Plasmid Selection Provided by 
pEGFP Kanamycin Clontech, US 
PRK5-PLC1 Ampicillin Prof. M. Falasca 
(BD, UK) 
PALM-PLC1 Kanamycin Dr. E. Bonvini 
(Macrogenics 
Inc., US) 
pEBG2t-GST-
PDK1 
Ampicillin Dr. D. Alessi 
pOZ-PDK1 Kanamycin Prof. R. Parsons 
pCDNA Ampicillin Invitrogen, UK 
 
2.2 siRNA 
2.2.1 siRNA SMARTpool siRNA D-003017-02-0010, PDK1 
target sequence 1: CAAGAGACCUCGUGGAGAA 
target sequence 2: GACCAGAGGCCAAGAAUUU 
target sequence 3: GGAAACGAGUAUCUUAUAU 
target sequence 4: UGGCCAAAUUGCACGGAAU 
 
 
2.2.3 siRNA SMARTpool siRNA D-003559-01-0010, PLC1 
 
target sequence 1: CCAACCAGCUUAAGAGGAA 
target sequence 2:GAAGUGAACAUGUGGAUCA 
target sequence 3:GAGCAGUGCCUUUGAAGAA 
target sequence 4:CCAAGAAGGACUCGGGUCA 
 
2.3 Primers 
ABCC1 forward: 5-AGTGGAACCCCTCTCTGTTT-3’ 
ABCC1 reverse: 5-CCTGATACGTCTTGGTCTTC-3 
ABCC5 forward: 5-GGAGCTCTCAATGGAAGACG-3’ 
ABCC5 reverse: 5-GTTTCACCATGAAGGCTGGT-3’ 
-actin forward:5’-CTGGCACCACACCTTCTACAATG-3’ 
-actin reverse: 5’-TCCAAAGGACAGGCTGGATG-3’ 
